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Abstract
Total versus partial knee replacement in patients with medial
compartment knee osteoarthritis: the TOPKAT RCT
David J Beard ,1* Loretta J Davies ,1 Jonathan A Cook ,2
Graeme MacLennan ,2 Andrew Price ,1 Seamus Kent ,3
Jemma Hudson ,2 Andrew Carr ,1 Jose Leal ,3 Helen Campbell ,3
Ray Fitzpatrick ,3 Nigel Arden ,1 David Murray 1 and
Marion K Campbell 2 on behalf of the TOPKAT Study Group†
1Nuffield Department of Orthopaedics, University of Oxford, Oxford, UK
2Health Services Research Unit, University of Aberdeen, Aberdeen, UK
3Department of Public Health, University of Oxford, Oxford, UK
*Corresponding author david.beard@ndorms.ox.ac.uk
†The full membership of the TOPKAT Study Group is listed in the Acknowledgements.
Background: Late-stage medial compartment knee osteoarthritis can be treated using total knee
replacement or partial (unicompartmental) knee replacement. There is high variation in treatment
choice and insufficient evidence to guide selection.
Objective: To assess the clinical effectiveness and cost-effectiveness of partial knee replacement
compared with total knee replacement in patients with medial compartment knee osteoarthritis.
The findings are intended to guide surgical decision-making for patients, surgeons and health-care
providers.
Design: This was a randomised, multicentre, pragmatic comparative effectiveness trial that included an
expertise component. The target sample size was 500 patients. A web-based randomisation system was
used to allocate treatments.
Setting: Twenty-seven NHS hospitals (68 surgeons).
Participants: Patients with medial compartment knee osteoarthritis.
Interventions: The trial compared the overall management strategy of partial knee replacement
treatment with total knee replacement treatment. No specified brand or subtype of implant was
investigated.
Main outcome measures: The Oxford Knee Score at 5 years was the primary end point. Secondary
outcomes included activity scores, global health measures, transition items, patient satisfaction
(Lund Score) and complications (including reoperation, revision and composite ‘failure’ – defined by
minimal Oxford Knee Score improvement and/or reoperation). Cost-effectiveness was also assessed.
Results: A total of 528 patients were randomised (partial knee replacement, n = 264; total knee
replacement, n = 264). The follow-up primary outcome response rate at 5 years was 88% and both
operations had good outcomes. There was no significant difference between groups in mean Oxford
Knee Score at 5 years (difference 1.04, 95% confidence interval –0.42 to 2.50). An area under the curve
analysis of the Oxford Knee Score at 5 years showed benefit in favour of partial knee replacement
DOI: 10.3310/hta24200 Health Technology Assessment 2020 Vol. 24 No. 20
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
vii
over total knee replacement, but the difference was within the minimal clinically important difference
[mean 36.6 (standard deviation 8.3) (n = 233), mean 35.1 (standard deviation 9.1) (n = 231), respectively].
Secondary outcome measures showed consistent patterns of benefit in the direction of partial knee
replacement compared with total knee replacement although most differences were small and
non-significant. Patient-reported improvement (transition) and reflection (would you have the operation
again?) showed statistically significant superiority for partial knee replacement only, but both of these
variables could be influenced by the lack of blinding. The frequency of reoperation (including revision)
by treatment received was similar for both groups: 22 out of 245 for partial knee replacement and
28 out of 269 for total knee replacement patients. Revision rates at 5 years were 10 out of 245 for
partial knee replacement and 8 out of 269 for total knee replacement. There were 28 ‘failures’ of
partial knee replacement and 38 ‘failures’ of total knee replacement (as defined by composite outcome).
Beyond 1 year, partial knee replacement was cost-effective compared with total knee replacement, being
associated with greater health benefits (measured using quality-adjusted life-years) and lower health-
care costs, reflecting lower costs of the index surgery and subsequent health-care use.
Limitations: It was not possible to blind patients in this study and there was some non-compliance
with the allocated treatment interventions. Surgeons providing partial knee replacement were
relatively experienced with the procedure.
Conclusions: Both total knee replacement and partial knee replacement are effective, offer similar
clinical outcomes and have similar reoperation and complication rates. Some patient-reported measures
of treatment approval were significantly higher for partial knee replacement than for total knee
replacement. Partial knee replacement was more cost-effective (more effective and cost saving) than
total knee replacement at 5 years.
Future work: Further (10-year) follow-up is in progress to assess the longer-term stability of these
findings.
Trial registration: Current Controlled Trials ISRCTN03013488 and ClinicalTrials.gov NCT01352247.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 24, No. 20. See the NIHR Journals Library website for further project information.
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What was the question?
Two types of knee replacement are available for patients with arthritis of the inner part of their knee:
a partial knee replacement or a total knee replacement. It is not known which replacement offers most
benefit for the patient or for the health-care system.
What did we do?
We performed a large study involving 528 patients at 27 hospitals with 68 experienced surgeons,
in which half of the patients underwent partial knee replacement and the other half underwent total
knee replacement. We took yearly scores and measures, including pain, function, whether or not the
operation was successful, and the costs of each patient for 5 years. Comparison between treatments
was assessed at 5 years post operation.
What did we find?
Good outcomes and relatively few complications were observed after both operations. The measurements
taken to assess the clinical benefit were largely very similar between the two groups. Where differences
did occur at 5 years, there were only small differences between the two knee replacements and partial
knee replacement was generally favoured. Some measurements, however, did show a larger difference
between the two groups, including whether or not the operation addressed the patients’ problems and
whether or not the patient would have the operation again. These measurements were also in favour
of partial knee replacement, but caution is required not to overstate importance, as patients in the
study knew which device they had had implanted. The number of patients requiring further operations
or revision surgery was similar in the two groups. This last finding contrasts with information from
previously obtained, mainly non-randomised, studies and is of high relevance. The cost of each
operation in relation to the benefit obtained was clearly in favour of partial knee replacement.
What does this mean?
Both operations are effective for use in the NHS. There appear to be some modest clinical advantages
for patients to undergo partial knee replacement over total knee replacement but, importantly, the
study casts doubt over previous concerns on high reoperation rates for partial knee replacement.
The study has shown that reoperation rates recorded from different sources (cohort or trials) can
be conflicting.
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Knee replacement for treatment of osteoarthritis of the knee is an effective and common procedure,
with > 700,000 procedures performed each year in the USA and 1,076,778 procedures performed in
the UK between 2003 and 2017. There are two main surgical options to replace the diseased areas of
late-stage medial compartment osteoarthritis of the knee. Some surgeons consider the treatment of
choice to be a total knee replacement, whereas others feel that it is best to replace just the damaged
component of the knee with a partial or unicompartmental knee replacement. Such variation in
decision-making for patients who have similar pathology is well recognised, with high levels of
disagreement between surgeons for implant choice. The best treatment option remains uncertain, with
little evidence to date to prove the clinical effectiveness and cost-effectiveness of either treatment
management option.
The literature to date has consisted of individual cohort studies, indirect comparisons and retrospective
studies, which often examine very specific aspects of knee replacement surgery (e.g. complications and the
ability to kneel). To our knowledge, no large, well-powered, multicentre randomised controlled trial has
been undertaken to directly compare partial knee replacement with total knee replacement. Joint registry
data have shown a trend towards total knee replacement having better implant survival, but other studies
are characterised by low-level evidence, consensus and peer influence. To provide robust and unbiased
estimates of the relative benefits and harms of the procedures and assess cost-effectiveness, a large
randomised controlled trial was required.
The trial was required to evaluate clinical effectiveness at the 5-year follow-up, a time point that is
considered the minimum for arthroplasty evaluation; however, early reoperation and complications were
also considered key to this comparison. Evaluation of 5-year revision was an important aspect of the
trial, as it has been implied that partial knee replacement is more technically demanding than total knee
replacement, a feature that may contribute to the increased incidence of complications/failure seen in
the larger national registry data.
Objectives
The main objective for TOPKAT (Total or Partial Knee Arthroplasty Trial) was to assess the clinical
effectiveness and cost-effectiveness of total knee replacement compared with partial (unicompartmental)
knee replacement in patients with medial compartment osteoarthritis of the knee in a formal randomised
comparison. The primary outcome measure was a patient-reported outcome measure, the Oxford Knee
Score. A second research question involved failure of each type of operation in terms of reoperation, revision
and a composite outcome measure of the Oxford Knee Score and reoperation. Other objectives included
investigation and comparison of post-operation activity levels, complications and patient satisfaction. The
findings are intended to guide surgical decision-making for patients, surgeons and health-care providers.
Methods
The study was a multicentre randomised controlled trial of patients who were randomised to either
partial knee replacement or total knee replacement. The target sample size was 500 patients. The
trial had a combined equipoise/expertise-based approach to randomisation. The expertise-based
randomisation enabled surgeons not in equipoise to participate in the trial by working in pairs, each
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providing the operation type that they felt was appropriate (as ‘experts’). Patients were randomised to the
partial knee replacement or the total knee replacement surgeon in the pair. The ‘in equipoise’-based
randomisation involved surgeons who had sufficient experience of both operation types and who were
willing to perform either operation. Minimum levels of expertise were ensured, with all surgeons having
had appropriate training in both operations and having performed a minimum of 10 partial knee
replacement and 10 total knee replacement procedures. Patients were not blinded to their intervention.
Outcome measures
The trial was designed and powered to examine both self-reported outcome (at 5 years) and complication/
reoperation differences between the groups at 5 years. The primary outcome measure was the Oxford
Knee Score, a well-validated patient-reported outcome questionnaire that is specifically developed to
assess function and pain after knee replacement surgery.
Of the secondary outcome measures recorded, the frequency of complications and failure of operation
were considered particularly important to assess differences between the two interventions.
Complications were assessed by distinguishing those that required re-admission and reoperation
(revision or other related procedure). Failure of intervention was assessed using a prespecified
composite outcome assessment (combination of reoperation and poor outcome as defined by Oxford
Knee Score); poor outcome was ascribed if the Oxford Knee Score did not improve by > 4 points.
Other secondary measures were:
l The American Knee Society Score at 2 months and 1 year post surgery and 5 years post
randomisation. Both clinical assessment and function were recorded.
l The University of California Los Angeles Activity Score at 2 months post surgery and 1–5 years
post randomisation.
l The High Activity Arthroplasty Score at 2 months post surgery and 1–5 years post randomisation.
l The EuroQol-5 Dimensions at 2 months (post surgery) and 1–5 years post randomisation.
l Self-reported anchor-type questions about satisfaction, transition in relation to problems, overall
health, transition in relation to overall health and reflection on whether or not they would still have
the operation again.
l Surgical (intra- and post-operative) complications.
l Health-care and patient resource use (e.g. length of hospital stay at time of operation, 2 months
post surgery and 1–5 years post randomisation).
l Reoperation rate following knee replacement surgery, including revision.
l Composite outcome assessment – failure of intervention defined as reoperation (including revision)
and/or poor outcome indicated by Oxford Knee Score.
l Oxford Knee Score-Activity and Participation Questionnaire adjunct score to the Oxford Knee
Score at years 4 and 5 post randomisation.
l Radiographic imaging of the knee preoperatively, immediately postoperatively and at 5 years
post randomisation.
Participants and setting
A total of 528 patients were recruited from 27 UK NHS sites (68 surgeons) from January 2010 to
September 2013. Participants had to have osteoarthritis of the medial compartment of the knee and
satisfy general requirements for a medial partial knee replacement. Potential participants were identified
in outpatient and at pre-assessment clinics by participating surgeons, or were identified from local
databases. Participants signed a consent form during their screening visit and were free to withdraw
from the study at any time.
Study interventions
The trial was pragmatic and compared partial knee replacement with total knee replacement using
any brand or model of implant in common use. For this reason, surgeons were free to use the implant
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of their own or their institution’s choice. A total knee replacement involved all surfaces of the knee
being replaced. The procedure involved excising both diseased and normal femoral condyles, the tibial
plateau and often the patella, as well as removing or releasing some of the ligaments. The artificial
implant could be cemented in position if desired. A partial knee replacement involved only the diseased
area of the joint being replaced. The healthy compartments of the knee and ligaments were retained
and artificial implants were inserted in place of the diseased area.
Recruitment and consent
The preoperative (baseline) assessment included the Oxford Knee Score, activity level, health-care
resource use and the American Knee Society Score. Routine preoperative X-rays were also performed.
Randomisation (which utilised minimisation) used a web-based randomisation service at the Centre for
Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen. The minimisation
algorithm incorporated sex, age (< 50, 50–70 or > 70 years) and baseline Oxford Knee Score band
(≤ 14, 15–21 or ≥ 22) and ‘delivery unit’. A delivery unit was either an ‘equipoise surgeon’ or a pair of
‘expertise surgeons’ who had complementary expertise.
Operative details were recorded in theatre and routine post-operative X-rays were conducted. Patients
then attended a clinic for the American Knee Society Score assessment at 2 months, 1 year and
5 years post operation. All other outcomes were collected using postal questionnaires. In cases where
there was > 12 weeks between randomisation and the operation date (owing to the waiting list), an
additional Oxford Knee Score was administered at the clinical assessment 1 year post surgery.
Statistics and analysis
The sample size was calculated on the Oxford Knee Score and the reoperation rate. Detection of a change
in reoperation rate of 7% between groups (from 5% to 12%) at 80% power and using a significance
level of p < 0.05 (two-sided) required a sample size of 250 patients per group. A total of 250 patients
per group also provided 90% power to detect a reoperation increase to 14% (difference of 9%). For the
primary end point at 5 years, a sample size of 500 patients (250 in each group) was also required to
identify clinically significant differences in Oxford Knee Score. This sample size provided 90% (and
80%) power to detect a mean difference of 3.0 (and 2.0) Oxford Knee Score points at 5% (two-sided)
significance level using a standard deviation of 10.0 points.
Statistical analysis was primarily on an ‘intention-to-treat’ basis and participants were analysed according
to their allocated group using all available participant data. Low frequency event data, such as reoperation
and revision, were also analysed on an ‘as-treated’ basis to avoid misrepresentation because of lack of
compliance to the allocated intervention (crossover). The Oxford Knee Scores for total knee replacement
and partial knee replacement were compared using multiple linear regression analysis adjusted for
minimisation factors and baseline Oxford Knee Score and using robust cluster variance to account for
surgery delivery unit. Any differential impact of expertise versus equipoise delivery of the intervention on
treatment effect was explored using an interaction effect. Prespecified subgroup analyses of sex, Oxford
Knee Score band and age were explored using treatment-by-subgroup interactions. Secondary outcomes
were analysed using the same approach as the primary outcome within a generalised linear models
framework. Binary variables (including complications and reoperations at 5 years) and length of hospital
stay (counted in full days) were compared using a Poisson regression to estimate risk ratios adjusted for
minimisation covariates with robust cluster variance to account for surgery delivery unit. Statistical
significance was judged at the two-sided 5% level and treatment effect estimates are presented with
corresponding 95% confidence intervals. Missing effectiveness data were not imputed in the principal
analysis. For Oxford Knee Score and EuroQol-5 Dimensions, three-level version, at 1 and 5 years,
sensitivity analyses explored the impact of imputing worse case (0 and –0.594, respectively) across both
groups and each of the randomised groups in turn.
For the health economics analysis, the total costs and quality-adjusted life-years for all 528 participants
were estimated from the date of recruitment until the earliest of death, withdrawal from study or the
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end of follow-up at 5 years. Both costs and quality-adjusted life-years were discounted at 3.5% per
year. Mean total health-care costs and quality-adjusted life-years were estimated using separate linear
regression models controlling for treatment allocation, age group, sex and baseline Oxford Knee Score
band, following the main clinical analysis. For quality-adjusted life-years, we also controlled for EuroQol-5
Dimensions score at baseline. Incremental cost-effectiveness ratios were calculated by dividing the
mean cost difference between partial knee replacement and total knee replacement by the mean
quality-adjusted life-year difference. The joint uncertainty around incremental total costs and quality-
adjusted life-years (i.e. the difference between partial knee replacement and total knee replacement)
was also investigated. Sensitivity analyses, using a complete-case analysis, were also provided.
Results
In total, 528 patients were randomised and baseline variables between groups were well balanced.
A representative range of implants was used in the trial when compared with UK National Joint Registry
data. The follow-up primary outcome response rate was 88%. At 5-year follow-up, both operations had good
outcomes. Patients in both groups had superior outcome to their preoperative baseline status. The changes
in Oxford Knee Score following partial knee replacement and total knee replacement intervention were
substantial (mean Oxford Knee Score change greater than 18 points for both procedures).
There was no evidence of difference between groups in the primary outcome of mean Oxford Knee
Score at the 5-year time point (difference 1.04, 95% confidence interval –0.42 to 2.50). Although
there was no evidence of difference in the primary outcome between groups at the 5-year time
point in a cross-sectional and marginal analysis, a post hoc area under the curve analysis of the
Oxford Knee Score for the duration of the study did show significant benefit in favour of partial
knee replacement over total knee replacement. More patients achieved higher outcome scores after
partial knee replacement than other total knee replacement. It should be noted that this difference
across operation types was similar and smaller than the minimal clinically important difference of the
score [mean 36.6 (standard deviation 8.3), mean 35.1 (standard deviation 9.1), respectively].
Secondary outcome measures showed consistent patterns of benefit for partial knee replacement,
although some differences were small and non-significant: Oxford Knee Score-Activity and Participation
Questionnaire difference 1.00 (95% confidence interval –3.50 to 5.50), University of California Los
Angeles difference 0.17 (95% confidence interval –0.009 to 0.43), EuroQol-5 Dimensions visual analogue
score difference 4.0 (95% confidence interval 1.36 to 6.67) and patient satisfaction (82% for partial knee
replacement and 77% for total knee replacement). The EuroQol-5 Dimensions visual analogue scale global
health instrument revealed significant differences in favour of partial knee replacement. Both transition
(problems better now than before operation: partial knee replacement 95% and total knee replacement
90%) and reflection (Would you have the operation again?: partial knee replacement 91% and total knee
replacement 84%) were significantly better for partial knee replacement, although both of these variables
are potentially susceptible to bias owing to the lack of blinding.
The frequency of reoperation (including revision) by the treatment received was similar in both groups:
22 out of 245 partial knee replacement patients and 28 out of 269 total knee replacement patients.
Revision rates at 5 years were 10 out of 245 for partial knee replacement and 8 out of 269 for total
knee replacement. There were 28 ‘failures’ of partial knee replacement, as defined by the composite
outcome, and 38 ‘failures’ of total knee replacement.
The health economic evaluation found partial knee replacement to be more effective (0.240 quality-
adjusted life-years, 95% confidence interval 0.046 to 0.434 quality-adjusted life-years) and to cost less
than total knee replacement (£910, 95% confidence interval £317 to £1503) over the 5 years of follow-up.
This finding was a result of slightly better outcome (as measured by the EuroQol-5 Dimensions), lower
partial knee replacement surgery costs and lower follow-up health-care costs. If cost of the implant devices
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is assumed to be equal partial knee replacement remains less costly and more effective than total knee
replacement.
Trials are susceptible to interpretation bias, especially if differences are small and investigators have
prior preference for a particular intervention. A summary set of blinded results was sent to a group
of entirely independent and unconnected assessors (trial experts and surgeons) to help interpret the
results and impact of the trial in an unbiased manner.
There are many strengths of this study. To our knowledge, it is the largest randomised controlled trial
to date in the world with the longest and most comprehensive follow-up. The study was well powered
and the follow-up rates were very high (88%). The pragmatic design, the large number of sites and
surgeons and the wide variety of implants used provided high external validity. The inclusion of an
expertise component allowed high surgeon participation, regardless of their personal equipoise.
Employment of independent assessors to interpret the results helped to neutralise personal and
institutional bias.
Limitations included lack of patient blinding and some non-compliance with allocated interventions,
although this had little effect on the overall results. Surgeons providing partial knee replacement were
all experienced with this procedure.
Conclusions
Both total knee replacement and partial knee replacement are effective, offer similar clinical outcomes
and have similar reoperation and complication rates. The revision rates for partial knee replacement in
this trial were, however, substantially lower than those found in other studies and in non-randomised
cohort data. The reasons require further investigation, one being that TOPKAT involved surgeons who
were already experienced at implanting partial knee replacement, leading to a lower revision rate. Several
secondary patient-reported measures were significantly higher for partial knee replacement, and partial
knee replacement was more cost-effective than total knee replacement at 5 years. Although total knee
replacement is safe and adequate, on the basis of the combined clinical and cost-effectiveness results,
partial knee replacement shows some advantages over total knee replacement for patients with
late-stage medial compartment osteoarthritis.
Clinical impact
Both total knee replacement and partial knee replacement remain treatment options for medial
compartment arthritis of the knee. This study has shown that partial knee replacement offers some
advantages over total knee replacement. However, the operation should be carried out by those with
sufficient experience and expertise, and surgical training programmes should address any unmet need
identified by this study.
Future work
Further follow-up is required to assess the longer-term stability of these findings over time (10-year
follow-up started in March 2020 and will be completed by October 2023). Further research is also
required into the effect of experience and the disparity between trial and cohort data.
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This trial is registered as ISRCTN03013488 and ClinicalTrials.gov NCT01352247.
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This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 20.
See the NIHR Journals Library website for further project information.
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Chapter 1 Introduction
Parts of this chapter have been adapted from Beard et al.1 This article is published under license toBioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited. The text
below includes minor additions and formatting changes to the original text.
Background
Osteoarthritis (OA) of the knee is a common condition that produces pain, swelling and stiffness in
the knee, which, in many cases, can result in a reduction in patient function.2,3 The pattern of arthritic
changes affects people differently. Epidemiological studies have shown that the predominant pattern of
OA change is found in the medial compartment of the knee joint, with lesser changes occurring on the
lateral side or patellofemoral joint.4 Patients can be managed conservatively or surgically, with treatment
aimed at relieving pain and discomfort, reducing stiffness and minimising further damage to the joint.
When patients develop joint symptoms (e.g. pain, stiffness and reduced function) that have a substantial
impact on their quality of life and have not been controlled by non-surgical treatment, surgical
intervention may be required.5
Current treatment/management options
Knee replacement for OA of the knee is an effective and common procedure, with 303,960 procedures
performed in the UK between 2015 and 2017.6 There are two main surgical options to replace the
diseased areas of late-stage medial compartment OA.The more commonly used procedure, total knee
replacement (TKR), is a highly effective treatment strategy that is associated with significant improvement
in pain, function and quality of life.7,8 Some surgeons consider TKR to be the treatment of choice for
this pathology, whereas others prefer to replace only the damaged component of the knee, partial (or
unicompartmental) knee replacement (PKR), preserving the cruciate ligaments, meniscus and tibial plateau
of the healthy compartment. Such variation in the decision-making for patients who have similar pathology
is well recognised, with high levels of disagreement between surgeons regarding implant choice.9 Fewer
than 9% of knee replacements in the UK are unicompartmental,6 although it is estimated that up to 47% of
patients who require knee replacement have unicompartmental disease that would be suitable for a PKR.4
There are arguments for both approaches. Both interventions are established and well-documented
procedures and each intervention is considered standard care. However, little evidence exists to prove
the clinical effectiveness and cost-effectiveness of either management option. Proponents of the TKR
procedure believe that the operation is less complex than PKR and, thus, in the short term, TKRs are
less susceptible to early problems and failure. Proponents of the TKR procedure also believe that in the
long term the joint disease will progress to the other, normal, compartments of the knee.10,11 It is felt
that a PKR would eventually fail and necessitate revision surgery, which involves a TKR procedure.11,12
In contrast, proponents of the PKR procedure believe that PKR results in faster recovery,13,14 fewer
complications15 and superior function.16 Proponents of the PKR procedure also believe that it is more
cost-effective than TKR4 and is associated with long-term survival of the joint.17,18
Rationale for TOPKAT
At the outset of the study, the evidence available to select the best treatment option for medial
compartment OA was limited. A literature search conducted before study submission was performed
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with no language restrictions for reports published between 1990 and 2008. We searched NLH, EMBASE,
MEDLINE, PEDro, MetaRegister of Controlled Trials (active and archived registers), ClinicalTrials.gov,
Centre for Reviews and Dissemination, Cochrane Database of Systematic Reviews and The Cochrane
Central Register of Controlled Studies databases, with the search terms ‘total’, ‘partial’, ‘unicompartmental’,
‘knee replacement’, ‘knee arthroplasty’, ‘trial’ and ‘outcome’. There was no systematic review of the
clinical effectiveness of PKR at the time owing to a lack of published evidence. There was one small
randomised controlled trial (RCT)17,18 as well as individual cohort studies, indirect comparisons and
retrospective studies. These had been undertaken to address specific, and often focused, aspects of
OA treatment and knee replacement and many involved short-term assessments only. These studies
included a comparison between TKR and PKR of the kinematics,19 proprioception,20 ability to kneel,16
ease of revision,21–23 success of revision after various procedures,24–27 appropriateness for specific
pathology,28 accuracy of implantation29–31 and complications.32,33 No large, well-powered, multicentre RCT
had been undertaken to directly compare PKR with TKR.
The only other previous attempt at comparing these operations on a large scale was one of the arms
of the Knee Arthroplasty Trial (KAT).34 However, this arm of the trial failed because of a lack of
equipoise and confidence towards PKR among surgeons. This led to such low levels of patient
recruitment that this arm of the KAT was stopped.
Other previous studies35–38 that showed a trend towards PKR being the more effective management
option are characterised by low-level evidence, consensus and peer influence. To test the validity of
these results and to examine the clinical effectiveness and cost-effectiveness of both treatment options,
further investigation was required using an appropriate patient base and long-term assessments.
Evidence update since study submission
During the course of the study, further studies have been completed. An update of the initial literature
search was conducted to inform this report and set the results in context.
Three RCTs39–41 and five ongoing trials42–46 were identified (Table 1). The three completed RCTs were
relatively small single-centre studies, ranging from 56 to 72 participants per trial, with a mean participant
age of 60–73 years. Two of the RCTs39,40 included patients who underwent a TKR in one knee and a PKR
in the contralateral leg and the other41 was of patients who received simultaneous bilateral TKR or PKR.
Overall, no RCT showed a statistically significant difference between the two types of procedure being
compared.47 Of the ongoing RCTs, three trials are currently recruiting,43,44,46 one is a feasibility study
(not yet recruiting)42 and the other has a recruitment status reported as ‘unknown’.45
Potential advantages of undergoing a PKR over a TKR for patients with medial compartment OA have
been discussed in several registry and cohort studies. For example, studies have demonstrated reduced
blood loss and risk of transfusion at the time of operation;48,49 shorter length of stay and a lower
30-day re-admission rate;50–52 more cost-effective,53,54 better restoration of physiological gait pattern;55
and better patient-reported pain and function scores and forgotten joint scores56–60 for PKR compared
with TKR. In addition, PKR has been reported to be more cost-effectiveness,53,54 have lower incidence
of medical complications, such as thromboembolism, infection, stroke and myocardial infarction,
and lower mortality rates than TKR.61
However, systematic reviews and unadjusted data from national registries show a significantly higher
revision rate for PKR than for TKR, with the chance of revision for PKR being more than double that
of TKR.6,62,63 Higher revision rate was also identified when comparing matched patients who were
undergoing PKR with those undergoing TKR: PKR had worse implant survival both for revision
[subhazard ratio 2.12, 95% confidence interval (CI) 1.99 to 2.26] and for revision/reoperation
(subhazard ratio 1.38, 95% CI 1.31 to 1.44) than TKR at 8 years post treatment.61
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TABLE 1 Completed and ongoing RCTs comparing PKR with TKR for patients with medial compartment OA
First author,
year of publication Study design Blinding Sample size Participants Interventions Primary outcome Results
Completed studies
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p = 0.2010)Total knee arthroplasty
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knee arthroplasty
KSS and range of
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significant difference
Total knee arthroplasty Mean KSS 80.5
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70–87) for TKR








KSS at 5 years Similar for both
groups
Total knee arthroplasty
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TABLE 1 Completed and ongoing RCTs comparing PKR with TKR for patients with medial compartment OA (continued )
First author,
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Despite large sample sizes and best efforts of propensity matching, retrospective cohort data to assess
clinical effectiveness and cost-effectiveness remain at risk of bias because of inherent selection bias for
individual patients between the two operations.
Research objectives
1. The primary objective for Total or Partial Knee Arthroplasty Trial (TOPKAT) was to assess the
clinical effectiveness of PKR compared with that of TKR in patients with medial compartment OA
of the knee.
2. Secondary objectives included investigation of the complications, patient satisfaction and cost
implications of the PKR and TKR replacements for patients, surgeons and health-care providers.
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Parts of this chapter have been adapted from Beard et al.1 This article is published under license toBioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is properly cited. The text
below includes minor additions and formatting changes to the original text.
Trial design
TOPKAT was designed as a multicentre parallel-group superiority RCT to evaluate the clinical
effectiveness and cost-effectiveness of TKR compared with PKR (unicompartmental) for medial
compartmental OA. The trial used a novel combined equipoise/expertise approach (hybrid expertise-
based design). The expertise-based design component was included to help address some of the known
challenges of conducting a RCT of skilled-based interventions, such as clinician preference for one
intervention over another.64 Use of this design helped to maximise surgeon participation in the study
and negate known obstacles arising from clinician preference, a feature that was observed in an earlier
attempt to evaluate the differences between PKR and TKR.34
The hybrid equipoise/expertise design allowed surgeons who were in equipoise (‘equipoise surgeon’)
and had sufficient expertise to perform both TKR and PKR to participate in the trial, as per a conventional
surgical trial design. The expertise-based randomisation component also enabled surgeons not in equipoise
to participate in the trial by working in pairs as a treatment allocation or delivery unit, one surgeon
providing the TKR expertise and one providing the PKR expertise, each providing only the operation
type that they felt was appropriate (as ‘experts’); patients were randomised to the TKR or PKR surgeon
in the pair. For this ‘expertise’ approach to succeed, there had to be a surgeon with expertise in TKR and
a surgeon with expertise in PKR in the same centre who could participate together as the ‘treatment
delivery unit’. Patients recruited to the study who were under the care of such a surgeon (‘expertise
surgeon’) were randomised to one of the two groups and were treated by the appropriate surgeon.
In cases where, following randomisation, allocation was to a surgeon different from that at the initial
consultation, a patient was internally referred to the other surgeon’s operating list.
No restriction was made on the number of ‘treatment delivery units’ within a participating site.
However, for practical and statistical reasons, a surgeon was able to be in one delivery unit only, that
is they were classified as either an ‘equipoise surgeon’ or an ‘expertise surgeon’.
Blinding patients to treatment allocation was considered for the study design, but was thought not to be
practicable for such a long-term study. However, clinical evaluators were masked from treatment allocation
where practical. Surgeons implanting the device could not be blinded from allocation.
The trial was designed as pragmatic in terms of both device choice (see Interventions) and delivery of
care. No formal restrictions were placed on clinical pathways and rehabilitation approach/content for
either group, but advice and minimal quality levels were shared with local site personnel at set-up visits.
The study protocol was published in 2013.1 The main changes to the protocol since 2013 included
the addition of two secondary outcomes measures: the High Activity Arthroplasty Score (HAAS) and
the Oxford Knee Score-Activity and Participation Questionnaire (OKS-APQ) (years 4 and 5 follow-up
questionnaire only). An additional Oxford Knee Score (OKS) questionnaire at 1 year post surgery
for participants with a time > 12 weeks of between randomisation and surgery was also included
(see Appendix 1, Table 26).
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Interventions
TOPKAT compared PKR with TKR. Surgeons were free to use any implant of their own or their institution’s
choice (i.e. brand and model), providing the device was in common clinical use and had no previous safety
issues recognised by the National Joint Registry. The implant type, model and manufacturer were recorded
on the primary procedure hospital form.
Total knee replacement
A TKR involves all surfaces of the knee being replaced. The procedure involves excising both diseased
and normal femoral condyles, the tibial plateau and often the patella. This is carried out through a large
skin incision that provides easy access to the knee joint. Each component is replaced with an artificial
implant that is secured in position with either a cemented or a cementless fixation. No stipulation was
provided for patella replacement or cement use, although these variables were recorded.
Partial knee replacement
A PKR or unicompartmental knee replacement involves replacing the diseased area of the joint only.
The healthy (or healthier) compartment of the knee is retained and artificial implants are inserted in
place of the diseased dysfunctional area. The implants are secured in position with either a cemented
or a cementless fixation. For this study, the medial compartment was replaced for medial compartment
OA, which was usually achieved using a minimally invasive surgical technique.
Participating surgeons required a ‘minimum level of expertise’ for the types of surgery undertaken.
A paper-based simple audit of participating surgeons’ routine practice was undertaken prior to
commissioning each participating centre. Levels of experience were set to allow participation. PKR
surgeons must have had appropriate training, been practising the technique for ≥ 1 year and had to
have performed the operation ≥ 10 times in the previous year. The implants used by PKR surgeons in
the study required evidence of good clinical results and had to be a commonly used knee system that
did not require patella dislocation. TKR surgeons had to satisfy similar criteria and use a conventional
approach with patella dislocation. ‘Equipoise surgeons’, who delivered both operations, were required
to satisfy the criteria for both operations, that is they had appropriate training in both operations and
had performed a minimum of 10 PKR and 10 TKR procedures in the previous year.
Participants
Patients with medial compartmental OA who satisfied general surgical requirements for a medial PKR
(see Inclusion criteria) were eligible for inclusion. If patients met the inclusion criteria with both of their
knees, only one knee (designated the ‘study’ knee) was operated on according to the random allocation
assigned to the patient as they entered the study. Patients requiring simultaneous bilateral knee
replacement were excluded. Previous knee replacement on the non-study knee was not an exclusion
criterion. Subsequent knee replacement on the other, non-study knee was recorded, but the subsequent
operation did not lead to a second random allocation.
Inclusion criteria
l Medial compartment OA with exposed bone on both the femur and the tibia.
l Functionally intact anterior cruciate ligament. Superficial damage or splitting of the ligament
was acceptable.
l Full-thickness and good-quality lateral cartilage present.
l Correctable intra-articular varus deformity (suggestive of adequate medial collateral ligament function).
l Medically fit with an American Society of Anesthesiologists (ASA) grade of 1 or 2.
METHODS
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Exclusion criteria
l Required revision knee replacement surgery.
l Had rheumatoid arthritis or other inflammatory disorders.
l Were unlikely to be able to perform the required clinical assessment tasks.
l Had concurrent symptomatic foot, hip or spinal pathology.
l Had previous knee surgery other than diagnostic arthroscopy and medial meniscectomy.
l Previously had septic arthritis.
l Had significant damage to the patellofemoral joint, especially on the lateral facet.
Setting and locations
Participants were recruited between January 2010 and September 2013 from 27 NHS secondary care
hospitals from across the UK. Each site is listed below:
l Chesterfield Royal Hospital, Chesterfield Royal Hospital NHS Foundation Trust.
l Cumberland Infirmary, North Cumbria University Hospitals NHS Trust.
l Great Western Hospital, Great Western Hospitals NHS Foundation Trust.
l Harrogate District Hospital, Harrogate and District NHS Foundation Trust.
l Hull Royal Infirmary, Hull and East Yorkshire Hospitals NHS Trust.
l Ipswich Hospital, The Ipswich Hospital NHS Trust.
l King’s Mill Hospital, Sherwood Forest Hospitals NHS Foundation Trust.
l Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust.
l Lincoln County Hospital, United Lincolnshire Hospitals NHS Trust.
l Medway Maritime Hospital, Maidstone and Tunbridge Wells NHS Trust.
l Milton Keynes General Hospital, Milton Keynes University Hospital NHS Foundation Trust.
l Musgrave Park Hospital, Belfast Health and Social Care Trust.
l Nuffield Orthopaedic Centre, Oxford University Hospitals NHS Foundation Trust.
l Pilgrim Hospital, United Lincolnshire Hospitals NHS Trust.
l Pinderfields Hospital, Mid Yorkshire Hospital NHS Trust.
l Royal Blackburn Hospital, East Lancashire Hospitals NHS Trust.
l Royal Gwent Hospital, Aneurin Bevan University Health Board.
l Royal Stoke University Hospital, University Hospitals of North Midlands NHS Trust.
l Royal United Hospital, Royal United Hospital Bath NHS Trust.
l Southampton General Hospital, University Hospital Southampton NHS Foundation Trust.
l Southmead Hospital, North Bristol NHS Trust.
l Stepping Hill Hospital, Stockport NHS Foundation Trust.
l Torbay Hospital, South Devon Healthcare NHS Foundation Trust.
l University Hospital of North Durham, County Durham and Darlington NHS Foundation Trust.
l University Hospital of North Tees, North Tees and Hartlepool NHS Foundation Trust.
l Woodend Hospital, NHS Grampian.
l Yeovil District Hospital, Yeovil District Hospital NHS Foundation Trust.
Recruitment and consent
Potential patients were identified and approached in routine orthopaedic outpatient and pre-assessment
clinics by the participating surgeon [or their late-stage trainee (registrar)].
Eligible patients who were interested in participating were provided with a letter of invitation and an
information sheet by the surgeon or a member of the research team. This information explained why
they had been approached and further details about the study. An ‘opt in’ form was also provided to
the patient that was used to indicate if they were willing to be contacted again by the research team.
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This form was either completed at this initial visit or returned to the research team in a prepaid
return envelope. Patients who indicated ‘yes’ were then contacted by local study staff to arrange a
screening visit.
At some participating sites, potential patients were also identified from local hospital databases. These
patients were sent a letter, information sheet and the ‘opt-in’ form with a prepaid envelope for its return,
which documented whether or not they were willing to be contacted subsequently by the research team.
During the screening visit, all eligible patients who agreed to participate in the trial signed the TOPKAT
consent form. Following consent and prior to randomisation a baseline assessment was undertaken by
the research team. The research nurse/practitioner then enrolled the patient details onto the automated
web-randomisation system (see Randomisation) to activate the randomisation and initiated appropriate
arrangements in line with the allocation.
Baseline assessment
The baseline preoperative assessment included a patient-reported questionnaire that examined pain
and function (OKS), activity level [the University of California, Los Angeles (UCLA), activity measure
and the HAAS measure] and health-care resource use (in the preceding 12-month period). In addition,
the American Knee Society Score (AKSS), a clinical assessment of the range of motion and function
of the knee, was carried out. Full details of these measures are provided in Outcomes. Routine
preoperative X-rays (anteroposterior and lateral views) were also collected.
Randomisation
Randomisation was performed by computer allocation (thus ensuring concealment of sequence generation)
using the web-based automated randomisation service provided by the Centre for Healthcare Randomised
Trials (CHaRT), Health Services Research Unit, University of Aberdeen. Random allocation to TKR or PKR
was in a 1 : 1 ratio and was minimised using sex, age (< 50, 50–70 or > 70 years), baseline OKS (≤ 14,
15–21 or ≥ 22) and ‘treatment delivery unit’. A treatment delivery unit was either an ‘equipoise surgeon’
or a pair of ‘expertise surgeons’ with complementary expertise (i.e. one TKR-focused surgeon and one
PKR-focused surgeon). The treatment delivery unit was included as a minimisation factor to ensure that
a balance was maintained for individual equipoise surgeons and more generally by centre. Randomisation
and allocation could not be conducted intraoperatively because of the expertise aspect to the design and
the requirement to set up the theatre and lists appropriately for each implant type. Randomisation took
place following the baseline assessment visit, which occurred either at the time of the patient’s outpatient
preoperative assessment visit or at a ‘separate research visit’ around these routine appointments,
depending on the local hospital set-up.
Participating surgeons were discouraged from changing their routine clinical practice during the course
of the trial.
There was no blinding of trial participants or care providers.
Outcomes
The primary outcome measure for the trial was the OKS completed at 5 years after randomisation.
The OKS is a 12-item patient-reported outcome questionnaire that is specifically designed and
developed to assess function and pain after TKR surgery. Each item on the OKS is scored from 0 to 4,
with 4 representing the best outcome. When the 12 items are summed, an overall score ranging from
0 to 48 is produced, with 48 representing the best outcome. The OKS has been demonstrated to be a
validated and effective measure of change over time for knee replacement patients, with appropriate
psychometric properties.65,66
METHODS
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Secondary outcome measures were used to further assess functional outcome, patient health-related
quality of life, frequency of complications and failure of operation. These were:
l The AKSS67 at 2 months and 1 year post surgery and 5 years post randomisation. This score is
divided into two separate components: (1) clinical assessment (Clinical AKSS – ‘Knee Score’) and
(2) an assessment of an individual’s functionality (Functional AKSS – ‘Function Score’). The Clinical
AKSS evaluates pain (50 points), stability (25 points) and range of motion (25 points). The maximum
score of 100 points is reached when there is no pain, with good alignment of the knee in extension and
at least 125° of range of motion, without any anteroposterior or mediolateral instability. Deductions
are made for flexion contracture, loss of extension and poor alignment. The AKSS Function Score
evaluates walking distance (50 points) and stair climbing ability (50 points). The maximum score of
100 points is attributed to an individual capable of walking unlimited distances without walking aids
and of climbing and descending stairs normally. Deductions are made for the use of crutches or a
walking frame/sticks.68
l The UCLA Activity Score69 at 2 months post surgery and 1–5 years post randomisation. This is a
measurement of activity level in arthroplasty patients who have mid-/lower-level activity. The score
has 10 descriptive activity levels ranging from wholly inactive and dependent on others (level 1), to
moderate activities such as unlimited housework and shopping (level 6), to regular participation in
impact sports such as jogging or tennis (level 10).
l The HAAS70 at 2 months post surgery and 1–5 years post randomisation. This is a measurement
of patient activity and accounts for patients with potentially higher levels of activity. The score is a
four-item self-assessment measure covering four domains of walking, running, stair climbing and
general activities, with a possible score ranging from 0 to 18 points (maximum score 18 points).
l The EuroQol-5 Dimensions, three-level version (EQ-5D-3L),71 at 2 months post surgery and 1–5 years
post randomisation. The EQ-5D-3L is a validated, generic, self-reported outcome measure of health-
related quality of life consisting of a five-dimension health status classification system and a separate
visual analogue scale (VAS). Responses to the health status classification system are used to facilitate
the calculation of quality-adjusted life-years (QALYs) in health economic evaluations. It consists of five
items on mobility, self-care, pain, usual activities and psychological status, with three possible answers
for each item (i.e. 1 = no problem, 2 =moderate problems and 3 = severe problems). Health utilities
or scores are generated from these responses using a validated algorithm.72 They summarise overall
health-related quality of life between 0 (death) and 1 (full health). In addition, health status was also
assessed using the EQ-5D-3L VAS, which requires participants to assess their own health from the
worst imaginable (0) to the best imaginable (100).
l Three self-reported anchor-type questions were also recorded at 2 months post surgery and
1–5 years post randomisation. These asked about satisfaction (the ‘Lund score’, a measure of patient
satisfaction),73 transition in relation to problems compared with an earlier time point, overall health,
transition in relation to overall health compared with the previous year and whether or not the
patient would have the operation again. Anchor-type questions are used in psychometrics and
evaluate the same type of area/domain as the primary outcome variable but have a different style or
format. They are useful to check concordance and, as a question, are often more meaningful to the
patient. The responses are outlined below and were dichotomised (in a prespecified manner) for the
analysis as follows:
¢ How satisfied are you with your knee? (Dissatisfied, uncertain, satisfied, very satisfied.) This was
analysed as a binary outcome of satisfied/very satisfied versus dissatisfied/uncertain.
¢ How are the problems related to your knee now, compared with before your knee surgery?
(No problems at all now, much better, slightly better, no change, slightly worse, much worse.)
This was analysed as a binary outcome of better (no problems at all now, much better, slightly
better) versus not better (no change, slightly worse, much worse).
¢ If you could go back in time, would you still choose to have the knee operation? (Yes, no, not sure.)
This was analysed as a binary outcome of yes (yes) versus no/unsure (no, not sure).
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l Surgical complications – any intraoperative and postoperative complications associated with the
knee replacement (study knee) throughout the study period were collected.
l Hospital length of stay.
l Other health care and patient resource use (e.g. length of hospital stay at time of operation, 2 months
post surgery and 1–5 years post randomisation).
l Reoperation rate following knee replacement surgery, including revision.
l Composite outcome assessment: failure of intervention was assessed using a prespecified composite
outcome assessment. Failure was defined as the patient having any reoperation (including revision)
and/or poor outcome indicated on the OKS. Poor outcome using the OKS was defined as an
improvement in score of < 4 points. The anchor-based minimally important change of the OKS was
used to identify poor outcome (‘lack of success’) for functional outcome.66
l The OKS-APQ adjunct score to the OKS was collected at years 4 and 5 post randomisation. This
eight-item patient-reported outcome measure was developed and validated74 to complement the
OKS as an additional scale for assessing higher levels of activity and (social) participation in patients
following knee replacement. Used in combination with the primary outcome measure, this would
capture additional data regarding patients’ activity and participation levels.
l Radiographic imaging of the knee to assess positioning and radiolucency was carried out
preoperative, immediately postoperatively and at 5 years post randomisation.
Data collection and management
Intraoperative and post-operative data on surgery, knee component used, length of stay, operation
time and complications were collected on a primary procedure hospital form. Postoperative X-rays
were collected immediately postoperatively and at 5 years post randomisation.
Follow-up
Follow-up outcome data were collected via postal questionnaires and clinical assessment visits. The
postal questionnaire [containing OKS, UCLA, HAAS, EuroQol-5 Dimensions (EQ-5D), Lund, health care
and patient resource use) was sent out to participants at 2 months post surgery and 1–5 years post
randomisation. The OKS-APQ was collected at 4 and 5 years post randomisation. The clinical assessment
visit (AKSS, health-care use and X-rays) was carried out at 2 months and at 1 year post surgery and
5 years post randomisation. Outcomes and time points are outlined in Table 2.
In cases where there were > 12 weeks between randomisation and the operation date (as a result of
hospital waiting lists), an additional OKS was administered at the clinical assessment 1 year post surgery.
This additional assessment was included because of the variation in waiting times for surgery at participating
sites. It was possible that some patients would have their 1-year assessment too early in their recovery
for the results to be valid, and the potential variation in follow-up time could cause problems with
interpretation. This was more meaningful when assessing early results (1 year) but is less significant for
the primary outcome at 5 years.
Participants whose questionnaires had not been returned were contacted by the central study teams
based at the Health Services Research Unit, University of Aberdeen, and the Surgical Intervention
Trials Unit (SITU), University of Oxford. In the first instance this was through a reminder letter by post.
If a questionnaire had still not been returned within a specified time frame, participants were offered
the option of completing the questionnaire over the telephone. A number of other initiatives were
taken to promote ongoing interest in, and commitment to, the trial, including participant newsletters
and annual Christmas cards.
METHODS
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Post-surgical complications and adverse events
The trial involved routine knee replacement surgery for OA. Knee replacement surgery was carried out
as per standard management regime and participants were informed of the standard risks associated
with anaesthetic and knee replacement operations.
Adverse events that may have been expected as a potential recognised complication or harm related to
the study treatments were recorded as complications. Adverse events attributed to medical comorbidities
or anaesthesia (part of normal care) were only recorded as complications and were not reported as
serious adverse events. Medical problems or surgery not associated with the study interventions were
not systematically collected or reported. A serious adverse event for TOPKAT was defined as any
untoward medical occurrence that was both unexpected and related to the study treatments that
(1) resulted in death, (2) was life-threatening, (3) required inpatient hospitalisation or prolongation of
existing hospitalisation or (4) resulted in persistent or significant disability/incapacity. Participating sites
were provided with adverse event (reporting) forms to record adverse events and to guide them when
determining whether an event was a serious/non-serious event or should be recorded as a complication.
Data on complications and reoperation were collected from various sources for cross-referencing and to
ensure completeness. Complication data were collected from participants in their follow-up questionnaires
and clinical assessment visits. Annual postal self-report questionnaires asked participants if they had
been admitted to hospital at any point over the last 12 months for any reason related to their study
knee. Any re-admissions were followed up by the trial manager in Oxford, who contacted the research
team at the patient’s hospital to check details on the local hospital system. Once confirmed, the trial
manager would record details on a re-admission operation form.
In addition, at the follow-up clinical visits, participants were asked if they had experienced any
complications related to their study knee since their last visit that had resulted in them visiting a
health-care practitioner.








Baseline 2 1 2 3 4 5
OKS (self-report function) ▲ ○ ○ ○ ○ ○ ○
OKS-APQ (self-report function) ○ ○
AKSS (clinical exam) ▲ ▲ ▲ ▲
UCLA (self-report activity) ▲ ○ ○ ○ ○ ○ ○
HAAS (self-report activity) ▲ ○ ○ ○ ○ ○ ○
Imaging (X-rays) ▲ ▲a ▲
EQ-5D (global heath) ▲ ○ ○ ○ ○ ○ ○
Lund (patient satisfaction) ○ ○ ○ ○ ○ ○
Complications ▲○ ▲○ ○ ○ ○ ▲○
Health care (hospital length of stay and further
operation) and resource use
▲ ○ ○ ○ ○ ○ ○
a Immediately post operation.
▲, clinical outpatient visit; ○, postal questionnaires.
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A final check by local research teams on hospital records was undertaken at 5 years post randomisation
to ensure that complication data were collected from all participants (i.e. those who had not returned a
questionnaire or attended a follow-up visit). Data from any identified re-admission events were recorded
on a re-admission operation form.
Statistical methods and study analysis
The methods outlined here are primarily for clinical effectiveness. The methods for the cost-
effectiveness analysis are included in Chapter 5.
Ground rules for statistical analysis
The trial analysis followed the statistical analysis plan that was agreed in advance by the Trial Steering
Committee (TSC). The main analysis was based on the intention-to-treat (ITT) basis (i.e. analysed as
randomised irrespective of non-compliance). Baseline and follow-up data were summarised using
appropriate descriptive statistics. The analysis was based on all available data and no attempt was
made to impute missing follow-up data; however, for baseline data for continuous variables, data were
imputed using the mean of that variable. Owing to the level of non-compliance with treatment allocation,
complications and further operations were also analysed on a treatment-received basis. This was not
carried out for any other outcomes. The principal set of analyses used data from baseline to 5-year
follow-up. An earlier more restricted in scope set of analyses used 1-year follow-up data. Statistical
significance was at the two-sided 5% level, with corresponding CIs and p-values reported for 1- and
5-year follow-up time points only where applicable (e.g. OKS).
Sample size
The sample size was calculated on both the OKS and the reoperation rate. Detection of change in
reoperation rate of 7% between groups (from 5% to 12%) at 80% power and using a significance level
of p < 0.05 (two-sided) required a sample size of 250 patients per group. A total of 250 patients per
group also provided 90% power to detect a reoperation increase to 14% (difference of 9%). For the
primary end point at 5 years, a sample size of 500 patients (250 in each group) was also required to
identify clinically significant differences in OKS. This sample size allowed detection of a 2.0-point
minimally important difference in OKS with 80% power at 5% (two-sided) significance level using a
standard deviation (SD) of 10.0 points (or equivalently 90% power to detect a 3.0-point change).75
(Note that, at the time of planning, a 2-point difference in OKS was considered the minimally important
difference to detect; however, subsequent research conducted and published after the trial had
commenced now suggests that a 5-point difference in OKS should become the appropriate minimally
important difference in OKS.) This difference of 3.0 points in the OKS is equivalent to a typical category
change in the AKSS.67 The analysis also adjusted for the baseline values (and for the surgical treatment
delivery unit), which would also have increased precision.
Primary/secondary outcome analysis
The primary outcome, OKS for PKR and TKR, was compared at the principal assessment point alone
using linear regression analysis adjusted for minimisation variables (age and sex as continuous and
binary variables, respectively), baseline OKS (as a continuous variable) and cluster robust variance to
account for surgery delivery unit. A secondary analysis using an independent t-test was also calculated.
Under a further planned secondary analysis, a marginal estimate of treatment effect over the whole
5-year period is also presented.
METHODS
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To explore the timing of follow-up for participants who received surgery > 12 weeks post randomisation,
their 1-year post-randomisation OKS was replaced with the 1-year post-surgery OKS in a sensitivity
analysis. A within-person difference was also analysed for participants who had both follow-up scores to
assess the impact of data collection timing.
Any effect of expertise versus equipoise on the treatments was explored using treatment-by-delivery
unit interaction in a planned analysis.
To explore the impact of surgeon experience on the analysis of OKS, the model was extended by
including the number of procedures previously performed by the surgeon in a further analysis (also
adding an additional factor and a treatment-by-experience interaction).76 For surgeons whose baseline
experience data were missing, the median number of procedures by intervention (TKR or PKR) was
imputed.
To assess the impact of compliance (the operation being delivered as intended), instrumental variable
methods were used to estimate the complier-average causal effect (CACE) for the 1 year and 5 years
post-randomisation OKS.
There was concern that the planned analyses may not have been sensitive to a small but consistent
difference over the 5-year period. Therefore, a post hoc analysis of OKS using area under the curve
(AUC), generated for each participant using the trapezoidal rule, was conducted given the findings of
the planned principal and secondary analysis. It was also analysed using linear regression.
For the secondary outcomes, AKSS, UCLA, HAAS, EQ-5D-3L index and VAS, OKS-APQ and overall health
were analysed using linear regression that was adjusted for minimisation variables and baseline score,
and the surgery delivery unit was accounted for using cluster robust variance. The self-reported anchor
questions, hospital length of stay (days in hospital postoperatively), complications and reoperations were
analysed using Poisson regression adjusted for minimisation variables and a cluster robust variance to
account for surgery delivery unit.
Planned subgroup analysis
Subgroup analyses (defined a priori) explored the possible effect modification through the use of
treatment-by-subgroup interactions for the following:
l age (< 55 years, 55–70 years and > 70 years)
l baseline OKS (0–14, 15–21 and 22–48)
l sex.
Independent interpretation of results
Trials are susceptible to interpretation bias, especially if differences are small and investigators have
prior preference for a particular intervention. A summary set of blinded results was sent to a group
of entirely independent and unconnected assessors (trial experts and surgeons) to help interpret the
results and the impact of the trial in an unbiased manner.
The results summary was masked for group identifier (i.e. group 1 and group 2, rather than implant type)
and was sent to six separate reviewers entirely independent of the study. The independent experts were
all familiar with orthopaedics and trial interpretation. They were selected, largely at random, from the
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trials network that David J Beard is involved in (Royal College of Surgeons, Versus Arthritis, National
Institute for Health Research, British Orthopaedic Association). These members were as follows:
l York – Professor David Torgerson – UK Professor of statistics and surgical clinical trials unit
director with substantial orthopaedic trial experience.
l Sydney – Professor Chris Maher – Australian Public Health Professor and Director of the
Institute for Musculoskeletal Health with substantial orthopaedic and musculoskeletal clinical
trials experience.
l Liverpool – Mr Peter Brownson – UK academic shoulder surgeon with an experience and interest in
clinical trials of efficacy.
l Norwich – Professor Simon Donell – UK academic knee surgeon (TSC chairperson) with experience
of both TKR and PKR.
l Swansea – Mr Mark Mullins – UK academic knee surgeon (teaching hospital) with experience of
both TKR and PKR.
l Bristol – Professor Jane Blazeby – UK academic upper gastrointestinal surgeon and surgical clinical
trials unit director with substantial trial interpretation experience.
The chosen members were each sent an e-mail (Box 1) and were asked to comment on the findings
without awareness of grouping.
BOX 1 E-mail sent to the independent experts
I write to request your help and (hopefully) a quick favour, in confidence.
We have now completed the 5 year follow up of the NIHR HTA TOPKAT study comparing Total versus
Partial Knee Arthroplasty. A brief summary of the project is enclosed before the results section.
To ensure appropriate interpretation of the results we have sent a summary of the data/results to a
selection of independent surgical trials or orthopaedic qualified individuals for them to make their own
assessment and interpretation of the data. In this way we hope to reduce or remove bias from any
interpretation.
We would be really grateful if you could spend 15–20 minutes reviewing the data and write in a few short
sentences (like the conclusion of an abstract) what you think the study shows. The main points involve the
primary outcome measure, any important secondary, re-operation and complications, and the health
economic plot at 5 years. Other data is shown but do not feel you have to examine it all.
The groups are anonymised and so the labels for your conclusions will have to refer to Group 1 and Group 2
rather than PKR or TKR. The received interpretations will help us provide an unbiased opinion of the results.
We have included some extra data in appendices but feel free to ignore this if short of time.
We would most appreciate it if you did not share or communicate the results, or even discuss your role in
this exercise. If able to do this task you will be acknowledged on the manuscript when published.
Your time is valuable and I really thank you for your assistance.
Please destroy the PDF when complete.
HTA, Health Technology Assessment; PDF, portable document format.
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A consolidated opinion of these individuals, alongside that of the chief investigator (DB), senior author
(MC) and the statistical team at Aberdeen, was utilised to achieve an unbiased interpretation of the
results and any clinical implications. A summary of the responses from this group of experts is available
on request.
Any investigation team members with strong personal opinion or conflicts of interest, although very
helpful in the setting up of the study in 2008, had little or no part in the conduct of the study or the
interpretation of the results.
Patient and public involvement
A patient representative was an active member of the TSC and, as part of this role, contributed to the
monitoring and supervision of the trial progress.
Ethics approval and monitoring
Favourable ethics opinion for TOPKAT was given by the Oxfordshire Research Ethics Committee (REC)
on 4 September 2009 (REC reference number 09/H0606/88).
Project Management Group
The Project Management Group (PMG) was responsible for the day-to-day management of the trial.
This group was a collaboration between the Oxford and Aberdeen teams, consisting of the chief
investigator, co-investigators, statisticians, trial managers and data co-ordinators.
Trial Steering Committee
The TSC was responsible for monitoring and supervising the progress of TOPKAT. The committee met
10 times between April 2010 and November 2016, at time points agreed by the committee. The TSC
consisted of four independent experts, a lay member, the chief investigator and key members of the
PMG. Membership of the TSC is given in the Acknowledgements section.
Data Monitoring Committee
The Data Monitoring Committee (DMC) was independent of the trial and was tasked with monitoring
ethics, safety and data integrity. The committee met four times between January 2011 and September
2013, at approximately yearly intervals. The trial statistician provided the data and reports requested by
the DMC at each of the meetings. No formal interim analyses were requested by the DMC; interim data
summarised were reviewed by the DMC. Membership of the DMC is given in the Acknowledgements section.
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Chapter 3 Description of the study population
Trial recruitment
In total, 27 sites across the UK recruited 528 participants from 18 January 2010 to 30 September 2013
(Table 3), with the 5-year follow-up ending in September 2018. Three individuals were randomised twice
in error, making a total of 531 randomisations. There were 264 participants randomised to the PKR
group and 264 to the TKR group. Figure 1 shows the trajectory of the number of participants randomised
over the recruitment period.
TABLE 3 Recruitment by site
Site PKR (N= 264), n (%) TKR (N= 264), n (%)
Randomised
(N= 528), n (%)
Musgrave Park Hospital 53 (20.1) 53 (20.1) 106 (20.1)
Great Western Hospital 29 (11.0) 28 (10.6) 57 (10.8)
University Hospital of North Tees 28 (10.6) 26 (9.8) 54 (10.2)
Royal Gwent Hospital 20 (7.6) 22 (8.3) 42 (8.0)
Nuffield Orthopaedic Centre 20 (7.6) 20 (7.6) 40 (7.6)
King’s Mill Hospital 13 (4.9) 13 (4.9) 26 (4.9)
Leicester Royal Infirmarya 12 (4.5) 14 (5.3) 26 (4.9)
Pilgrim Hospitala,b 12 (4.5) 13 (4.9) 25 (4.7)
University Hospital of North Staffordshire 11 (4.2) 13 (4.9) 24 (4.5)
Yeovil District Hospitala 8 (3.0) 8 (3.0) 16 (3.0)
Ipswich Hospitala,b 7 (2.7) 7 (2.7) 14 (2.7)
Chesterfield Royal Hospitala 7 (2.7) 6 (2.3) 13 (2.5)
Lincoln County Hospitala 6 (2.3) 6 (2.3) 12 (2.3)
Royal United Hospital Bath NHS Trust 5 (1.9) 5 (1.9) 10 (1.9)
Harrogate District Hospital 5 (1.9) 5 (1.9) 10 (1.9)
Stepping Hill Hospital 4 (1.5) 5 (1.9) 9 (1.7)
Aberdeen Royal Infirmary 5 (1.9) 4 (1.5) 9 (1.7)
North Bristol NHS Trust 3 (1.1) 4 (1.5) 7 (1.3)
Royal Blackburn Hospital 3 (1.1) 3 (1.1) 6 (1.1)
University Hospital of North Durham 4 (1.5) 2 (0.8) 6 (1.1)
Medway Hospital 3 (1.1) 2 (0.8) 5 (0.9)
Milton Keynes General Hospitala 2 (0.8) 1 (0.4) 3 (0.6)
Southampton General Hospital 1 (0.4) 1 (0.4) 2 (0.4)
Cumberland Infirmary – 2 (0.8) 2 (0.4)
Pindefields Hospitala 1 (0.4) 1 (0.4) 2 (0.4)
Torbay Hospital 1 (0.4) – 1 (0.2)
Hull and East Yorkshire Hospitals NHS Trust 1 (0.4) – 1 (0.2)
a Sites with expertise surgeon pairs who randomised one patient or more.
b These sites each randomised one patient and then changed from participating as an ‘expertise’ to an ‘equipoise’ site
because of local decisions regarding participation.
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Equipoise versus expertise-based randomisation
A total of 68 surgeons were involved with recruitment, of whom 50 surgeons randomised a patient to
the study. Thirty-six surgeons at 23 sites participated as ‘equipoise surgeons’ and randomised 454
participants (227 in each group). Eighteen surgeons at eight sites participated as ‘expertise surgeons’
and randomised 74 participants (37 in each group) (one surgeon in an ‘expertise pair’ did not randomise
a patient). Of these, three surgeons changed from participating as an ‘equipoise’ to an ‘expertise’
surgeon (or the alternative) shortly after starting recruitment because of local decisions regarding
participation. For this reason, these surgeons randomised participants as both ‘equipoise’ and ‘expertise’
surgeons at different time points during the study.
Participant flow
The Consolidated Standards of Reporting Trials (CONSORT) flow diagram is shown in Figure 2. There
were 962 participants assessed for eligibility, of whom 528 were randomised. Three participants were
randomised twice in error (resulting in 531 randomisations). The reasons for exclusion were that
121 individuals did not meet the inclusion criteria and 310 individuals declined to participate.
In the PKR group, all participants completed the baseline assessment, 263 participants received surgery
and one withdrew before surgery. In the TKR group, 251 received surgery, four withdrew before surgery,
one died before surgery and the remaining eight did not receive surgery (further details of treatment
received are provided in Figure 2). At the 5-year follow-up, a total of 467 participants responded to the
questionnaire and 397 attended the clinical assessments. Fifteen (PKR, n = 5; TKR, n = 10) participants
withdrew (i.e. the participant no longer wanted to be in the study from this point forward) and there




















































































































































































































FIGURE 1 Recruitment graph: January 2010 to October 2013.
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Assessed for eligibility
(n = 962) 
Excluded
(n = 431)
• Not meeting inclusion criteria, n = 121
• Declined to participate, n = 310





• Non-completion of OKS
• Component of questionnaire, n = 20
• Withdrawn, n = 5
• Deceased, n = 6
5-year follow-up
• Responded to questionnaire, n = 235
• Non-response to questionnaire, n = 18
• Withdrawn, n = 5




• Responded to questionnaire, n = 232
• Non-response to questionnaire, n = 11
• Withdrawn, n = 10





• Received TKR, n = 238
• Received PKR, n = 13
• Did not receive surgery, n = 8
• Withdrawn before surgery, n = 4
• Died before surgery, n = 1
• Received PKR, n = 232
• Received TKR, n = 31
• Did not receive surgery, n = 0
• Withdrawn before surgery, n = 1
• Died before surgery, n = 0




(n = 33) 
• Non-completion of OKS
• Component of questionnaire, n = 12
• Withdrawn, n = 10
• Deceased, n = 11
Randomised
(n = 531)
Completed baseline assessment 
(n = 531)
• Patient randomised twice (PKR, n = 2;





FIGURE 2 The CONSORT flow diagram.
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Baseline characteristics
Table 4 shows that the baseline characteristics in the two groups were, in general, equally balanced.
The mean age was 65 years, 58% of participants were male and the mean body mass index (BMI)
was 31 kg/m2 in both groups. The time since onset of OA in the study knee was < 3 years for 28% of
participants in both groups, and > 10 years for 14% of participants in the PKR group and for 11% in the
TKR group. The frequency of a previous TKR in the non-study leg was 9% in the PKR group and 5% in the
TKR group, whereas 6% of participants in both groups had previous PKR replacement in the non-study
leg. The mean OKS was 19 points for both groups, and the EQ-5D-3L was 0.428 in the PKR group and
0.381 in the TKR group.
TABLE 4 Baseline characteristics
Characteristic PKR (N= 264) TKR (N= 264)
Age (years), mean (SD); n 65.2 (8.8); 264 64.7 (8.5); 264
Sex, n (%)
Male 153 (58.0) 153 (58.0)
Female 111 (42.0) 111 (42.0)
Study knee, n (%)
Left 140 (53.0) 141 (53.4)
Right 124 (47.0) 123 (46.6)
Time of OA, n (%)
< 3 years 75 (28.4) 73 (27.7)
3–5 years 82 (31.1) 72 (27.3)
6–10 years 59 (22.3) 73 (27.7)
> 10 years 36 (13.6) 30 (11.4)
Missing 12 (4.5) 16 (6.1)
Medical history, n (%)
Other joint problems 106 (40.2) 96 (36.4)
Cardiovascular 80 (30.3) 86 (32.6)
Diabetes 27 (10.2) 26 (9.8)
Gastrointestinal 17 (6.4) 18 (6.8)
Respiratory 19 (7.2) 12 (4.5)
Cancer 6 (2.3) 8 (3.0)
Renal/urological 8 (3.0) 8 (3.0)
Neurological 7 (2.7) 6 (2.3)
Mental health 7 (2.7) 6 (2.3)
Thyroid problems 3 (1.1) 2 (0.8)
Othera 5 (1.9) 4 (1.5)
Employment status, n (%)
Retired 159 (60.2) 162 (61.4)
Not in employment 15 (5.7) 21 (8.0)
In paid employment 82 (31.1) 73 (27.7)
Missing 8 (3.0) 8 (3.0)
BMI (kg/m2), mean (SD); n 31.0 (4.6); 210 31.1 (4.8); 221
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TABLE 4 Baseline characteristics (continued )
Characteristic PKR (N= 264) TKR (N= 264)
Extent of knee arthritis affecting mobility (Charnley ABC), n (%)
Single 99 (37.5) 119 (45.1)
Both 142 (53.8) 121 (45.8)
Multiple 6 (2.3) 11 (4.2)
Missing 17 (6.4) 13 (4.9)
General health, mean (SD); n 2.6 (0.9); 259 2.8 (0.9); 260
General health compared with 1 year ago, mean (SD); n 3.3 (0.8); 259 3.3 (0.8); 260
Previous treatment on study knee, n (%)
Analgesia 207 (78.4) 184 (69.7)
Arthroscopy 44 (16.7) 47 (17.8)
Arthroscopic investigative washout/debridement 44 (16.7) 36 (13.6)
Open/arthroscopic meniscus 33 (12.5) 30 (11.4)
Knee injection: steroid 19 (7.2) 21 (8.0)
Knee injection: viscosupplementation 2 (0.8) 3 (1.1)
Knee injection not stated 4 (1.5) 6 (2.3)
Acupuncture 4 (1.5) 5 (1.9)
Chiropractor/osteopath 1 (0.4) 3 (1.1)
Cartilage implantation 1 (0.4) 2 (0.8)
Anterior cruciate ligament repair 1 (0.4) –
Otherb – 3 (1.2)
None 13 (4.9) 26 (9.8)
Problems with the other knee, n (%)
None 86 (32.6) 99 (37.5)
Mild 93 (35.2) 74 (28.0)
Moderate 63 (23.9) 52 (19.7)
Severe 18 (6.8) 30 (11.4)
Missing 4 (1.5) 9 (3.4)
Contralateral knee, n (%)
TKR 24 (9.1) 14 (5.3)
PKR 16 (6.1) 16 (6.1)
Unsure 1 (0.4) 1 (0.4)
None 208 (78.8) 217 (82.2)
Missing 15 (5.7) 16 (6.1)
OKS, mean (SD); n 18.8 (7.0); 264 19.0 (7.2); 264
HAAS, mean (SD); n 4.8 (2.3); 258 4.6 (2.3); 256
UCLA activity score, mean (SD); n 3.6 (1.5); 260 3.7 (1.5); 260
AKSS: objective, mean (SD); n 41.0 (16.1); 260 42.3 (16.0); 259
AKSS: functional, mean (SD); n 59.3 (15.6); 262 58.7 (15.5); 259
EQ-5D-3L, mean (SD); n 0.428 (0.301); 257 0.381 (0.324); 252
EQ-5D VAS, mean (SD); n 62.8 (27.0); 249 60.7 (28.7); 257
a Other previous medical history included high BMI (n = 2), antiphospholipid syndrome (n = 1), thyroid problems
(n = 5), glaucoma (n = 1), cataracts (n = 1), anaemia (n = 2), appendicectomy and lipoma of intra-abdominal
organs (n= 1).
b Other previous treatment included laser treatment (n = 1), off loader knee brace (n= 1) and aspiration (n = 1).
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Treatment received
Of the 263 participants who had surgery in the PKR group (Table 5), 232 (88%) received their allocated
treatment and 31 (12%) received TKR. For the participants who had a non-allocated trial operation
(‘crossed over’), 25 were intraoperative decisions [pattern of OA not suitable for PKR (n = 20) and anterior
cruciate ligament absent/deterioration (n = 5)] and six were preoperative decisions [pattern of OA not
suitable for PKR (n = 2), patient decision (n = 1), inflammatory arthropathy (not suitable for PKR) (n = 1),
diagnosis (post randomisation) patient not suitable for PKR (although randomised, later found not to
have suitable inclusion criteria, i.e. incorrect diagnosis of medial compartment OA) (n = 1) and error in
communication of randomisation allocation (n = 1)].
TABLE 5 Treatment received
Treatment details PKR (N= 264) TKR (N= 264)
Received surgery, n (%)
Yes 263 (99.6) 251 (95.1)
No 1 (0.4) 13 (4.9)
Received allocated knee replacement surgery, n (%)
Yes 232 (88.2) 238 (94.8)
No 31 (11.8) 13 (5.2)
n= 263 n= 251
Surgical technique (and implant used), n (%)
PKR 232 (88.2) 13 (5.2)
Oxford® Partial Knee (Zimmer Biomet, Warsaw, IN, USA) 150 (64.7) 7 (53.8)
Zimmer (Zimmer Biomet) 36 (15.5) 4 (30.8)
M/G® Unicompartmental Knee System (Zimmer Biomet) 22 (9.5) 1 (7.7)
Uniglide™ (Corin Group, Cirencester, UK) 9 (3.9) –
AMC (Corin Group) 5 (2.2) –
DePuy (DePuy Orthopaedics Inc., Warsaw, IN, USA) 4 (1.7) –
Mathys (Mathys Ltd, Bettlach, Switzerland) 4 (1.7) –
Medacta (Medacta International, Castel San Pietro, Switzerland) 1 (0.4) –
Sigma (DePuy Orthopaedics Inc.) 1 (0.4) –
Vanguard® (Zimmer Biomet) – 1 (7.7)
TKR 31 (11.8) 238 (94.8)
Low Contact Stress (DePuy Orthopaedics Inc.) 10 (32.3) 61 (25.6)
PFC/Sigma (DePuy Orthopaedics Inc.) 3 (9.7) 54 (22.7)
Vanguard (Zimmer Biomet) 3 (9.7) 41 (17.2)
NexGen® (Zimmer Biomet) 8 (25.8) 29 (12.2)
Triathlon® Knee System (Stryker, Mahwah, NJ, USA) 4 (12.9) 27 (11.3)
Genesis (Smith & Nephew, Memphis, TN, USA) 2 (6.5) 7 (2.9)
Scorpio/Kinemax (Stryker) 1 (3.2) 7 (2.9)
ACS® (Implantcast, Buxtehude, Germany) – 6 (2.5)
EUROS (Euros SAS, La Ciotat, France) – 2 (0.8)
AGC (Zimmer Biomet) – 1 (0.4)
AllPoly (Zimmer Biomet) – 1 (0.4)
Oxinium (Smith & Nephew) – 1 (0.4)
Unknown – 1 (0.4)
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Of the 251 participants who received surgery in the TKR group, 238 (95%) received their allocated
treatment and 13 (5%) received PKR. For the 13 participants who crossed over, five were
intraoperative decisions (independent surgeon decision, i.e. all of the eligibility criteria were met but
decision made for PKR) and eight were preoperative decisions [patient decision (n = 5) and error in
communication of randomisation allocation at site (n = 3)]. Ten different PKR implants were used, with
the majority receiving the Oxford mobile bearing implant. For the TKR group, 12 (one was missing)
different implants were used, none of which was used more often than any other (see Table 5).
The median waiting time to surgery was 6 weeks in the PKR group [interquartile range (IQR) 2–14 weeks],
with 85 participants waiting > 12 weeks. For TKR the median waiting time was 4 weeks (IQR 1–11 weeks),
with 53 participants waiting > 12 weeks.
Details of the operation for those who received surgery are shown in Table 6. Three-quarters of the
participants (PKR 73%, TKR 75%) who were operated on were classified as ASA grade 2. The ASA
grade of 17 participants in both groups was classified as grade 3 at the time of operation. Over 90%
of participants in both groups had a straightforward replacement. A mobile bearing device was used
in 63% of the participants in the PKR group compared with 34% of participants in the TKR group.
A fixed bearing was used in 37% of the PKR patients compared with 64% of the TKR patients. For the
remaining participants (PKR 1%, TKR 2%), the implant information was missing. The median operation
time was 68 minutes in the PKR group and 65 minutes in TKR group.
TABLE 6 Operation details
Measure PKR (N= 264) TKR (N= 264)
Received surgery n = 263 n = 251
ASA grade, n (%)
1 46 (17.5) 39 (15.5)
2 192 (73.0) 188 (74.9)
3 17 (6.5) 17 (6.8)
Missing 8 (3.0) 7 (2.8)
Ease of replacement, n (%)
Straightforward 245 (93.2) 236 (94.0)
Difficult 16 (6.1) 14 (5.6)
Missing 2 (0.8) 1 (0.4)
Patella replaced, n (%)
Yes 2 (0.8) 20 (8.0)
No 258 (98.1) 229 (91.2)
Missing 3 (1.1) 2 (0.8)
Bearing, n (%)
Mobile 165 (62.7) 84 (33.5)
Fixed 96 (36.5) 161 (64.1)
Missing 2 (0.8) 6 (2.4)
Size of bearing, mean (SD); n 6.3 (2.9); 250 10.0 (1.7); 235
continued
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TABLE 6 Operation details (continued )
Measure PKR (N= 264) TKR (N= 264)
Cement, n (%)
Palacos 145 (55.1) 137 (54.6)
CMW I 11 (4.2) 18 (7.2)
Optipac 13 (4.9) 11 (4.4)
Smart ser 15 (5.7) 7 (2.8)
Simplex 1 (0.4) 2 (0.8)
None 77 (29.3) 74 (29.5)
Missing 1 (0.4) 2 (0.8)
X-ray performed, n (%)
Yes 2 (0.8) 1 (0.4)
No 253 (96.2) 240 (95.6)
Missing 8 (3.0) 10 (4.0)
Type of anaesthetic, n (%)
Spinal 201 (76.4) 198 (78.9)
Periarticular LA 125 (47.5) 92 (36.7)
Femoral block 68 (25.9) 104 (41.4)
GA 61 (23.2) 66 (26.3)
Sciatic block 15 (5.7) 12 (4.8)
Epidural 7 (2.7) –
Received surgery n = 262 n = 250
Knee structure (ACL), n (%)
Normal 221 (84.0) 197 (78.5)
Mild damage 34 (12.9) 39 (15.5)
Severe damage 2 (0.8) 6 (2.4)
Absent 3 (1.1) 1 (0.4)
Missing 3 (1.1) 8 (3.2)
Knee structure (PFJ), n (%)
Lateral
Normal 214 (81.4) 184 (73.3)
Partial thickness 35 (13.3) 53 (21.2)
Exposed bone 6 (2.3) 6 (2.4)
Missing 8 (3.0) 8 (3.2)
Medial
Normal 146 (55.5) 120 (47.8)
Partial thickness 84 (31.9) 78 (31.1)
Exposed bone 24 (9.1) 46 (18.3)
Missing 9 (3.4) 7 (2.8)
DESCRIPTION OF THE STUDY POPULATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
TABLE 6 Operation details (continued )
Measure PKR (N= 264) TKR (N= 264)
Trochlear
Normal 110 (41.8) 118 (47.0)
Partial thickness 123 (46.8) 105 (41.8)
Exposed bone 22 (8.4) 18 (7.2)
Missing 8 (3.0) 10 (4.0)
Operation time (minutes), median (IQR); n 68.0 (55.0–80.0); 261 65.0 (55.0–80.0); 249
Theatre time (minutes), median (IQR); n 113.0 (95.0–129.0); 260 110.0 (90.0–128.0); 249
ACL, anterior cruciate ligament; GA, general anaesthetic; LA, local anaesthetic; PFJ, patellofemoral joint.
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Chapter 4 Clinical results
Primary outcome: Oxford Knee Score
The mean OKS for patients who were allocated to PKR and TKR at baseline was 18.8 and 19.0 points,
respectively (Table 7). Figures 3a and 3b show the mean (SD) OKS for the post-randomisation time
points, as well as the kernel density plot for the OKS at baseline and 5-year follow-up, respectively.
The OKS was available for 491 participants (93%) at 1 year and for 464 participants (88%) at 5 years.
At 1 year post randomisation, the mean OKS increased to 36.9 in the PKR group and 35.1 in the TKR
group, with evidence of a difference in favour of PKR [mean difference (MD) 1.91, 95% CI 0.20 to
3.62; p = 0.029]. At the further follow-up time points, the mean OKS was higher in the PKR group than
in the TKR group (see Figure 3a) but there was no evidence of a difference for the principal analysis, where
the 5-year estimate was MD 1.04 (95% CI –0.42 to 2.50; p = 0.159). Figure 3c shows the estimated
treatment effect (95% CI) at each follow-up time point. Sensitivity analyses exploring imputation of the
worse case value did not substantially alter the 1- and 5-year OKS findings, except for extreme one-way
assumptions. A planned secondary analysis, an unadjusted analysis using an independent t-test, was
carried out and showed similar results (MD 1.79, 95% CI < 0.01 to 3.58, p = 0.0497 and MD 1.02, 95% CI
–0.86 to 2.91 for 1 and 5 years, respectively), as did the marginal estimate of the treatment effect over the
whole 5-year follow-up from the mixed model, which was 1.39 (95% CI –0.12 to 2.90; p = 0.071). A post
hoc analysis of AUC for participants who had a 5-year follow-up was statistically significant: for the 233
participants in the PKR group the mean was 36.6 (SD 8.3) and for the 231 participants in the TKR group
the mean was 35.1 (SD 9.1) (MD 1.54, 95% CI 0.07 to 3.01; p = 0.040).
Impact of timing of follow-up
As expected in elective surgery in the NHS, there were delays to intervention (surgery) in several patients.
This may have had some impact on the results and was, therefore, explored.
Of the 528 participants randomised, 514 (97.3%) received surgery. In total, 138 out of 514 participants
(26.8%) waited > 12 weeks from randomisation to surgery.
These 138 participants were distributed across the two groups as follows: 85 out of 263 (32.3%)
participants in the PKR group waited more than 12 weeks and 53 out of 251 (21.1%) in the TKR
group waited more than 12 weeks. Figure 4 shows the mean (SD) OKS at baseline, 1 year post
randomisation and post surgery.
TABLE 7 The OKS at each follow-up time point
Time point PKR (N= 264), mean (SD); n TKR (N= 264), mean (SD); n MD 95% CI
Baseline 18.8 (7.0); 264 19.0 (7.2); 264
2 months post surgery 31.1 (9.6); 247 29.4 (9.0); 239 1.81 –0.52 to 4.15
1 year 36.9 (9.9); 247 35.1 (10.3); 244 1.91 0.20 to 3.62
2 years 37.7 (10.3); 240 36.4 (10.4); 238 1.43 –0.23 to 3.10
3 years 38.3 (9.2); 218 36.2 (11.2); 226 2.15 –0.01 to 4.31
4 years 38.5 (9.4); 205 36.7 (10.6); 219 1.78 –0.23 to 3.79
5 years 38.0 (10.1); 233 37.0 (10.6); 231 1.04 –0.42 to 2.50
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FIGURE 3 (a) Mean (SD) OKS by group at each follow-up time point post randomisation; (b) kernel density plot for OKS
at baseline and 5-year follow-up by treatment group; and (c) estimated treatment effect on OKS (95% CI) at each follow-up
time point.
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The MD was 1.91 favouring PKR (95% CI 0.20 to 3.62). Using data from 1 year post surgery for
participants who had a 12-week delay, the MD was slightly lower but still favouring PKR (1.62, 95% CI
–0.17 to 3.41). In the 91 participants with both a 1-year post-randomisation and a 1-year post-surgery
follow-up (53 PKR, 38 TKR), the within-participant difference was –1.61 (95% CI –3.47 to 0.24),
showing an improvement at the later time point but with uncertainty.
Any delay to surgery was thus considered to have minimal impact on the results.
Surgeon experience
The experience of the surgeon (as defined by the number of procedures of each operation type
performed prior to the study) may have had an effect on the results and was, therefore, explored.
The median (IQR) number of procedures completed by surgeons for participants undergoing PKR at
baseline was 100 procedures (50–200 procedures), and for those undergoing TKR was 300 procedures
(260–400 procedures). Table 8 shows the standard OKS model that was used previously and also
an extended model that adjusts for the number of procedures performed by each surgeon (as a proxy
TABLE 8 Impact of surgeon experience or clustering by surgeon on OKS
Model
Treatment difference




Standard OKS model 1.91 (0.20 to 3.62)
Model extended to adjust
for surgeon experience
3.10 (1.34 to 4.86) 0.0004 (0.0002 to 00006) –0.0030 (–0.0056 to –0.0004)
5 years
Standard OKS model 1.04 (–0.42 to 2.50)
Model extended to adjust
for surgeon experience

















FIGURE 4 Mean (SD) OKS by group at baseline and 1 year post randomisation and post surgery, and effect estimates.
Post-randomisation difference 1.91 (95% CI 0.20 to 3.62; p = 0.029). Post-surgery difference 1.62 (95% CI –0.17 to 3.41;
p = 0.074). Within-person difference –1.61 (95% CI –3.47 to –0.24; p = 0.084).
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of experience, including within-trial experience). There was statistical evidence for an improvement in
OKS outcome with an increased number of procedures performed at 1 year, which is indicated by the
non-zero ‘learning effect’. This was not the case for the equivalent 5-year post-randomisation OKS
analysis. There was, however, evidence of a differential learning effect by treatment group (as shown by
the significant interaction terms) for the analysis of the 1-year OKS, although the impact that this had
on the predicted level and the treatment difference was small.
Surgeon expertise
Figure 5 shows the differences between ‘expertise pair’ and ‘equipoise surgeons’ at the different follow-up
time points. At the 5-year analysis, there was no evidence of a difference between the surgeon groupings
(interaction effect –1.31, 95% CI –5.34 to 2.73; p = 0.518).
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FIGURE 5 Summary plots to compare expertise with equipoise randomisation (surgeon groups) and other subgroup
analysis (age, sex and baseline OKS) in primary outcome OKS for PKR versus TKR (a) 2 months post surgery; (b) 1 year
post randomisation; (c) 2 years post randomisation; (d) 3 years post randomisation; (e) 4 years post randomisation; and
(f) 5 years post randomisation. (continued )
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FIGURE 5 Summary plots to compare expertise with equipoise randomisation (surgeon groups) and other subgroup
analysis (age, sex and baseline OKS) in primary outcome OKS for PKR versus TKR (a) 2 months post surgery; (b) 1 year
post randomisation; (c) 2 years post randomisation; (d) 3 years post randomisation; (e) 4 years post randomisation; and
(f) 5 years post randomisation. (continued )
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Subgroup analysis
Age, baseline OKS and sex were all considered a priori to have some potential effect on the final outcome.
Figure 5 also shows the prespecified subgroup analyses for OKS, age (< 55, 55–70 or > 70 years), baseline
OKS (0–14, 15–21 or 22–48) and sex (male or female). There was no clear evidence that sex, baseline
OKS or age modified the treatment effect. The only apparent moderating effect of age at 4-year follow-up
is most likely a statistical artefact, given the number of tests and the pattern of age by treatment
interactions at other time points.
Compliance with treatment allocation
Not all patients allocated to the specific treatment type underwent their allocated treatment. Among
the 262 participants who had been allocated to the PKR group and underwent surgery, 232 received a
PKR and 31 received a TKR. In the TKR group, 251 participants were allocated to TKR and underwent
surgery and, of these, 238 received a TKR and 13 received a PKR. Treatment effects from a CACE analysis
for OKS at 1 year showed evidence of a difference in favour of PKR (MD 1.97, 95% CI 0.11 to 3.83;
p = 0.038). At 5 years there was no evidence of a difference between groups (MD 0.86, 95% CI –0.62 to
2.34; p= 0.254).
Secondary outcomes
All of the secondary outcomes are shown in Table 9.
American Knee Society Score
There was no difference in the baseline mean clinical AKSS (PKR 41.0 vs. TKR 42.3) or functional AKSS
(PKR 59.3 vs. TKR 58.7). At 1 year, there was evidence of a difference in favour of PKR for clinical AKSS
(1 year: 3.07, 95% CI 0.57 to 5.56; p = 0.027). There was no difference at 5 years (MD –0.89, 95% CI
–5.18 to 3.41; p = 0.678). For functional AKSS, there was no evidence of a difference at 1 year
(MD 1.79, 95% CI –0.85 to 4.43; p = 0.179) or at 5 years (MD 0.37, 95% CI –3.81 to 4.55; p = 0.859).
(f)
Favours TKR Favours PKR
Interaction (95% CI); p-value
–1.31 (–5.34 to 2.73); 0.518
–3.29 (–11.82 to 5.24); 0.440
–3.49 (–9.09 to 2.12); 0.216
0.35 (–2.52 to 3.21); 0.808
0.83 (–6.11 to 7.78); 0.809
0.59 (–5.87 to 7.05); 0.854




















FIGURE 5 Summary plots to compare expertise with equipoise randomisation (surgeon groups) and other subgroup
analysis (age, sex and baseline OKS) in primary outcome OKS for PKR versus TKR (a) 2 months post surgery; (b) 1 year
post randomisation; (c) 2 years post randomisation; (d) 3 years post randomisation; (e) 4 years post randomisation; and
(f) 5 years post randomisation.
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TABLE 9 Secondary outcomes
Measure PKR (N= 264) TKR (N= 264) Estimatea 95% CI
AKSS Knee Score, mean (SD); n
Baseline 41.0 (16.1); 260 42.3 (16.0); 259
2 months 78.2 (16.8); 249 74.4 (18.1); 237 3.66 0.44 to 6.87
1 year 86.0 (16.1); 228 83.0 (16.5); 229 3.07 0.57 to 5.56
5 years 85.8 (16.6); 191 86.6 (16.4); 185 –0.89 –5.18 to 3.41
AKSS Function Score, mean (SD); n
Baseline 59.3 (15.6); 262 58.7 (15.5); 259
2 months 73.7 (18.0); 251 69.9 (17.8); 241 3.47 1.02 to 5.93
1 year 84.2 (18.0); 232 82.1 (18.2); 237 1.79 –0.85 to 4.43
5 years 82.6 (18.5); 195 81.7 (19.0); 192 0.37 –3.81 to 4.55
UCLA, mean (SD); n
Baseline 3.6 (1.5); 260 3.7 (1.5); 260
2 months 4.3 (1.6); 239 4.0 (1.3); 235 0.29 0.07 to 0.51
1 year 5.1 (1.8); 238 4.8 (1.8); 232 0.26 –0.09 to 0.61
2 years 5.1 (1.9); 235 4.8 (1.8); 232 0.23 –0.03 to 0.50
3 years 5.0 (2.0); 215 4.8 (1.9); 221 0.19 –0.12 to 0.50
4 years 5.2 (1.8); 204 5.0 (1.9); 211 0.21 –0.13 to 0.56
5 years 5.0 (1.9); 221 4.9 (2.0); 215 0.17 –0.09 to 0.43
HAAS, mean (SD); n
Baseline 4.8 (2.3); 258 4.6 (2.3); 256
2 months 6.4 (2.9); 233 5.7 (2.4); 223 0.60 0.10 to 1.10
1 year 8.0 (3.2); 228 7.6 (3.1); 228 0.35 –0.15 to 0.84
2 years 8.3 (3.3); 227 7.5 (3.4); 226 0.71 0.29 to 1.14
3 years 8.1 (3.4); 209 7.8 (3.5); 216 0.20 –0.40 to 0.79
4 years 7.9 (3.4); 199 7.8 (3.5); 203 0.09 –0.52 to 0.70
5 years 7.9 (3.5); 218 7.6 (3.4); 207 0.22 –0.24 to 0.67
EQ-5D-3L, mean (SD); n
Baseline 0.428 (0.301); 257 0.381 (0.324); 252
2 months 0.689 (0.243); 238 0.664 (0.226); 235 0.022 –0.019 to 0.063
1 year 0.766 (0.241); 240 0.723 (0.260); 232 0.038 –0.003 to 0.079
2 years 0.775 (0.261); 234 0.719 (0.282); 238 0.051 –0.007 to 0.110
3 years 0.771 (0.249); 214 0.729 (0.289); 220 0.034 –0.026 to 0.094
4 years 0.770 (0.251); 205 0.719 (0.301); 214 0.043 0.003 to 0.084
5 years 0.744 (0.293); 224 0.717 (0.318); 212 0.018 –0.033 to 0.069
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TABLE 9 Secondary outcomes (continued )
Measure PKR (N= 264) TKR (N= 264) Estimatea 95% CI
EQ-5D VAS, mean (SD); n
Baseline 62.8 (27.0); 249 60.7 (28.7); 257
2 months 75.2 (16.1); 241 74.1 (16.2); 236 0.91 –3.16 to 4.98
1 year 76.4 (17.0); 239 75.5 (16.0); 236 0.69 –1.71 to 3.09
2 years 76.4 (16.4); 233 74.3 (16.6); 233 1.81 –0.91 to 4.53
3 years 76.1 (16.1); 217 73.2 (16.9); 222 2.37 –0.55 to 5.29
4 years 75.1 (16.3); 208 72.6 (18.0); 216 2.12 –0.11 to 4.35
5 years 75.4 (16.5); 228 71.1 (19.7); 217 4.02 1.36 to 6.67
Composite outcome: failure, n (%)
1 year 26 (9.9) 37 (14.0) 0.70 0.45 to 1.08
5 years 28 (10.6) 38 (14.4) 0.74 0.51 to 1.08
OKS-APQ
4 years 58.5 (31.7); 205 53.2 (33.2); 211 5.52 –1.34 to 12.38
5 years 56.7 (31.8); 221 55.5 (33.5); 216 1.00 –3.50 to 5.50
Overall health now
Baseline 2.6 (0.9); 259 2.8 (0.9); 260
2 months 2.7 (0.8); 243 2.7 (0.8); 235 –0.01 –0.15 to 0.13
1 year 2.8 (0.9); 244 2.7 (0.9); 238 0.12 0.02 to 0.22
2 years 2.8 (0.9); 237 2.8 (1.0); 235 0.06 –0.11 to 0.24
3 years 2.7 (0.9); 217 2.8 (1.0); 226 0.02 –0.16 to 0.19
4 years 2.8 (0.9); 208 2.9 (1.0); 217 0.03 –0.11 to 0.16
5 years 2.9 (0.9); 226 2.9 (1.0); 220 0.01 –0.21 to 0.24
Overall health now compared with 1 year ago
Baseline 3.3 (0.8); 259 3.3 (0.8); 260
2 months 2.4 (0.9); 243 2.6 (0.9); 235 –0.13 –0.32 to 0.06
1 year 2.2 (1.1); 244 2.3 (1.0); 238 –0.13 –0.33 to 0.07
2 years 2.6 (1.0); 237 2.6 (0.9); 234 –0.04 –0.19 to 0.10
3 years 2.8 (0.8); 217 3.0 (0.8); 225 –0.16 –0.29 to -0.0
4 years 2.9 (0.8); 209 2.9 (0.8); 216 –0.00 –0.12 to 0.12
5 years 3.0 (0.8); 226 3.0 (0.7); 219 –0.02 –0.19 to 0.16
Satisfied with knee, n/N (%)
2 months 184/245 (75.1) 169/236 (71.6) 1.05 0.93 to 1.18
1 year 195/243 (80.2) 173/237 (73.0) 1.10 1.00 to 1.22
2 years 197/236 (83.5) 173/229 (75.5) 1.11 1.02 to 1.20
3 years 182/217 (83.9) 172/222 (77.5) 1.08 0.99 to 1.18
4 years 169/204 (82.8) 164/213 (77.0) 1.08 0.99 to 1.17
5 years 190/233 (81.5) 173/225 (76.9) 1.06 0.99 to 1.13
Received surgery n= 262 n = 250
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University of California, Los Angeles, score
The baseline mean UCLA score for PKR and TKR was 3.6 and 3.7, respectively. At the later follow-up
time points this increased but there was no evidence of a difference between groups at 1 year
(MD 0.26, 95% CI –0.09 to 0.61; p = 0.140) or at 5 years (MD 0.17, 95% CI –0.009 to 0.43; p = 0.188).
High Activity Arthroplasty Score
The baseline mean HAAS for PKR and TKR was 4.8 and 4.6, respectively. At 1 year the HAAS MD
was 0.35 (95% CI –0.15 to 0.84; p = 0.163) and at 5 years the MD was 0.22 (95% CI –0.24 to 0.67;
p = 0.334). The scores at both time points show that there is no evidence of a difference between groups.
EuroQol-5 Dimensions, three-level version
The mean baseline score for EQ-5D-3L was 0.428 in the PKR group and 0.381 in the TKR group. At
both 1 year (MD 0.038, 95% CI –0.003 to 0.079; p = 0.066) and 5 years (MD 0.018, 95% CI –0.033 to
0.069; p = 0.478) there was no evidence of a difference between PKR and TKR. Sensitivity analyses
assuming worst case findings did not alter the results.
TABLE 9 Secondary outcomes (continued )
Measure PKR (N= 264) TKR (N= 264) Estimatea 95% CI
Problems with knee better now compared with before surgery, n/N (%)
2 months 217/245 (88.6) 202/235 (86.0) 1.03 0.95 to 1.12
1 year 225/244 (92.2) 207/236 (87.7) 1.05 1.01 to 1.10
2 years 224/236 (94.9) 200/226 (88.5) 1.07 1.03 to 1.12
3 years 206/218 (94.5) 192/222 (86.5) 1.09 1.03 to 1.16
4 years 195/207 (94.2) 191/210 (91.0) 1.04 0.99 to 1.09
5 years 219/230 (95.2) 200/222 (90.1) 1.06 1.01 to 1.11
Still would choose to have a knee operation, n/N (%)
2 months 206/245 (84.1) 185/236 (78.4) 1.07 0.97 to 1.19
1 year 213/240 (88.8) 177/230 (77.0) 1.16 1.06 to 1.26
2 years 207/236 (87.7) 181/225 (80.4) 1.09 1.04 to 1.16
3 years 195/213 (91.5) 177/219 (80.8) 1.13 1.05 to 1.22
4 years 190/206 (92.2) 177/210 (84.3) 1.09 1.02 to 1.18
5 years 208/228 (91.2) 183/217 (84.3) 1.08 1.02 to 1.15
Length of hospital stay (days)
Mean (SD); n 3.3 (1.5); 263 4.3 (3.7); 249
Median (IQR) 3.0 (2.0–4.0) 4.0 (3.0–5.0) 0.77 0.66 to 0.90
a MD for continuous variables and risk ratios for dichotomous variables.
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EuroQol-5 Dimensions Visual Analogue Scale
The mean baseline score for EQ-5D VAS was 62.8 in the PKR group and 60.7 in the TKR group.
At 1 year the MD was 0.69 (95% CI –1.71 to 3.09; p = 0.56), but at the 5-year follow-up there was
evidence of a difference in favour of PKR (MD 4.02, 95% CI 1.36 to 6.67; p = 0.004).
Failure
Failure is a composite outcome and reflects both an incidence of reoperation or revision surgery and
a low level (or no) post-operation improvement, as defined by OKS (< 4-point improvement from
baseline). At 1 year there were 26 (9.9%) failures in the PKR group and 37 (14.0%) in the TKR group,
but there was no evidence of a difference [rate ratio (RR) 0.70, 95% CI 0.45 to 1.08; p = 0.104];
the results were similar at 5 years (RR 0.74, 95% CI 0.51 to 1.08; p = 0.118).
Oxford Knee Score-Activity Participation Questionnaire
At 5 years, the mean OKS-APQ score was 56.7 in the PKR group and 55.5 in the TKR group, with no
evidence of a difference (MD 1.00, 95% CI –3.50 to 5.50; p = 0.656).
Overall health now
The mean baseline overall health now was 2.6 in the PKR group and 2.8 in the TKR group. These
figures slightly increased and there was evidence of a difference at only 1 year in favour of PKR (MD
0.12, 95% CI 0.02 to 0.22; p = 0.023). At 5 years, the MD was 0.01 (95% CI –0.21 to 0.24; p = 0.895).
Overall health now compared with 1 year ago
The mean baseline score was the same in both groups (3.3 points). These figures decreased at the
follow-up time points and there was no evidence of a difference at any time point. At 1 year the MD
was –0.13 (95% CI –0.33 to 0.07; p = 0.190) and at 5 years the MD was –0.02 (95% CI –0.19 to 0.16;
p = 0.833).
Self-reported anchor questions
The Lund Score73 was used to assess patient satisfaction. For ‘How satisfied are you with your knee?’,
there was no evidence of a difference at 1 year (RR 1.10, 95% CI 1.00 to 1.22; p = 0.059) or at 5 years
(RR 1.06, 95% CI 0.99 to 1.13; p = 0.097).
There were differences in how the two groups answered the question ‘How are the problems related
to your knee now, compared with before your knee surgery?’. Among participants who received
surgery, 92.2% in the PKR group and 87.7% in the TKR group reported that the problems related to
their knee were better now than before surgery at 1 year, with evidence of a difference in favour of
PKR (RR 1.05, 95% CI 1.01 to 1.10; p = 0.021). At 5 years the results were similar (RR 1.06, 95% CI
1.01 to 1.11; p = 0.016).
Similarly, differences existed for the question ‘If you could go back in time, would you still choose to
have the knee operation?’. At 1 year, 88.8% of participants who had a PKR would choose to have the
operation again, whereas only 77.0% of participants who had a TKR would have the operation again.
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Therefore, at 1 year there is evidence of a difference in favour of PKR and there was a similar result at
5 years (RR 1.08, 95% CI 1.02 to 1.15; p = 0.010).
Although these patient-reported outcome findings are important, they should not be overemphasised
as they could be chance findings and are susceptible to bias from lack of blinding.
Length of hospital stay
The mean number of days spent in hospital by treatment allocation was 3.3 days for the PKR group
and 4.3 days for the TKR group, with evidence of a difference in favour of PKR [incidence rate ratio
(IRR) 0.77, 95% CI 0.66 to 0.90; p = 0.001]. For treatment received, the results were similar (IRR 0.74,
95% CI 0.63 to 0.87; p = < 0.001).
Complications, reoperation and revision
Complications, reoperations and revisions are reported both per allocation and per treatment received
(for completeness). Per treatment received analyses are considered more meaningful from a surgical
perspective for these particular data. For the low frequency (but critical) complication and revision data,
it would be highly misleading to state that a TKR had failed or has been revised when the primary
implant was actually a PKR, and vice versa.
Complications
By allocation
During the 5-year follow-up, 19% (50/263) of the PKR group and 28.3% (71/251) of the TKR group had
a complication (Table 10; RR 0.67, 95% CI 0.51 to 0.88; p = 0.004). Four participants (and complications)
(1.5%) in the PKR group and eight participants (3.2%) in the TKR group were re-admissions requiring
medical treatment only. There were 14 participants in the PKR group (5.3%) who required re-admission
and further surgery (21 separate events). There were 22 participants in the TKR group (8.7%) who
required re-admission and further surgery (32 separate events). The main reasons for the complication
were unexplained pain (PKR, n = 6; TKR, n = 11), knee stiffness (PKR, n = 1; TKR, n = 9) and unexplained
pain as well as knee stiffness (PKR, n = 1; TKR, n = 6).
TABLE 10 Complications at 5 years by allocation
Measure
PKR (N= 263),a
number of events (%)
TKR (N= 251),a
number of events (%)
Number of participants with a complication
(RR 0.67, 95% CI 0.51 to 0.88)
50 (19.0) 71 (28.3)
Total number of complications 79 111
Details of complications, related to primary operation
Intra-operative
Number of participants (and complications) – 3 (1.2)
Blood transfusion – 2
Medical reasons – 1
continued
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TABLE 10 Complications at 5 years by allocation (continued )
Measure
PKR (N= 263),a
number of events (%)
TKR (N= 251),a
number of events (%)
Postoperative
Number of participants (and complications) 10 (3.8) 19 (7.6)
Blood transfusions – 6
Respiratory problems 2 4
Renal and urological problems 3 2
Miscellaneous 2 3
Treated DVT or PE 2 1
Cardiac problems – 2
Treated DVT or PE/cardiac problems – 1
Anaesthetic problems 1 –
Required re-admission
Required medical treatment only
Number of participants (and complications) 4 (1.5) 8 (3.2)
Unexplained pain 1 3
Bearing dislocation 1 –
Wound breakdown – 2
Bronchopneumonia – 1
Cardiac problems – 1
Cellulitis 1 –
Treated DVT or PE – 1
Superficial infection 1 –
Required surgery
Number of participants 14 (5.3) 22 (8.7)
Number of complications 21 32
Unexplained pain 6 11
Knee stiffness 1 9
Bearing dislocation 4 –
Device loosening (tibia) 1 1
Infection 1 1
Ligamentous instability 1 1
Pain from trauma – 1
Periprosthetic fracture 1 –
Unexplained pain and knee stiffness 1 6
Mechanical failure and infection – 1
Unexplained pain and swelling 1 –
Unexplained pain and skin complication 1 –
Unexplained pain and bearing dislocation 1 –
Device loosening (tibia) and renal/urological problems 1 –
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TABLE 10 Complications at 5 years by allocation (continued )
Measure
PKR (N= 263),a
number of events (%)
TKR (N= 251),a
number of events (%)
Bearing dislocation and renal/urological problems 1 –
Unknown – 1
Re-admission further surgery intra-operative
Number of participants (and complications) – 1 (0.4)
Medical reasons – 1
Re-admission further surgery postoperative
Number of participants 3 (1.1) –
Number of events 4 –
Blood transfusion 1 –
Renal and urological problems 1 –
Skin complications 1 –
Bearing dislocation, renal/urological problems and blood
transfusion
1 –
Did not require re-admission
2-month follow-up
Number of participants 7 (2.7) 13 (5.2)
Number of events 9 14
Wound infection 3 6
Unexplained pain 2 1
Wound breakdown 1 2
Swelling 1 2
Miscellaneous – 2
Knee stiffness 1 1
Skin complication 1 –
1-year follow-up
Number of participants 14 (5.3) 17 (6.8)
Number of events 16 20
Unexplained pain 9 11
Knee stiffness 1 5
Swelling 3 1
Instability 1 1
Wound infection 1 –
Periprosthetic fracture – 1
Miscellaneous 1 –
Skin complication – 1
5-year follow-up
Number of participants 14 (5.3) 14 (5.6)
Number of events 15 14
continued
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By treatment received
Table 11 shows the complications by the treatment received. During the 5-year follow-up, 19.6%
(48/245) of the PKR group and 27.1% (73/269) of the TKR group had a complication (RR 0.72, 95% CI
0.53 to 0.98; p= 0.036). The number of participants (and complications) who were re-admissions requiring
medical treatment only was three (1.2%) in the PKR group and nine (3.3%) in the TKR group. There were
15 (6.1%) PKR participants who required re-admission and further surgery (25 separate events). There
were 21 (7.8%) participants in the TKR group who required re-admission and further surgery (28 separate
events). The main reasons for the complications were unexplained pain (PKR, n= 9; TKR, n = 8), knee
stiffness (PKR, n= 0; TKR, n = 10) and unexplained pain as well as knee stiffness (PKR, n= 1; TKR, n= 6).
Suspected complications (i.e. adverse medical events) that were thought to be related to the study but
were found to be false positives were also documented. These are listed in Appendix 3, Table 28.
TABLE 10 Complications at 5 years by allocation (continued )
Measure
PKR (N= 263),a
number of events (%)
TKR (N= 251),a
number of events (%)
Unexplained pain 12 8
Knee stiffness 1 1
Medical reasons – 2
Miscellaneous 1 1
Wound infection – 1
Wound infection – 1
Ligamentous instability 1 –
DVT, deep-vein thrombosis; PE, pulmonary embolus.
a Number of participants who received surgery.
TABLE 11 Complications at 5 years by treatment received
Measure
PKR (N= 245),a
number of events (%)
TKR (N= 269),a
number of events (%)
Number of participants with a complication
(RR 0.72, 95% CI 0.53 to 0.98)
48 (19.6) 73 (27.1)
Total number of complications 76 114
Details of complications, related to primary operation
Intra-operative
Number of participants (and complications) 1 (0.4) 2 (0.7)
Blood transfusion – 2
Medical reasons 1 –
Postoperative
Number of participants (and complications) 10 (4.1) 19 (7.1)
Blood transfusion – 6
Respiratory problems 3 3
Renal and urological problems 2 3
Miscellaneous 2 3
Treated DVT or PE 2 1
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TABLE 11 Complications at 5 years by treatment received (continued )
Measure
PKR (N= 245),a
number of events (%)
TKR (N= 269),a
number of events (%)
Cardiac problems – 2
Treated DVT or PE/cardiac problems – 1
Anaesthetic problems 1 –
Required re-admission
Required medical treatment only
Number of participants (and complications) 3 (1.2) 9 (3.3)
Unexplained pain 1 3
Bearing dislocation 1 –
Wound breakdown – 2
Bronchopneumonia – 1
Cardiac problems – 1
Cellulitis – 1
Treated DVT or PE – 1
Superficial infection 1 –
Required surgery
Number of participants 15 (6.1) 21 (7.8)
Number of complications 25 28
Unexplained pain 9 8
Knee stiffness – 10
Bearing dislocation 4 –
Device loosening (tibia) 2 –
Infection 1 1
Ligamentous instability 1 1
Pain from trauma 1 –
Periprosthetic fracture 1 –
Unexplained pain and knee stiffness 1 6
Mechanical failure and infection – 1
Unexplained pain and swelling 1 –
Unexplained pain and skin complication 1 –
Unexplained pain and bearing dislocation 1 –
Device loosening (tibia) and renal/urological problems 1 –
Bearing dislocation and renal/urological problems 1 –
Unknown – 1
Re-admission further surgery intra-operative
Number of participants (and complications) – 1
Medical reasons – 1
Re-admission further surgery postoperative
Number of participants 3 (1.2) –
continued
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TABLE 11 Complications at 5 years by treatment received (continued )
Measure
PKR (N= 245),a
number of events (%)
TKR (N= 269),a
number of events (%)
Number of events 4 –
Blood transfusion 1 –
Renal and urological problems 1 –
Skin complications 1 –
Bearing dislocation, renal/urological problems and blood
transfusion
1 –
Did not require re-admission
2-month follow-up
Number of participants 5 (2.0) 15 (5.6)
Number of events 5 18
Wound infection 3 6
Unexplained pain 1 2
Wound breakdown – 3
Swelling – 3
Miscellaneous – 2
Knee stiffness – 2
Skin complication 1 –
1-year follow-up
Number of participants 13 (5.3) 18 (6.7)
Number of events 15 21
Unexplained pain 8 12
Knee stiffness 1 5
Swelling 3 1
Instability 1 1
Wound infection 1 –
Periprosthetic fracture – 1
Miscellaneous 1 –
Skin complication – 1
5-year follow-up
Number of participants 12 (4.9) 16 (5.9)
Number of events 13 16
Unexplained pain 10 10
Knee stiffness 1 1
Medical reasons – 2
Miscellaneous 1 1
Wound infection – 1
Wound infection – 1
Ligamentous instability 1 –
DVT, deep-vein thrombosis; PE, pulmonary embolus.
a Number of participants who received surgery.
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Among those who had surgery, 5.3% (14/263) had a reoperation in the PKR group and 8.8% (22/251)
had a reoperation in the TKR group (RR 0.60, 95% CI 0.30 to 1.19; p = 0.143) (Table 12). One additional
participant had a reoperation, but this event was a result of trauma and, therefore, was not related to
the trial, so is not included in the table. The number of revisions was eight (3.0%) in the PKR group and
12 (4.8%) in the TKR group, with the reason mainly being unexplained pain (PKR, n = 1; TKR, n = 6) or
bearing dislocation (PKR, n = 3; TKR, n = 0).
TABLE 12 Reoperations at 5 years by allocation
Measure
PKR (N= 263),a
number of events (%)
TKR (N= 251),a
number of events (%)
Number of participants having a reoperation
(RR 0.60, 95% CI 0.30 to 1.19)
14 (5.3) 22 (8.8)
Total number of reoperations 18 32
Number of participants who had a revision, n (%) 8 (3.0) 12 (4.8)
Reasons for revisions
Unexplained pain 1 6
Bearing dislocation 3 –
Device loosening (tibia) 1 1
Bearing dislocation and unexplained pain 1 –
Ligamentous instability 1 –
Infection 1 –
Infection and mechanical failure – 1
Unknown – 2
Knee stiffness and unexplained pain – 1
Ligamentous instability and malalignment – 1
Number of other procedures 10 20




Arthroscopy and debridement/exploration/washout 1 1
Debridement/exploration/washout – 2
Open reduction and internal fixation of avulsion fracture
(tibial tuberosity)
1 –
MUA and marcaine injection 1 –
Marcaine injection, MUA and ROM achieved, without
manipulation
– 1
Arthroscopy and MUA – 1
Arthroscopy and biopsy – 1
Arthroscopy and partial medial meniscectomy – 1
MUA, manipulation under anaesthetic; ROM, range of motion.
a Number of participants who received surgery.
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By treatment received
For those that had surgery, 6.1% (15/245) of participants who underwent PKR had a reoperation and
7.8% (21/269) of participants who underwent TKR had a reoperation (RR 0.75, 95% CI 0.37, 1.53;
p = 0.432) (see Table 13). The number of revision operations after PKR was 10 (4.1%) and after TKR
was eight (3.0%), with the reason for revision mainly being a result of unexplained pain (PKR, n = 2;
TKR, n = 5) or bearing dislocation (PKR, n = 3; TKR, n = 0). Table 13 shows the reoperations by
treatment received.
TABLE 13 Reoperations at 5 years by treatment received
Measure
PKR (N= 245),a
number of events (%)
TKR (N= 269),a
number of events (%)
Number of participants having a reoperation
(RR 0.75, 95% CI 0.37 to 1.53)
15 (6.1) 21 (7.8)
Total number of reoperations 22 28
Number of participants who had a revision, n (%) 10 (4.1) 10 (4.0)
Reasons for revisions
Unexplained pain 2 5
Bearing dislocation 3 –
Device loosening (tibia) 2 –
Bearing dislocation and unexplained pain 1 –
Ligamentous instability 1 –
Infection 1 –
Infection and mechanical failure – 1
Unknown – 2
Knee stiffness and unexplained pain – 1
Ligamentous instability and malalignment – 1
Number of other procedures 12 18




Arthroscopy and debridement/exploration/washout 1 1
Debridement/exploration/washout 2 –
Open reduction and internal fixation of avulsion fracture
(tibial tuberosity)
1 –
Marcaine injection, MUA and ROM achieved without
manipulation
1 –
MUA and marcaine injection 1 –
Arthroscopy and MUA – 1
Arthroscopy and biopsy – 1
Arthroscopy and partial medial meniscectomy – 1
MUA, manipulation under anaesthetic; ROM, range of motion.
a Number of participants who received surgery.
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Mortality
During the 5-year follow-up there were a total of 17 deaths [PKR, n = 6 (2.3%); TKR, n = 11 (4.2%)]
(Table 14). The main cause of death was cancer (PKR, n = 4; TKR, n = 6) and there were two deaths in
each group the cause of which was unknown.
Radiographic imaging of the knee
Although at the start of the trial we had anticipated that routine 5-year follow-up radiological data
might provide insight into the failure mechanism, the differences in clinical practice across sites
resulted in these data being insufficiently complete and reliable. The low rate of implant failure
observed in both groups also contributes to the limitation of interpreting these data. This issue is also
discussed in Chapter 6, Limitations.
Summary
To our knowledge, TOPKAT is by far the largest RCT comparing TKR with PKR. In addition, we had
very good retention up to 5 years post randomisation. A hybrid design was used to allow surgeons to
deliver either both procedures or only the surgery of their stated preference and expertise. Minimum
criteria were applied to participating surgeons for both procedures to ensure generalisability, and the
data collected suggest that they are an experienced group of surgeons (although more experienced in
TKR than PKR given that the latter is a less common operation).
We found no difference in the primary outcome of OKS at 5 years, despite finding a statistically
significant, albeit small, difference at 1 year. Secondary and sensitivity analyses provided similar
findings, but one post hoc AUC analysis was statistically significant for 5 years. All analyses are
consistent with a small difference in OKS (around 1 point) in favour of PKR. This difference is of
uncertain clinical value. Other pain and function knee outcomes and quality-of-life outcomes have a
similar pattern of some small statistically significant differences up to 1 year, but by 5 years there is
little evidence of a difference.
A more compelling pattern in favour of PKR was observed for a range of other outcomes, including
EQ-5D VAS (but not EQ-5D-3L), patient satisfaction, willingness to choose the same operation again
and perception of their knee problem. Hospital length of stay was also favourable for PKR.
TABLE 14 Deaths
Measure PKR (N= 264) TKR (N= 264)
Number of deaths, n (%) 6 (2.3) 11 (4.2)




Multi-organ failure/sepsis – 1
Unknown 2 2
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The level of non-compliance is worthy of comment. Some non-compliance was anticipated and clinically
understandable (conversion from PKR to TKR from operative findings), other occurrences stem from a
variety of factors. We used a CACE analysis to assess potential impact of non-compliance on effect and
it did not appear to indicate this was an issue. The pattern of observed complications and reoperation
reflected this and for this reason we analysed it as both ITT and treatment received. Statistical findings
were similar in terms of overall level of complications and reoperations, favouring PKR for both. This is
contrary to some previous work,6 which has suggested that PKR has a higher level of both complications
and reoperation. The finding that PKR had lower levels of complications and reoperations than TKR may
reflect the more experienced group of surgeons in this trial and the more robust nature of this comparison
in terms of controlling for selection bias than previous observational research studies.
Overall, the findings show some modest clinical benefit for PKR, although minimal in terms of knee
pain and function. Other benefits appeared to be in terms of lower complication rate and reoperation
and recovery. Notably, not one observed outcome provided evidence in favour of TKR over PKR.
The cost-effectiveness of the two procedures is considered in Chapter 5.
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Chapter 5 Cost-effectiveness analysis
Introduction
This chapter reports the methods and results of a within-trial cost-effectiveness analysis of TOPKAT.
Between January 2010 and October 2013, TOPKAT randomly allocated 528 adults with OA of the
medial compartment of the knee to receive either PKR (n = 264), in which only the diseased area of
the knee is replaced, or TKR (n = 264), in which all surfaces of the knee are replaced. Participants have
been followed up to 5 years following randomisation. Information on recruitment, including inclusion
and exclusion criteria, is presented in more detail in Chapter 2. Participant characteristics at recruitment
and clinical results are presented in Chapters 3 and 4.
In this chapter, we compared PKR with TKR in terms of QALYs gained and health-care costs and
calculated incremental cost-effectiveness ratios (ICERs) that give the additional spending required to
generate one additional QALY.
Methods
Health economic data collection
Information was collected for each participant in the trial on the resources consumed during initial
surgery, including the type of implant, time in theatre, days in hospital and any intraoperative or
postoperative complications. At baseline, data were reported during a clinic visit about participants’
use of health-care services related to the study knee [inpatient stays, outpatient appointments,
consultations with a general practitioner (GP) or practice nurse and visits to a physiotherapist or
occupational therapist] in the preceding year and their current health status including the EQ-5D-3L
questionnaire. In the EQ-5D-3L questionnaire, participants are asked to report whether they have no
problems, some problems or extreme problems in the following domains: mobility, self-care, usual
activities, pain and discomfort and anxiety/depression.
At 2 months, 1 year and annually thereafter to 5 years, patients were asked via postal questionnaire to
report their health-care use related to the study knee since the last follow-up and their current health
status. Hospital admissions potentially related to the study knee were identified from data reported
in the postal questionnaires; clinic visits at 2 months, 1 year and 5 years post randomisation; and the
assessment of hospital records for all participants by local research teams. Where potentially relevant
admissions were identified, a data extraction sheet was completed providing details of the admission.
Health-care costs
Unit costs were derived from national databases77–79 or published studies,80 and are reported in Appendix 4.
All unit costs were inflated, where necessary, to 2016–17 prices using the health care and community
health services inflation index.78
The initial admission was costed according to the type of implant used (if any), time in theatre, number
of days in hospital, days in an intensive care unit or high-dependency unit (from here on, critical care)
and any intra- or post-operative complications. We did not separately cost the anaesthetic used or the
staff present during the operation, as this is all included within the cost per minute of theatre time.
We did not include an additional cost for interoperative conversion from PKR to TKR, and the cost did
not depend on whether or not cement was used.
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Appendix 4, Table 29, presents the number of implants and the mean cost by implant type and treatment
allocation. Fourteen participants received an implant type for which there were no costs (data on implant
type was imputed using mean imputation by treatment allocation). Theatre time was reported in minutes
and the costs were attached per minute of theatre time. Data were collected on the total length of
hospital stay and the hours spent in critical care. Hours in critical care were converted to days and
subtracted from total length of stay to estimate the days spent in other wards (see Appendix 4,
Table 30, for unit cost data).
Intraoperative and postoperative complications that required blood transfusion were costed per unit of
blood (see Appendix 4, Table 30). Other post-operative complications were costed using a Healthcare
Resource Group (HRG) approach. This involved attaching the World Health Organization’s International
Classification of Diseases, Tenth Revision (ICD-10), codes81 to each complication (see Appendix 4, Table 30),
and using the Costing – HRG4+ 2016/17 Reference Costs Grouper82 from NHS Digital to attach a HRG.
Mean costs for elective patients for each HRG were derived from the NHS Reference Costs Schedule
2016–1783 (see Appendix 4, Table 31) using a recommended approach.84 We assumed that the absence
of data on complications is indicative of the absence of complications.
Unit costs were attached to self-reported data on consultations with GPs or practice nurses, outpatient
appointments and visits to a physiotherapist or occupational therapist (see Appendix 4, Table 30).
ICD-10 diagnostic and Office of Population, Censuses and Surveys Classification of Surgical Operations and
Procedures, Fourth Revision (OPCS-4), procedural codes85 were attached to each hospital admission
(see Appendix 4, Tables 32 and 33) and costing followed a HRG approach, as described above for post
operative complications (see Appendix 4, Table 34). Because of the multifaceted identification process
(questionnaire, clinic visits and hospital records), data on inpatient care were considered complete.
Quality-adjusted life-years
Responses to EQ-5D-3L questionnaires were converted into utility scores using the standard UK tariff.72
QALYs are calculated using the AUC approach, which involves estimating the average EQ-5D-3L utility
between each follow-up time point, and weighting by survival time.
Methods for dealing with missing data
We followed best practice methods for addressing missing data in cost-effectiveness studies.86 Missing
data on characteristics of participants at baseline were imputed using mean imputation, and missing
data on components of the index surgery (e.g. implant type) were imputed using mean imputation by
treatment allocation. Data on deaths and admitted patient care costs were considered to be complete;
therefore, no imputation was performed. For non-admitted patient care health-care costs, we imputed
missing values as zero if any components of resource use were reported.
We used multiple imputation by chained equations to impute missing data on EQ-5D-3L utility scores,
total health-care costs (except inpatient care, which is complete) and OKS at each follow-up time
point. Each missing value was imputed as a function of follow-up period, sex and BMI at randomisation,
and OKS and age at follow-up. Total non-admitted patient care health-care costs were also imputed as
a function of EQ-5D-3L score and inpatient care costs at each follow-up point, and EQ-5D-3L score
was also imputed as a function of total health-care costs at each follow-up point in addition to the
above stated covariates. We used predictive mean matching to create 10 imputed data sets.We imputed
annual costs and EQ-5D-3L utility score in each period; in periods when death was observed, these
were adjusted. For costs, we assumed that they were incurred linearly over time, such that, if an
individual died 6 months into an annual period, they incurred half of the predicted costs. For EQ-5D-3L
utility, we assumed that the imputed utility score prevailed until the time of death. Imputation was
performed separately in subgroups by treatment allocation.
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Analysis
We report descriptive statistics (mean, SD) for resource use, costs and EQ-5D utilities at each follow-up
time point using complete data only. Differences between groups were estimated using linear regression,
controlling for treatment allocation, age group (< 50, 50–70 or > 70 years), sex and baseline OKS band
(0–14, 15–21 or 22–48). For EQ-5D, we additionally controlled for baseline EQ-5D utility, and for
health-care costs (except relating to the index admission), we controlled for health-care costs in the year
preceding randomisation. Standard errors were adjusted to reflect clustering by the delivery unit.
Following multiple imputation, we estimated total costs and QALYs for all 528 participants in TOPKAT
from the date of study recruitment to the earliest of death, withdrawal from the study or the end of
follow-up at 5 years. Both costs and QALYs were discounted at 3.5% per year following guidelines
from the National Institute for Health and Care Excellence.87 Our analysis used ITT principles, with
health-care resource use, costs and EQ-5D-3L scores analysed according to treatment allocation,
regardless of the treatment that the participant actually received.
On each imputed data set we estimated mean total health-care costs (and by cost type) and QALYs
using separate linear regression models with the same covariate patterns as described above for
descriptive analyses, and cluster-robust standard errors. Estimates derived from each imputed data set
were combined using Rubin’s rule to estimate the adjusted MD and standard error for each outcome.
We calculated the ICER by dividing the mean cost difference between PKR and TKR by the mean
QALY difference. The ICER reports the amount that must be spent to generate one additional QALY.
We also present results within participant subgroups defined by age at recruitment (< 55, 55–70 or
> 70 years), sex (male or female) and OKS band (0–14, 15–21 or 22–48) at recruitment.
We estimated the joint uncertainty around incremental total costs and QALYs (i.e. the difference between
PKR and TKR) by bootstrapping 500 times from each of our 10 imputed data sets, running the estimation
model on each bootstrapped dataset and extracting the estimated treatment effects. We presented these
data graphically in a cost-effectiveness scatterplot. From these bootstrapped results, we also calculated
the probability that PKR is more cost-effective than TKR for different threshold values per QALY gained.88
These are calculated by estimating the proportion of bootstrap replicates with a net monetary benefit
(NMB) above 0 for each threshold value, where the NMB is given by the product of the MD in QALYs
and the threshold value minus the MD in costs.
As a sensitivity analyses, we explored using a complete-case analysis including only individuals who
provided complete data over 5 years. In those periods in which an individual died, we used the last
observation carried forward for EQ-5D and non-admitted patient care health-care costs. As with the
main analysis, we adjusted these estimates for death by assuming that costs were incurred linearly over
time, and that the EQ-5D utility prevailed until death. We re-estimated the base-case analysis assuming
equal costs for the PKR and TKR implant devices. In a preliminary analysis, we also considered the use of
different imputation models using linear regression rather than predictive mean matching. Finally, we
repeated the main analysis but compared groups by treatment received rather than treatment allocated.
All analyses were conducted using R version 3.4 (The R Foundation for Statistical Computing,
Vienna, Austria).
Results
Study participant follow-up time
Of the 528 study participants, 17 died and 15 withdrew from the study.
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Table 15 presents the percentage of missing data observations for EQ-5D utility and the total
non-admitted patient care health-care costs at each follow-up point. Patterns of missing data are
very similar for these two outcomes and in both treatment groups. We found no strong evidence that
the probability that data were missing depended on baseline participant characteristics, or on lagged
outcomes. Across all time periods, 13% of questionnaires on health-care costs and EQ-5D were missing.
Health-care costs
Index admission
Table 16 presents costs and cost differences by treatment allocation for total costs associated with
the allocated procedure and each major component of these costs. Overall, the index admission cost
an additional £470 (95% CI £211 to £729) in those allocated to the TKR group compared with those
allocated to the PKR group, and this was due, in roughly equal parts, to the additional costs of the
implants and time in hospital (mean 0.77 additional days). Assuming equal costs for the device,
the cost difference reduced to £179 (95% CI –£67 to £425) and still favoured PKR, but was no
longer statistically significant.
Follow-up health-care use
Table 17 presents self-reported use of different health-care services in the year preceding recruitment
and between subsequent follow-up periods. On average, participants allocated to TKR had substantially
more outpatient appointments in the first 2 years following randomisation, in addition to somewhat
elevated rates of GP consultations and visits to physiotherapists or occupational therapists. Towards
the end of the 5-year follow-up, differences in resource use between groups were minimal.
TABLE 15 Missing data on health-care resource use and EQ-5D utility by treatment allocation in each follow-up period
Follow-up time
Health-care resource use, number of
missing questionnaires (%)
EQ-5D utility, number of
missing questionnaires (%)
PKR TKR PKR TKR
Baseline 6 (2.3) 7 (2.7) 7 (2.7) 12 (4.5)
2 months 20 (7.6) 28 (10.6) 26 (9.8) 29 (11.0)
1 year 24 (9.1) 27 (10.3) 24 (9.1) 29 (11.1)
2 years 31 (11.8) 29 (11.2) 29 (11.0) 20 (7.8)
3 years 47 (18.0) 36 (14.0) 47 (18.0) 37 (14.4)
4 years 57 (22.0) 44 (17.3) 54 (20.8) 41 (16.1)
5 years 34 (13.2) 43 (17.0) 33 (12.8) 41 (16.2)
TABLE 16 Index surgery costs by treatment allocation
Type of cost PKR (£), mean (SD) TKR (£), mean (SD)
Difference (£) (PKR vs.
TKR), mean (95% CI)
Total admission costs 3991 (889) 4463 (1709) –470 (–729 to –211)
Implant device 915 (199) 1205 (340) –292 (–408 to –176)
Time in theatre 1932 (479) 1820 (639) 112 (18 to 207)
Hospital stay 1101 (536) 1358 (1212) –256 (–463 to –50)
Complications 44 (278) 79 (382) –35 (–91 to 21)
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TABLE 17 Number of contacts for different health-care resources by treatment allocation and follow-up period
Follow-up
period
PKR, mean (SD) TKR, mean (SD)
n GP Inpatienta Nurse Physiotherapist Outpatient n GP Inpatienta Nurse Physiotherapist Outpatient
Year before
baseline
258 2.70 (2.10) 0.11 (0.96) 0.17 (0.63) 1.96 (1.55) 1.17 (2.30) 257 2.77 (2.68) 0.02 (0.14) 0.15 (0.64) 2.04 (1.46) 1.37 (4.30)
Baseline–
2 months
244 0.66 (1.09) 0.00 (0.06) 0.83 (1.21) 1.03 (1.66) 2.26 (5.05) 236 0.97 (1.30) 0.02 (0.17) 0.99 (1.77) 1.11 (1.16) 2.70 (3.07)
2 months–
1 year
240 0.81 (1.52) 0.03 (0.17) 0.40 (0.87) 0.95 (1.20) 1.20 (2.50) 234 1.04 (1.79) 0.04 (0.19) 0.26 (0.63) 1.39 (2.07) 3.17 (6.29)
1–2 years 232 0.44 (1.28) 0.02 (0.15) 0.11 (0.47) 0.34 (0.71) 0.35 (1.20) 229 0.48 (1.19) 0.02 (0.17) 0.11 (0.57) 0.62 (1.22) 0.66 (3.19)
2–3 years 214 0.33 (0.89) 0.00 (0.06) 0.09 (0.54) 0.21 (0.61) 0.13 (0.68) 221 0.47 (1.57) 0.02 (0.15) 0.04 (0.41) 0.31 (1.09) 0.33 (1.83)
3–4 years 202 0.29 (0.94) 0.03 (0.32) 0.05 (0.26) 0.22 (0.77) 0.20 (1.09) 211 0.44 (1.44) 0.03 (0.16) 0.02 (0.14) 0.29 (0.94) 0.38 (1.84)
4–5 years 223 0.27 (0.91) 0.00 (0.00) 0.06 (0.34) 0.31 (1.69) 0.30 (1.25) 210 0.27 (0.77) 0.01 (0.11) 0.05 (0.27) 0.60 (1.97) 0.53 (2.16)















































































































































































































































































































































Table 18 presents health-care costs (excluding inpatient care) for each follow-up period. In line with
observed differences in resource use by treatment allocation, average costs were lower among those
allocated to PKR than to TKR, with differences especially large in the first year of follow-up.
Table 19 presents inpatient care costs at each time point. There was no clear pattern by treatment
allocation, with PKR having higher average costs in some years and lower costs in others.
EuroQol-5 Dimensions utility
Table 20 presents EQ-5D-3L utility scores and differences by treatment allocation at each time point.
EQ-5D-3L score was higher in the PKR group than the TKR group, albeit largely not statistically
significant. The distribution of responses to each EQ-5D domain at each follow-up time point is
presented by treatment allocation in Appendix 5, Table 35. Differences in EQ-5D scores cannot be
explained by differences in any single dimension of the EQ-5D.
Main analysis
Table 21 shows the main analysis results at 5 years (see Appendix 5, Table 34, for descriptive statistics on
health-care costs and EQ-5D utility at each follow-up time point following multiple imputation). There was
a small difference in life-years lived favouring PKR (MD 0.085 years, 95% CI –0.032 to 0.202 years).
Differences in QALYs were larger and significantly favoured PKR (MD 0.240 QALYs, 95% CI 0.046 to
0.434 QALYs). Total costs were, on average, lower among those allocated to PKR (MD £910, 95% CI
£317 to £1503), reflecting, in equal part, the lower costs of the index admission (MD £471, 95% CI
£214 to £729) and the lower health-care costs during follow-up (MD £433, 95% CI –£114 to £979).
TABLE 18 Health-care costs (excluding inpatient care) by treatment allocation in each follow-up period
Follow-up period
PKR TKR Difference (PKR vs. TKR)a
n Cost (£), mean (SD) n Cost (£), mean (SD) Cost (£), mean (95% CI)
Baseline–2 months 244 286 (371) 236 332 (232) –46 (–111 to 20)
2 months–1 year 240 222 (254) 234 388 (511) –172 (–258 to –85)
1–2 years 232 80 (146) 229 136 (284) –56 (–98 to –15)
2–3 years 214 49 (123) 221 77 (230) –25 (–56 to 5)
3–4 years 202 52 (164) 211 75 (223) –21 (–67 to 24)
4–5 years 164 68 (248) 163 118 (325) –50 (–112 to 13)
a Linear regression model adjusted for age, sex, OKS band at recruitment and health-care costs in year
preceding baseline.
TABLE 19 Inpatient care costs by treatment allocation in each follow-up period
Follow-up period
PKR TKR Difference (PKR vs. TKR)a
n Cost (£), mean (SD) n Cost (£), mean (SD) Cost (£), mean (95% CI)
Baseline–2 months 264 6 (99) 264 28 (214) –22 (–47 to 3)
2 months–1 year 264 128 (1002) 261 49 (246) 80 (–78 to 238)
1–2 years 263 124 (1008) 258 166 (1864) –47 (–299 to 206)
2–3 years 261 3 (51) 257 124 (1013) –121 (–245 to 3)
3–4 years 259 163 (1955) 255 99 (843) 70 (–215 to 356)
4–5 years 257 0 (0) 253 82 (837) –83 (–187 to 22)
a Linear regression model adjusted for age, sex, OKS band at recruitment and health-care costs in year
preceding baseline.
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PKR, therefore, dominated TKR with lower costs and higher QALYs. Assuming equal costs of PKR and
TKR the implant device, the MD in total costs fell to £618 (95% CI –£7 to £1243) and PKR remained
dominant (cheaper and more effective than TKR). When comparing outcomes by treatment received
rather than treatment allocated at 5 years (Table 22), the difference in costs was greater, at £1033
(95% CI £368 to £1697), mostly because of higher costs of the surgery, whereas differences in QALYs
were similar, at 0.209 QALYs (95% CI 0.044 to 0.373 QALYs).
TABLE 20 The EQ-5D utility score by treatment allocation at each follow-up time point
Follow-up period
PKR TKR
Difference (PKR vs. TKR),a
mean (95% CI)n Mean (SD) n Mean (SD)
Baseline 257 0.428 (0.301) 252 0.381 (0.324) –
2 months 238 0.689 (0.243) 235 0.664 (0.226) 0.022 (–0.019 to 0.063)
1 year 240 0.766 (0.241) 232 0.723 (0.260) 0.038 (–0.003 to 0.079)
2 years 234 0.775 (0.261) 238 0.719 (0.282) 0.051 (–0.007 to 0.110)
3 years 214 0.771 (0.249) 220 0.729 (0.289) 0.034 (–0.026 to 0.094)
4 years 205 0.770 (0.251) 214 0.719 (0.301) 0.043 (0.003 to 0.084)
5 years 224 0.744 (0.293) 212 0.717 (0.318) 0.018 (–0.033 to 0.069)
a Linear regression model adjusted for age, sex, OKS band at recruitment and (except when modelling EQ-5D at
baseline) EQ-5D score at recruitment.
TABLE 21 Life-years, QALYs, health-care costs and cost-effectiveness for the base-case analysis at 5 years following






Difference (PKR vs. TKR),
mean (95% CI)
Life-years 4.917 (0.709) 4.831 (0.888) 0.085 (–0.032 to 0.202)
QALYs 3.448 (0.970) 3.193 (1.060) 0.240 (0.046 to 0.434)
Total costs (£) 5149 (56) 6048 (60) –910 (–1503 to –317)
Initial admission 3991 (30) 4463 (41) –471 (–729 to –214)
Follow-up 1158 (54) 1585 (55) –433 (–979 to 114)
ICER (£) – – –3792
TABLE 22 Life-years, QALYs, health-care costs and cost-effectiveness for the base-case analysis at 5 years following






Difference (PKR vs. TKR),
mean (95% CI)
Life-years 4.931 (0.666) 4.918 (0.681) –0.038 (–0.101 to 0.026)
QALYs 3.456 (0.965) 3.280 (1.015) –0.209 (–0.373 to –0.044)
Total costs (£) 5167 (55) 6323 (59) 1033 (368 to 1697)
Initial admission 4007 (29) 4694 (38) 802 (545 to 1059)
Follow-up 1160 (53) 1629 (56) 230 (–288 to 748)
ICER (£) – – –4943
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Figure 6 presents the cost-effectiveness scatterplot giving differences in mean total costs and QALYs for
PKR versus TKR, using observed (blue) and assumed equal (orange) device costs. In both scenarios, most
bootstrap replicates remained largely in the south-east quadrant of the cost-effectiveness scatterplot,
indicating that PKR dominated TKR with higher QALYs and lower costs. The probability of PKR being
the most cost-effective option was > 99.9% for all reasonable threshold values.
Table 23 reports the cumulative costs and QALYs at each follow-up time point. Mean costs are higher
for TKR than for PKR at each time point, and the difference increases with time. For QALYs, there was
a negligible difference in QALYs at 2 months, but QALY differences between PKR and TKR increase
steadily with follow-up time.
Table 24 presents cost-effectiveness results at 5 years by subgroups of participants. There is no clear
evidence that cost-effectiveness differs between participant subgroups.
Table 25 presents the complete-case analysis results at 5 years. Only 297 participants (57%) contributed
data to the complete-case analysis (PKR, 57%; TKR, 55%). Compared with the multiple imputation
analysis, PKR is still the most effective intervention albeit associated with fewer additional QALYs,
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FIGURE 6 Cost-effectiveness scatterplot for the base-case analysis and assuming equal implant device costs (the larger
black points present mean values for each modelled scenario).
















2 months 4290 (32) 4828 (43) –545 (–814 to –275) 0.092 (0.189) 0.086 (0.189) 0.002 (–0.001 to 0.006)
1 year 4638 (39) 5250 (46) –619 (–975 to –264) 0.691 (0.455) 0.647 (0.463) 0.037 (–0.001 to 0.076)
2 years 4846 (47) 5542 (53) –711 (–1173 to –248) 1.422 (0.640) 1.320 (0.667) 0.093 (0.011 to 0.175)
3 years 4903 (47) 5728 (55) –841 (–1307 to –374) 2.126 (0.769) 1.971 (0.820) 0.144 (0.018 to 0.270)
4 years 5095 (55) 5886 (58) –804 (–1369 to –238) 2.805 (0.873) 2.598 (0.947) 0.193 (0.031 to 0.356)
5 years 5149 (56) 6048 (60) –910 (–1503 to –317) 3.448 (0.970) 3.193 (1.060) 0.240 (0.046 to 0.435)
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TABLE 24 Quality-adjusted life-years, health-care costs and cost-effectiveness for the base-case analysis at 5 years in participant subgroups
Follow-up time point














All participants 264 264 5149 (56) 6048 (60) –910 (–1503 to –317) 3.448 (0.970) 3.193 (1.060) 0.240 (0.046 to 0.434) –3792
Age (years)
< 55 33 31 5602 (135) 8077 (112) –3725 (–7786 to 335) 3.207 (1.043) 2.682 (1.196) 0.426 (–0.376 to 1.227) –8755
55–70 161 162 5128 (52) 5900 (55) –779 (–1288 to –269) 3.472 (0.961) 3.171 (1.050) 0.258 (0.077 to 0.440) –3012
> 70 70 71 5127 (63) 6053 (66) –869 (–2226 to 489) 3.426 (0.983) 3.341 (1.048) 0.065 (–0.199 to 0.329) –13,318
Sex
Male 153 153 5167 (59) 5972 (65) –846 (–1628 to –65) 3.475 (0.974) 3.206 (1.083) 0.250 (–0.022 to 0.521) –3390
Female 111 111 5124 (53) 6153 (58) –1042 (–1791 to –293) 3.411 (0.965) 3.175 (1.028) 0.271 (0.043 to 0.499) –3840
OKS group
0–14 75 74 5136 (66) 6104 (64) –950 (–1883 to –16) 3.048 (0.983) 2.672 (1.096) 0.334 (–0.077 to 0.745) –2841
15–21 102 100 5275 (50) 6150 (66) –882 (–1582 to –181) 3.399 (0.954) 3.130 (1.052) 0.252 (–0.077 to 0.581) –3503
22–48 87 90 5012 (63) 5890 (65) –864 (–1937 to 209) 3.849 (0.888) 3.691 (0.916) 0.164 (–0.107 to 0.436) –5252
















































































































































































































































































































































Over 5 years of follow-up in TOPKAT, we found that PKR led to improved health-related quality
of life and reduced health-care costs compared with TKR in individuals with OA of the medial
compartment of the knee, even when assuming equal device costs. The cost-effectiveness results are
consistent with a recent modelling study based on data from the National Joint Registry (NJR),54 which
found that PKR is expected to generate better health outcomes at lower costs over a patient’s lifetime
compared with TKR.54
Following the index surgery, participants in both treatment groups saw considerable improvements in
their EQ-5D utility, reflecting the known clinical benefits of knee replacement surgery in patients with
OA and poor functional outcomes.89 Differences in EQ-5D utility at all follow-up time points favoured
PKR but were not typically significantly different by treatment group. However, QALYs, which reflect
cumulative health-related quality-of-life adjusted for survival, were found to be significantly higher among
those allocated to the PKR group than those allocated to the TKR group beyond 1 year.
Costs of the index surgery were significantly lower among those allocated to the PKR group than those
allocated to the TKR group. Follow-up health-care costs were significantly lower among those allocated
to PKR than among those allocated to TKR over the first 2 years of follow-up, driven predominantly by
fewer outpatient visits. Cumulative health-care costs were significantly different through the trial
follow-up and favoured PKR, even when assuming equal device costs.
Our cost-effectiveness analysis is based on the largest, to our knowledge, RCT comparison of PKR and
TKR in the UK. The analysis has several limitations, including the sizeable number of missing data on
use of health-care resources and EQ-5D-3L, particularly in the later years of follow-up. We accounted
for this using multiple imputation.86 This assumes that data are missing at random, conditional on
modelled covariates. We found no strong evidence to contradict this assumption and indeed found that
the qualitative conclusions were the same in the multiple imputation and complete cases analyses.
In addition, results were calculated over 5 years only. Longer follow-up could confirm whether or not
the observed differences in costs and quality of life are maintained.
TABLE 25 Life-years, QALYs, health-care costs, and cost-effectiveness for the complete-case analysis at 5 years
Outcomes PKR, mean (SD) TKR, mean (SD)
Difference (PKR vs. TKR),
mean (95% CI)
n 151 146 –
Life-years 5.000 (0.000) 4.921 (0.526) 0.065 (–0.002 to 0.132)
QALYs 3.575 (0.930) 3.413 (1.016) 0.150 (–0.103 to 0.402)
Total costs (£) 5040 (2947) 6327 (3681) –1232 (–1995 to –468)
Initial surgery 3947 (820) 4711 (1683) –779 (–1110 to –447)
Follow-up 1093 (2755) 1616 (3307) –453 (–1140 to 234)
ICER (£) – – –8224
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Chapter 6 Discussion and conclusion
TOPKAT was designed as a large, multicentre, parallel group, superiority RCT to address the uncertaintyaround which type of knee replacement treatment provides the most benefit for patients with medial
compartmental OA of the knee. The trial evaluated the clinical effectiveness and cost-effectiveness of PKR
compared with TKR for this condition. To our knowledge, the trial, which randomised 528 patients, is the
largest of its kind to date and provides the longest follow-up (5 years) for this size of cohort.
Summary of main findings
The trial showed that at the 5-year follow-up both types of operation had good outcomes. Patients in
both groups had a superior outcome to their preoperative baseline status. The changes in OKS following
PKR and TKR intervention were substantial (mean OKS change > 18 points for both procedures). There
was no evidence of difference in the primary outcome of mean OKS between groups at the 5-year time
point, despite there being evidence of a difference at 1 year. However, a post hoc AUC analysis of the
primary outcome over the duration of the study did show significant benefit in favour of PKR over TKR,
although this difference was smaller than the minimal clinically important difference in the score.
All analyses are consistent with a small difference (around 1-point OKS) in favour of PKR.
The secondary outcome measures all showed a consistent pattern of benefit in the direction of PKR,
although most differences were small and many were not statistically significant. This included measures
of self-reported activity (OKS-APQ, AKSS, HAAS and UCLA), global health (EQ-5D-3L) and patient
satisfaction. The EQ-5D VAS global health instrument revealed significant differences in favour of PKR.
Anchor questions of transition (how are your problems now compared with before the operation?) and
self-reflection on benefit (would you have the operation again?) suggested that PKR was superior to
TKR, but both variables are open to some bias as the study was not blinded.
The reoperation rate (including revision) was similar for both groups: 22 out of 245 PKR participants
and 28 out of 269 TKR participants. The 5-year revision rates were 10 PKR revisions from 245 patients
(4.1%) and 10 TKR revisions from 269 patients (4%). The 5-year revision rate for PKR in the NJR (and
other worldwide registries) is 6.1%, which is substantially higher than that found in TOPKAT (discussed
further below).6,61,62 In view of the limitation of using revision data alone to indicate ‘failure’ of an implant
or operation, a conservative measure of failure was also employed in this study. This composite outcome
(with failure defined as reoperation/revision and/or poor improvement in OKS) showed that there was
28 failures of PKR and 38 failures of TKR over 5 years. This difference of 10 fewer failures of PKR was
not found to be significant.
Independent opinion was also sought to aid wide-ranging and unbiased interpretation of the trial.
Although TKR was not seen to be advantageous to PKR using any variable (significantly or otherwise),
the trial also did not reveal any convincing clinical advantage of PKR over TKR, including for the primary
outcome measure. However, informed by the consistent patterns of direction of effect across all variables
in favour of PKR and the lack of perceived advantage of TKR in any domain, both independent opinion
and investigators not clinically aligned with any implant or type were inclined to suggest that there was
a modest benefit of PKR over TKR from these mid-term clinical results.
The health economic evaluation provided very strong evidence in favour of PKR, with PKR being found
to be more cost-effective than TKR. This finding was primarily driven by slightly better quality-of-life
outcome (as measured by the EQ-5D), lower surgery costs and lower follow-up health-care costs. PKR,
therefore, dominated TKR with lower costs and higher QALYs. Even assuming equal costs of the implant
device, the MD in total costs remained substantial [£619 (95% CI –£6 to £1244)] and PKR remained
cheaper and more effective than TKR.
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Discussion of findings in the light of other literature
The previous evidence and literature, and their limitations, were presented in Chapter 1. Most of the
previously published cohort data provided results in favour of PKR for early outcome, including the
work of Liddle et al.,60,90 findings that have been echoed by previous and recent systematic reviews.47,63,91
The current study provides further evidence that PKR provides modest clinical advantages and larger
health-care economic benefits over TKR for this condition. The robust study design and execution
provided strong protection against selection bias potentially influencing other results. This large and
definitive randomised study was deemed necessary as any previous cohort data, no matter how well
matched, will have the inherent risk of selection and likely residual bias even after adjustment for this.
Selection bias is important, as the decision-making for which patients should undergo TKR and PKR
outside a randomised study is influenced by multiple factors and characteristics. For example, not
all surgeons would offer a PKR to all patients with medial compartment OA. To date, it has been
considered as an operation for younger patients with less widespread disease and fewer comorbidities,
all of which have the potential to influence outcome.
There are several issues regarding the trial findings that warrant specific discussion.
The observed consistent patterns in the direction of PKR found in the primary and secondary outcome
variables was striking (although many effects were small and not statistically significant). Possible
explanations could include either a lack of sensitivity in the measurement instruments used or a true
underlying, but very modest, difference between TKR and PKR. Although the outcome measures may
not be perfectly sensitive for this particular comparative research question, as TKR and PKR are both
widely used interventions of known benefit, they were chosen carefully and represent the best
indicators of outcome available when the study was designed.
The magnitude of the difference observed in the primary outcome at 5 years (a MD of 1.04 points in OKS)
is worthy of comment. This level of difference lies well within a revised estimate of the true minimally
important difference in OKS,66 and is unlikely to have any discernible impact on practice. However,
clinicians and patients themselves must decide whether or not this level of difference, and the evidence
from other variables, would constitute enough of a difference to change or support their current practice.
Some discussion is warranted over the contrasting significance of the primary analysis using cross-
sectional means (at each year and finally at 5 years) and the AUC analysis. There is an argument that
the AUC analysis is more appropriate and takes into account the cumulative changes over the duration
of the study. As can be seen in Figure 1 there were more patients with OKS outcome scores of ≥ 40 in
the PKR group than in the TKR group. If the objective is to deliver more patients with higher scores,
then PKR appears to be able to deliver this. The earlier cross-sectional data are also less informative
from a clinical perspective. Arthroplasty is an intervention aimed at long-term benefit, and 5 years is
often considered the minimum follow-up required to make reasonable conclusions. That said, the early
(1 year) revision data do provide insight into early failure. It was previously thought that most failures
occur within the first year of implantation and that PKR was more susceptible to this. This study has
shown that failure of intervention in the first year can be more common than in subsequent years,
but there was no obvious difference between implant types.
When exploring confounders, it was important to assess the effect of any delay to undergoing surgery.
As seen in Figure 4, it was reassuring to see that the delays in surgery had similar effects with neither
PKR nor TKR patients being disadvantaged by a delay in surgery.
In terms of mortality after knee replacement, this was low overall and similar in both groups. The study
was not designed to substantiate the findings of higher mortality seen for TKR shown by other large
cohort studies.61,92
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The reoperation and revision data are a point of notable interest. The trial findings differ significantly
from previously reported worldwide joint registry data and from the perceived clinical understanding
of the performance of the procedure. PKR is generally thought to have a much higher revision rate
(at least 6%) than TKR.6 The high revision rate is one reason put forward in opposition to more
frequent use of PKR. This trial has shown that evaluation in a controlled trial (where selection bias is
minimised) yields revision and reoperation rates of PKR and TKR that are very similar. This demands
consideration, and there are several possible reasons for the contrast.
First, the threshold for revision, outside a closely monitored trial, is much lower for PKR than for TKR.
Surgeons are more likely to offer revision of partial to total replacement (PKR to TKR) than total to
total replacement (TKR to TKR) because of the likely outcome of these revision scenarios.93 This
normal threshold may have been disrupted in TOPKAT, with surgeons less likely to revise without
high levels of justification. An important side issue, therefore, is whether or not the routine clinical
pathway and threshold for revision surgery outside a trial should always be as well justified as it
appears to have been for the patients in this trial.
Second, the issue of surgeon experience or expertise may influence personal surgeon thresholds for
revision. The trial involved surgeons who had to have met a minimum experience and qualification
threshold and were all self-selected and volunteered to be part of the study. Although they were
not considered (or desired) to be top-level experts, by definition, all involved surgeons considered
themselves to be highly competent at the knee replacements they were performing (either both types
if in equipoise or one of PKR/TKR if not). PKR is considered to be more technically demanding than
TKR, and patients undergoing PKR outside the study (and who will thus contribute to the registry
data) are likely to have had surgeons less experienced in the technique. The analysis that adjusted for
the learning suggested that this has a small impact on OKS at 1 year but not at 5 years. Similarly, there
was no clear evidence of a difference between equipoise and expertise surgeons. Many of the surgeons
outside the trial will have been on a learning curve or perform the operation infrequently. This is
known to affect success94 and could account for the disparity in revision data between the trial and
registries. The UK NJR shows that, over a 3-year period (1 January 2015 to 31 December 2017),
272,133 primary TKR procedures were performed by 1976 surgeons (median= 103, IQR 29–202.5
procedures) in 403 separate units (median = 599 cases per unit, IQR 278–944 cases per unit). In the same
time period, 28,573 primary PKR procedures were performed by 809 consultant surgeons (median= 15,
IQR 4–39 procedures) in 358 units (median= 42 cases per unit, IQR 16–92 cases per unit). This difference
in average arthroplasties performed per surgeon per year for each implant type (TKR, n = 34; PKR, n = 5)
is marked and could account for the differences between registry and TOPKAT data.6
The side issue to this point is that a minimal level of surgeon competence or experience is required to
undertake PKR to achieve success. The revision rate for the lowest volume surgeons has been shown
to be four times higher than that for the highest volume surgeons, with a minimal annual volume
number of 13 procedures stated for competence.95–97
The numbers of reoperations and revisions were too low to draw many conclusions above those involving
simple frequency. However, it was noted that more PKR patients underwent subsequent revision surgery
for bearing dislocation (as the majority of PKRs were mobile bearing implants) and more TKR patients
underwent revision for unexplained pain. Notably, 12 patients who had undergone TKR had a manipulation
under anaesthetic for stiffness compared with no patients who had undergone PKR. Although manipulation
under anaesthetic may be considered a relatively benign non-invasive reoperation procedure (compared
with component revision), it could be argued that the long-term consequences of a stiff knee after
arthroplasty are likely to have more of an impact on function than a single operation to perhaps replace
a bearing to establish a normal functioning arthroplasty in the future.
There was some debate as to whether or not bearing exchange should be classified as true revision surgery.
However, it is defined in the protocol as a reoperation and, therefore, reported as such for this study.
DOI: 10.3310/hta24200 Health Technology Assessment 2020 Vol. 24 No. 20
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
61
The issue of surgeon experience in relation to external validity and generalisation is dealt with in
Strengths below.
Strengths
There are many general strengths of this study. Globally, to the best of our knowledge, it is the largest,
most complete and longest randomised follow-up of any comparison of TKR with PKR to date. The
study was sufficiently large to have detected clinically meaningful differences in OKS and probably
all of the other key outcomes also. Well-established and well-validated outcome measures were
used. Follow-up of the primary outcome variable at 5 years was 88% (94% of those who were sent
a questionnaire returned it). The use of simple patient-reported success questions (e.g. satisfaction,
transition and reflection) was found to be particularly useful. There was little issue over fidelity, with
highly visible signals as to whether or not the intervention (operation) had been carried out. The
conduct of the trial was considered a strength with strong support from the knee surgery community
(British Association for Surgery of the Knee) and the same trial co-ordination and management team
throughout. The trial was completed in two trials units with strong expertise in rigorous surgical
evaluation (the Royal College of Surgeons of England Surgical Intervention Trials Unit surgical trial
unit in Oxford and the CHaRT in Aberdeen). It was well supported by the funder [National Institute
for Health Research (NIHR)]; long-term studies such as this one are expensive and require commitment.
It is entirely independent of commercial interests, a problem for many similar comparative studies of
implantable devices.
Some strengths of the study demand exploration in more detail. The external validity of the study is
high and the findings are considered generalisable across the UK. It involved a large number of sites,
from varied geographic regions, and had surgeons with different levels of experience. Uniquely, for
arthroplasty, the study includes surgeons both in equipoise and not in equipoise regarding their beliefs
about the benefit for each operation type.
Another strength of the study was that it was designed as a pragmatic study. This permitted and took
into account a level of acceptable local variation with clinical arthroplasty pathways and expected
variation of expertise within the surgeons. However, a minimum threshold for training and experience
level was stipulated for the study, and each surgeon was screened before being admitted to recruit to
TOPKAT. This aspect was essential to ensure that the procedures were performed competently. Such
minimum experience thresholds were especially important for the PKR procedure, as the technically
challenging nature of this type of knee replacement would have allowed criticisms about recruiting
surgeons who could be considered ill-equipped to perform the operation. The competence for performing
the procedure across the trial would have been imbalanced. TKR operations are performed by all knee
surgeons in training and are routine and regular operations that they perform. The same cannot be
said of PKR. The potential for imbalance in surgical expertise for two or more different procedures
is a problem for all surgical trials and methodologies are continually being refined to address this.
The inclusion of an expertise randomisation component to the study did, in part, assuage the above threats
and strengthened external validity further. The study was able to reflect current practice by allowing
any surgeon who believed strongly in one technique over another, or who considered themselves
imbalanced in their own competency for performing the operation, to participate and randomise
patients. The expertise aspect of the study was also thought to offer insights into the possible negative
effects of dilution of expertise (for surgeons in equipoise) or any positive effects of superspecialisation
(for surgeons out of equipoise). It can be suggested, a priori, that having self-declared experts in one
operation over another would presuppose greater effects; surgeons implanting their device of choice
and performing their operation of highest competency would be expected to produce superior results.
However, in reality, surgeons performing TKR only (and not PKR) may have considered themselves ill at
ease with the more challenging PKR operation for a variety of reasons. It follows that overall capability
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(and surgical expertise) could be be elevated in the equipoise group of surgeons as they are the ones
who are more able, and comfortable, to perform both procedures. The counter argument, alluded to
above, is that the expertise surgeons performing TKR have independently decided on the benefits of
TKR outside their ability to perform PKR. Regardless, the analysis between expert and non-expert
randomisation groups did not show any strong effects.
External validity of the trial results is further supported by wide range of implants used in the study;
all common implants could be used in the study, again reflecting current practice. The demographic
data for implant type for the study closely mirrored that of the UK NJR (see Appendix 6). This meant
that both fixed and mobile bearing devices were evaluated and some implants that are less frequently
used are also included in the study. The limitation of this approach (revisited in Limitations) is that some
types of implant have a naturally greater prevalence (i.e. the Low Contact Stress implant for TKR and
the Oxford mobile bearing for PKR). Although deliberately pragmatic, with the most common implants
dominating, if more of the other types of implants had been included it is possible that different results
could have been generated.
The composite score for failure is a strength and a particularly judicious outcome (and conservative for
success), as it does not rely solely on reoperation or revision to define lack of success. The score allows
patients who may not have undergone reoperation or have been revised (obvious failure), but who
have not improved sufficiently by a specified number of points on self-reported outcome (for success),
to be classified as ‘failures’. Few other studies have used this metric.
A final notable strength of the study was the employment of external independent assessors to help
interpret the results and their review of the data blind to allocation. This was considered especially
important to neutralise any real, or perceived, personal bias (of persons involved in the study with
conflicts of interest) or institutional bias (the lead institution has long-standing connections with
various arthroplasty manufacturers and specific devices). It will be impossible to remove every aspect
of perceived bias, but the work has benefited from considerable effort throughout the course of the
study to minimise such potential bias.
Limitations
Several limitations to TOPKAT should also be outlined.
First, the study was not blinded. Patients were aware of which implant had been inserted. Any bias of
expectation, on behalf of the patient, could have influenced the self-reported measurements and affected
clinical results. It was not considered feasible to blind patients to their implant for ≥ 5 years (now 10 years).
Although this remains a design limitation, it was considered in great detail at the outset and was thought to
be a relatively minor threat to conclusions. Outside self-report, objective measures of function (AKSS), the
incidence of complications, the need for reoperation and revision and the health economics message are
relatively immune to this sort of expectancy bias.
There was some non-compliance with allocated intervention. Some patients allocated to the TKR group
underwent PKR and some patients allocated to the PKR group underwent TKR. The main reason for
this was a change in clinician equipoise during the operation. Having previously considered individual
patients suitable for randomisation (and allocation), surgeons observed interoperative features that
influenced the indications for a specific procedure and reversed their original decision. For patients
who were allocated to the PKR group but underwent TKR, these were features related to the indications
for PKR, such as an intact anterior cruciate ligament or greater degeneration of other compartments in
the knee than expected. For patients who were allocated to TKR but underwent PKR, these were features
such as finding a relatively healthy knee and being uncomfortable removing large amounts of healthy
tissue. Usefully, these events were in the minority with only 31 patients (12%) moving from PKR to TKR
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and 13 patients (5%) moving from TKR to PKR. Understandably, the higher percentage of the total
number of patients who were non-compliant with allocated treatment was from PKR to TKR (71%).
Although only a small number of patients had compliance with allocation issues, this problem did pose
some minor difficulties with the analysis. Correctly, the primary analysis of the trial was ITT throughout.
For the primary outcome, a CACE analysis allowed for this non-compliance and showed that the possible
impact on magnitude of effect was very low. However, this non-compliance had a disproportionate effect
on low-frequency events such as reoperation and revision. The possibility existed (and occurred) that out
of only a very small number of revision procedures of one type of implant, several of these had actually
had the contrasting device implanted at primary operation (for the reasons explained above). The use of
allocated classifications for revision could have been misleading. This was especially important as the
revision data in TOPKATwas different from that found in other registries and cohorts. A compromise of
reporting both ‘as allocated’ and ‘as treated’ analyses appears to satisfy this issue.
The experience of surgeons implanting PKR could be listed as a limitation, especially when considering
extrapolation to routine NHS care. All surgeons providing PKR were experienced at this procedure and
had self-identified as PKR surgeons. In routine NHS care, this may not be the case at the present time.
Many of the revision cases in the NJR may be the result of ‘learning curve cases’ that would not be
seen in TOPKAT. Therefore, extrapolation of management recommendation into the NHS must be
cautious. Although having generally strong external validity (from multisite data), the caveat that the
results here apply to experienced surgeons only is important. Rolling out more PKR without adequate
training or expertise would likely have negative consequences.
Follow-up data were largely of good quality and were complete. The 88% follow-up of the primary
variable at 5 years (94% of questionnaires sent out at this time point were returned) is considered
exceptional. There was, however, some loss to follow-up of other variables, particularly the AKSS
score, which provided objective clinical outcome data. The reason for this was that completion of the
AKSS score required a clinic appointment, and many patients, although willing to complete self-reports
over the telephone, were less willing to attend hospital 5 years into the study. In addition, the AKSS
required some unfamiliar physical measurements to be taken, and these were often carried out by
research support teams at sites, who, despite efforts to provide training, still often found this instrument
demanding. The lower levels of follow-up for the AKSS has little impact on the study, as this was a
secondary variable and the manifestations of some of the clinical deficiencies expressed in the AKSS
are reflected in other, better completed, outcome measures, such as the activity scores. The clinical
effectiveness and cost-effectiveness analyses dealt with the potential impact of missing outcome data
in different ways (use of multiple imputation or not for the principal analyses), but both sets of analyses
suggest robustness of the findings to this.
Other limitations include, as reported previously, high prevalence of specific implants. Most notable
are the Oxford mobile bearing partial knee implant and the Low Contact Stress total knee implant.
The justification of this is that the study was pragmatic and sampled those implants in current use.
The distribution mirrored that from national joint registries. Having said that, it could be argued that
different results may have been obtained if the study had been limited or had set criteria for implant
type. It is suggested that TOPKAT, in its highly pragmatic form, is more informative for the HTA
programme, NIHR and the NHS than a tightly controlled more mechanistic study.
The length of hospital stay data showed that a benefit for PKR led to lower costs for the PKR group.
Length of hospital stay was not controlled or strongly advised for either implant type. However,
there is an anecdotal sentiment and observation in normal practice that PKR patients are expected
to be discharged earlier than TKR patients.98 The reasons for this are complex and may include habit,
shibboleths, the TKR population being more aged in general and clinical reasons related to a decreased
insult to the tissues of PKR compared with TKR. Regardless, length of hospital stay should be viewed
cautiously as an outcome variable for clinical success by itself. Until the same discharge criteria are
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applied to TKR (if this is possible), the shorter length of stay may have been dictated by uncontrolled
factors within the study. Note that this does not make the health economics data less valid; moreover,
the length of hospital stay can be considered more of a fixed variable, similar to cost data, rather than
an independent outcome-related variable.
Some secondary outcome variables proved difficult to collect. Radiographic data were insufficiently
complete across sites and, therefore, unreliable and added little to the study findings. This was often
the result of differences in clinical practice across sites.
Clinical implications
Although one overall message could be that PKR has advantages for patients with medial compartment
OA over TKR, such a conclusion must be made cautiously. There are some nuances associated with
both the interpretation and further issues about provision of PKR that would affect any clinical
recommendation.
On a clinical basis only, given the small and non-significant difference in OKS, it could also be argued
that TKR is an effective and reliable operation and there is no evidence from this study to discontinue
it. Surgeons using TKR are providing a good clinical service and good outcome with this operation in
this population. Similarly, the study has shown that PKR is an effective operation and it may achieve
slightly improved clinical outcome over TKR. Clinicians themselves must decide whether or not this
level of difference would constitute enough to change or support their current practice. Interestingly,
the risk of revision, previously thought to be much higher for PKR, is not apparent in this study
(providing that surgeons are equipped and have sufficient expertise to conduct the operation, as here
in TOPKAT). Although the power for this finding is low, it has a substantial impact on the choice of
implant once combined with the health economics data. The cost-effectiveness analysis shows clear
superiority of PKR over TKR and, in the absence of any negative factors such a risk of revision, would
imply that PKR should be considered a valuable treatment for patients requiring arthroplasty.
Integrating such findings and recommendations into the NHS is not straightforward. It has already
been discussed that PKR can be more technically challenging operation and, if not performed correctly,
could produce inferior results, especially outside a trial. TKR is more forgiving in terms of precision of
implantation and technical skill requirements. More knee surgeons are likely to be more comfortable
with TKR. There is a danger that, if widespread encouragement and promotion of PKR were
established, without checks on experience and capability the outcomes and benefits seen in TOPKAT,
and especially the revision data, would not been seen universally. Indeed, this is what is believed to have
happened to some extent already at a national level96,99 and is reflected in the high revision rates seen in
the national registry data.
The solution may be to still recommend PKR but to ensure that it is performed only by suitably
qualified personnel. This may mean an improved training emphasis and higher levels of quality control
on PKR implantation. Surgeons without capability or who perform the operation infrequently should
perhaps consider other options. The obvious alternative is a TKR, which this study has shown to be
nearly as clinically effective as PKR.
Recommendations for future work
Further follow-up is required to assess the longer-term stability of these findings over time (10-year
follow-up in progress). Further research is also required into the effect of experience and the disparity
between trial and cohort data. Which set of data should be used to formulate policy? There may also
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be a case to discuss which subgroups of patients might be more appropriately treated with one approach
or the other and this might be the subject of further research.
The trial clearly shows results for a comparison in which experienced surgeons conducted the operations.
The input needed to bring all knee surgeons to a level of capability and competency, particularly for
PKR, is yet to be completed and could be an avenue for further work. In pools of surgeons without the
necessary expertise, results may be different from TOPKAT, and this could also be explored. It is even
possible that a new trial may be required in which centres with experience in using PKR allow PKR to
be carried out with various types of supervision or training given to young surgeons to understand how
to make the learning curve as short as possible.
The outcome measures used for TOPKAT may not have been ideal. Further work is also required to
generate more sensitive outcome measures and also to decide which measures are most appropriate to
answer the primary research question.
The expertise/equipoise aspect of the trial was of great interest and could be explored further.
It may be a useful model for other research questions in surgery. The issues around why expertise
randomisation models do not recruit as well as device-based requires further work.
Further work will also be required to investigate any changes in practice as a result of the trial.
The overall message is that PKR may be more suitable than TKR but there are many caveats to this
position and such discussions are required with any potential patient about to undergo arthroplasty.
Research work around decision-making for knee replacement type should, therefore, continue but
hopefully utilise some of the output from TOPKAT.
Conclusions
To our knowledge, TOPKAT is the largest RCT of longest follow-up to date and provides the most robust
evidence on which to choose between TKR and PKR. Both TKR and PKR are effective and they offer
similar clinical outcomes and have similar reoperation/revision and complication rates. Some patient-
reported outcome measures were significantly higher for PKR. PKR had substantial cost-effectiveness
benefits over TKR at 5 years.
DISCUSSION AND CONCLUSION







Nigel Arden (Oxford), Helen Campbell (Oxford), Marion Campbell (Aberdeen), Andrew Carr (Oxford),
Jonathan Cook (Aberdeen then Oxford), Helen Doll (Oxford), Ray Fitzpatrick (Oxford), David Murray
(Oxford) and Andrew Price (Oxford).
Trial management
Mayret Castillo (until 2011), Cushla Cooper, Loretta Davies, Anne Duncan (until 2017), Gordon Fernie,
Sophie Halpin (until 2015) and Alison McDonald.
Trial administration
Katie Chegwin, Jiyang Li (until 2018), Elena Rabaiotti (until 2013), Sandra Regan (until 2012) and
Victoria Stalker (until 2014).
Data management




Charles Boachie (until 2013), Jemma Hudson and Graeme MacLennan.
Health economists
Helen Campbell (until 2015), Francesco Fusco (until 2018), Seamus Kent and Jose Leal.
We would also like to thank Hannah Wilson (DPhil student, University of Oxford) for her help with the
update to the literature search.
Research teams
We are grateful to the participants and research teams at collaborating hospital sites:
Aneurin Bevan University Health Board, Royal Gwent Hospital
Ruth Jenkins, Mark Lewis [principal investigator (PI)] and Witek Mintowt-Czyz.
Belfast Health and Social Care Trust, Musgrove Park Hospital, Belfast
David Beverland (PI), Leeann Bryce, Julie Catney, Ian Dobie, Emer Doran and Seamus O’Brien.
Chesterfield Royal Hospital NHS Foundation Trust
Fazal Ali, Heather Cripps, Amanda Whileman, Phil Williams (PI) and Julie Toms.
County Durham and Darlington NHS Foundation Trust
Ellen Brown, Gillian Horner, Andrew Jennings (PI) and Glynis Rose.
DOI: 10.3310/hta24200 Health Technology Assessment 2020 Vol. 24 No. 20
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
67
East Lancashire Hospitals NHS Trust, Royal Blackburn Hospital
Frances Bamford, Wendy Goddard, Hans Marynissen (PI), Haleh Peel and Lyndsey Richards.
Great Western Hospitals NHS Foundation Trust, Swindon
Amanda Bell, Sunny Deo, Sarah Grayland, David Hollinghurst, Suzannah Pegler, Venkat Satish (PI) and
Claire Woodruffe.
Harrogate and District NHS Foundation Trust, Harrogate
Nick London (PI), David Duffy, Caroline Bennett and James Featherstone.
Hull and East Yorkshire Hospitals NHS Trust
Joss Cook, Kim Dearnley, Nagarajan Muthukumar (PI), Laura Onuoha and Sarah Wilson.
Maidstone and Tunbridge Wells NHS Trust, Medway
Sandhu Banher, Eunice Emeakaroha, Jamie Horohan, Sunil Jain (PI) and Susan Thompson.
Mid Yorkshire Hospitals NHS Trust
Sarah Buckley, Aaron Ng (PI), Ajit Shetty and Karen Simeson.
Milton Keynes University Hospital NHS Foundation Trust
Julian Flynn, Meryl Newsom, Cheryl Padilla-Harris and Oliver Pearce (PI).
NHS Grampian, Woodend Hospital, Aberdeen
James Bidwell (PI), Alison Innes, Winifred Culley and Bill Ledingham and Janis Stephen.
North Bristol NHS Trust
Rachel Bray, Hywel Davies, Debbie Delgado, Jonathan Eldridge, Leigh Morrison, James Murray (PI),
Andrew Porteous and James Robinson.
North Cumbria University Hospitals NHS Trust, Carlisle
Matt Dawson (PI), Raj Dharmarajan, David Elson, Will Hage, Nicci Kelsall and Mike Orr.
North Tees and Hartlepool NHS Foundation Trust, Stockton-On-Tees
Jackie Grosvenor, SS Maheswaran (PI), Claire McCue, Hemanth Venkatesh, Michelle Wild and
Deborah Wilson.
Oxford University Hospitals NHS Trust, Nuffield Orthopaedic Centre
Chris Dodd, William Jackson (PI), Pam Lovegrove, David Murray, Jennifer Piper and Andrew Price.
Royal United Hospitals Bath NHS Foundation Trust, Bath
Neil Bradbury, Lucy Clark, Stefanie Duncan, Genevieve Simpson and Allister Trezies (PI).
Sherwood Forest Hospitals NHS Foundation Trust, Kings Mill Hospital,
Sutton in Ashfield
Vikram Desai (PI), Cheryl Heeley, Kramer Guy and Rosalyn Jackson.
South Devon Healthcare NHS Foundation Trust, Torbay
Alan Hall, Gordon Higgins (PI), Michael Hockings, David Isaac and Pauline Mercer.
Stockport NHS Foundation Trust, Stockport
Lindsey Barber, Helen Cochrane, Janette Curtis, Julie Grindey, David Johnson (PI), and Phil Turner.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
68
The Hillingdon Hospitals NHS Trust
David Houlihan-Burne (PI), Briony Hill, Ron Langstaff and Mariam Nasseri.
The Ipswich Hospital NHS Trust, Ipswich
Mark Bowditch, Chris Martin, Steven Pryke, Bally Purewal, Chris Servant (PI), Sheeba Suresh and
Claire Tricker.
University Hospitals of Leicester NHS Trust, Leicester
Robert Ashford, Manjit Attwal, Jeanette Bunga, Urjit Chatterji, Susan Cockburn, Colin Esler (PI),
Steven Godsiff, Tim Green, Christina Haines and Subash Tandon.
University Hospitals of North Midlands NHS Trust, Stoke on Trent
Racquel Carpio, Sarah Griffiths, Natalie Grocott and Ian dos Remedios (PI).
University Hospital Southampton NHS Foundation Trust
David Barrett, Phil Chapman-Sheath, Caroline Grabau, Jane Moghul, William Tice (PI) and
Catherine Trevithick.
United Lincolnshire Hospitals NHS Trust, Boston
Rajiv Deshmukh, Mandy Howes, Kimberley Netherton, Dipak Raj (PI) and Nikki Travis.
United Lincolnshire Hospitals NHS Trust, Lincoln
Mohammad Maqsood, Rebecca Norton, Farzana Rashid, Alison Raynor, Mark Rowsell and Karen Warner.
We would like to thank the external members of the TSC and DMC for their advice and support for
the project.
Trial Steering Committee
Donna Dodwell as our patient representative, Simon Donell (chairperson) (University of East Anglia),
Shawn Tavares (Royal Berkshire Hospital) and Jonathan Waite (South Warwickshire NHS
Foundation Trust).
Data Monitoring Committee
Karen Barker (Oxford University Hospitals NHS Foundation Trust), Gordon Murray (chairperson)
(University of Edinburgh) and Hamish Simpson (University of Edinburgh).
Independent review and interpretation of results
l Professor David Torgerson (University of York).
l Professor Chris Maher (University of Sydney).
l Mr Peter Brownson (The Royal Liverpool and Broadgreen University Hospitals NHS Trust).
l Professor Simon Donell (University of East Anglia, Norwich).
l Mr Mark Mullins (Abertawe Bro Morgannwg University Health Board).
l Professor Jane Blazeby (Bristol University).
DOI: 10.3310/hta24200 Health Technology Assessment 2020 Vol. 24 No. 20
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
69
Ethics
Approval obtained from the UK National Research Ethics Service, Oxfordshire REC C, September 2009
(09/H0606/88).
Contributions of authors
David J Beard (https://orcid.org/0000-0001-7884-6389) (Professor of Musculoskeletal and Surgical
Science, University of Oxford) was the chief investigator, led the funding application, study conception
and design, provided overall study supervision, and prepared and reviewed the report.
Loretta J Davies (https://orcid.org/0000-0002-4721-356X) (Trial Manager, University of Oxford)
contributed to overall study conduct, and preparation and review of the report.
Jonathan A Cook (https://orcid.org/0000-0002-4156-6989) (Associate Professor, University of
Oxford) contributed to study design, advised on expertise-based design, overall study conduct, review
of statistical aspects, and preparation and review of the report.
Graeme MacLennan (https://orcid.org/0000-0002-1039-5646) (Director of the CHaRT, University
of Aberdeen) was responsible for overseeing the clinical analysis, contributed to overall study design,
and preparation and review of the report.
Andrew Price (https://orcid.org/0000-0002-4258-5866) (Professor of Orthopaedic Surgery, University
of Oxford) contributed to study design, advised on clinical aspects of trial, overall study conduct and
review of the report. (Note that he did not contribute to analysis or interpretation of data.)
Seamus Kent (https://orcid.org/0000-0001-7298-3163) (Senior Researcher, University of Oxford)
conducted the health economic evaluation and contributed to preparation and review of the report.
Jemma Hudson (https://orcid.org/0000-0002-6440-6419) (Research Fellow, University of Oxford)
conducted the clinical analysis and contributed to preparation and review of the report.
Andrew Carr (https://orcid.org/0000-0001-5940-1464) (Nuffield Professor of Orthopaedics, University
of Oxford) contributed to study design, was the orthopaedic clinical advisor and reviewed the report.
Jose Leal (https://orcid.org/0000-0001-7870-6730) (Senior Research Officer, University of Oxford)
was responsible for overseeing the health economic evaluation and contributed to preparation and
review of the report.
Helen Campbell (https://orcid.org/0000-0003-2070-7794) (Senior Researcher, University of Oxford)
contributed to early study design regarding health economic evaluation.
Ray Fitzpatrick (https://orcid.org/0000-0003-0607-0563) (Professor of Public Health and Primary
Care, University of Oxford) contributed to study design, outcome choice and review of the report.
Nigel Arden (https://orcid.org/0000-0002-3452-3382) (Professor in Rheumatic Diseases, University of
Oxford) contributed to study design and review of the report.
David Murray (https://orcid.org/0000-0002-0839-3166) (Professor of Orthopaedic Surgery, University
of Oxford) contributed to study design (particularly early in grant history), clinical guidance and review
of the report. (Note that he did not contribute to analysis or interpretation of data.)
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Marion K Campbell (https://orcid.org/0000-0001-5386-4097) (Professor of Health Services Research,
University of Aberdeen) contributed to study design, advised on methodological aspects and overall
study conduct and contributed to preparation and review of the report.
Publications
Beard DJ, Holt MD, Mullins MM, Malek S, Massa E, Price AJ. Decision making for knee replacement:
variation in treatment choice for late stage medical compartment osteoarthritis. Knee 2012;19:886–9.
Beard D, Price A, Cook J, Fitzpatrick R, Carr A, Campbell M, et al. Total or Partial Knee Arthroplasty
Trial – TOPKAT: study protocol for a randomised controlled trial. Trials 2013;14:292.
Beard DJ, Davies LJ, Cook JA, MacLennan G, Price A, Kent S, et al. The clinical and cost-effectiveness
of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT):
5-year outcomes of a randomised controlled trial. Lancet 2019;394:746–56.
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to
anonymised data may be granted following review.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to make
better use of information from people’s patient records, to understand more about disease, develop
new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure, to
protect everyone’s privacy, and it’s important that there are safeguards to make sure that it is stored and
used responsibly. Everyone should be able to find out about how patient data are used. #datasaveslives
You can find out more about the background to this citation here: https://understandingpatientdata.org.uk/
data-citation.
DOI: 10.3310/hta24200 Health Technology Assessment 2020 Vol. 24 No. 20
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,




1. Beard D, Price A, Cook J, Fitzpatrick R, Carr A, Campbell M, et al. Total or Partial Knee
Arthroplasty Trial –TOPKAT: study protocol for a randomised controlled trial. Trials 2013;14:292.
https://doi.org/10.1186/1745-6215-14-292
2. Bennell KL, Hunter DJ, Hinman RS. Management of osteoarthritis of the knee. BMJ
2012;345:e4934. https://doi.org/10.1136/bmj.e4934
3. Litwic A, Edwards MH, Dennison EM, Cooper C. Epidemiology and burden of osteoarthritis.
Br Med Bull 2013;105:185–99. https://doi.org/10.1093/bmb/lds038
4. Willis-Owen CA, Brust K, Alsop H, Miraldo M, Cobb JP. Unicondylar knee arthroplasty in
the UK National Health Service: an analysis of candidacy, outcome and cost efficacy. Knee
2009;16:473–8. https://doi.org/10.1016/j.knee.2009.04.006
5. National Institute for Health and Care Excellence (NICE). Guideline Scope Hip, Knee and
Shoulder Joint Replacement (GID-NG10084). London: NICE; 2018. URL: www.nice.org.uk/
guidance/gid-ng10084/documents/draft-scope (accessed December 2018).
6. National Joint Registry. National Joint Registry for England, Wales, Northern Ireland and the Isle of
Man. 15th Annual Report 2018. URL: https://reports.njrcentre.org.uk/Portals/7/PDFdownloads/
NJR%2015th%20Annual%20Report%202018.pdf (accessed January 2019).
7. Ethgen O, Bruyère O, Richy F, Dardennes C, Reginster JY. Health-related quality of life in
total hip and total knee arthroplasty. A qualitative and systematic review of the literature.
J Bone Joint Surg Am 2004;86:963–74. https://doi.org/10.2106/00004623-200405000-00012
8. Kane RL, Saleh KJ, Wilt TJ, Bershadsky B. The functional outcomes of total knee arthroplasty.
J Bone Joint Surg Am 2005;87:1719–24. https://doi.org/10.2106/00004623-200508000-00008
9. Beard DJ, Holt MD, Mullins MM, Malek S, Massa E, Price AJ. Decision making for knee
replacement: variation in treatment choice for late stage medial compartment osteoarthritis.
Knee 2012;19:886–9. https://doi.org/10.1016/j.knee.2012.05.005
10. Weale AE, Murray DW, Baines J, Newman JH. Radiological changes five years after
unicompartmental knee replacement. J Bone Joint Surg Br 2000;82:996–1000. https://doi.org/
10.1302/0301-620x.82b7.10466
11. Khan OH, Davies H, Newman JH, Weale AE. Radiological changes ten years after St. Georg
Sled unicompartmental knee replacement. Knee 2004;11:403–7. https://doi.org/10.1016/
j.knee.2004.07.003
12. Pearse AJ, Hooper GJ, Rothwell A, Frampton C. Survival and functional outcome after revision
of a unicompartmental to a total knee replacement: the New Zealand National Joint Registry.
J Bone Joint Surg Br 2010;92:508–12. https://doi.org/10.1302/0301-620X.92B4.22659
13. Cameron HU, Jung YB. A comparison of unicompartmental knee replacement with total knee
replacement. Orthop Rev 1988;17:983–8.
14. Price AJ, Webb J, Topf H, Dodd CA, Goodfellow JW, Murray DW, Oxford Hip and Knee Group.
Rapid recovery after oxford unicompartmental arthroplasty through a short incision. J Arthroplasty
2001;16:970–6. https://doi.org/10.1054/arth.2001.25552
15. Brown NM, Sheth NP, Davis K, Berend ME, Lombardi AV, Berend KR, Della Valle CJ. Total knee
arthroplasty has higher postoperative morbidity than unicompartmental knee arthroplasty:
a multicenter analysis. J Arthroplasty 2012;27(Suppl. 8):86–90. https://doi.org/10.1016/
j.arth.2012.03.022
DOI: 10.3310/hta24200 Health Technology Assessment 2020 Vol. 24 No. 20
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
73
16. Hassaballa MA, Porteous AJ, Newman JH. Observed kneeling ability after total, unicompartmental
and patellofemoral knee arthroplasty: perception versus reality. Knee Surg Sports Traumatol Arthrosc
2004;12:136–9. https://doi.org/10.1007/s00167-003-0376-5
17. Newman JH, Ackroyd CE, Shah NA. Unicompartmental or total knee replacement? Five-year
results of a prospective, randomised trial of 102 osteoarthritic knees with unicompartmental
arthritis. J Bone Joint Surg Br 1998;80:862–5. https://doi.org/10.1302/0301-620X.80B5.0800862
18. Newman J, Pydisetty RV, Ackroyd C. Unicompartmental or total knee replacement: the 15-year
results of a prospective randomised controlled trial. J Bone Joint Surg Br 2009;91:52–7.
https://doi.org/10.1302/0301-620X.91B1.20899
19. Dennis D, Komistek R, Scuderi G, Argenson JN, Insall J, Mahfouz M, et al. In vivo three-dimensional
determination of kinematics for subjects with a normal knee or a unicompartmental or total
knee replacement. J Bone Joint Surg Am 2001;83–A:104–15. https://doi.org/10.2106/
00004623-200100022-00008
20. Isaac SM, Barker KL, Danial IN, Beard DJ, Dodd CA, Murray DW. Does arthroplasty type
influence knee joint proprioception? A longitudinal prospective study comparing total
and unicompartmental arthroplasty. Knee 2007;14:212–17. https://doi.org/10.1016/
j.knee.2007.01.001
21. Gill T, Schemitsch EH, Brick GW, Thornhill TS. Revision total knee arthroplasty after
failed unicompartmental knee arthroplasty or high tibial osteotomy. Clin Orthop Relat Res
1995;321:10–18. https://doi.org/10.1097/00003086-199512000-00003
22. Padgett DE, Stern SH, Insall JN. Revision total knee arthroplasty for failed unicompartmental
replacement. J Bone Joint Surg Am 1991;73:186–90. https://doi.org/10.2106/00004623-
199173020-00005
23. Saldanha KA, Keys GW, Svard UC, White SH, Rao C. Revision of Oxford medial unicompartmental
knee arthroplasty to total knee arthroplasty - results of a multicentre study. Knee 2007;14:275–9.
https://doi.org/10.1016/j.knee.2007.03.005
24. Cameron HU, Park YS. Total knee replacement following high tibial osteotomy and
unicompartmental knee. Orthopedics 1996;19:807–8. https://doi.org/10.3928/0147-7447-
19960901-30
25. Jackson M, Sarangi PP, Newman JH. Revision total knee arthroplasty. Comparison of outcome
following primary proximal tibial osteotomy or unicompartmental arthroplasty. J Arthroplasty
1994;9:539–42. https://doi.org/10.1016/0883-5403(94)90102-3
26. Johnson S, Jones P, Newman JH. The survivorship and results of total knee replacements
converted from unicompartmental knee replacements. Knee 2007;14:154–7. https://doi.org/
10.1016/j.knee.2006.11.012
27. Levine WN, Ozuna RM, Scott RD, Thornhill TS. Conversion of failed modern unicompartmental
arthroplasty to total knee arthroplasty. J Arthroplasty 1996;11:797–801. https://doi.org/10.1016/
S0883-5403(96)80179-3
28. Myers TG, Cui Q, Kuskowski M, Mihalko WM, Saleh KJ. Outcomes of total and unicompartmental
knee arthroplasty for secondary and spontaneous osteonecrosis of the knee. J Bone Joint Surg Am
2006;88(Suppl. 3):76–82. https://doi.org/10.2106/00004623-200611001-00012
29. Fisher DA, Watts M, Davis KE. Implant position in knee surgery: a comparison of
minimally invasive, open unicompartmental, and total knee arthroplasty. J Arthroplasty
2003;18(Suppl. 7):2–8. https://doi.org/10.1016/S0883-5403(03)00291-2
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
30. Jenny JY, Boeri C. Accuracy of implantation of a unicompartmental total knee arthroplasty
with 2 different instrumentations: a case-controlled comparative study. J Arthroplasty
2002;17:1016–20. https://doi.org/10.1054/arth.2002.34524
31. Manzotti A, Confalonieri N, Pullen C. Unicompartmental versus computer-assisted total knee
replacement for medial compartment knee arthritis: a matched paired study. Int Orthop
2007;31:315–19. https://doi.org/10.1007/s00264-006-0184-x
32. Engh GA, Dwyer KA, Hanes CK. Polyethylene wear of metal-backed tibial components in total
and unicompartmental knee prostheses. J Bone Joint Surg Br 1992;74:9–17. https://doi.org/
10.1302/0301-620X.74B1.1732274
33. Weale AE, Murray DW, Newman JH, Ackroyd CE. The length of the patellar tendon after
unicompartmental and total knee replacement. J Bone Joint Surg Br 1999;81:790–5.
https://doi.org/10.1302/0301-620x.81b5.9590
34. Murray DW, MacLennan GS, Breeman S, Dakin HA, Johnston L, Campbell MK, et al. A randomised
controlled trial of the clinical effectiveness and cost-effectiveness of different knee prostheses:
the Knee Arthroplasty Trial (KAT). Health Technol Assess 2014;18(19). https://doi.org/10.3310/
hta18190
35. Amin AK, Patton JT, Cook RE, Gaston M, Brenkel IJ. Unicompartmental or total knee
arthroplasty?: Results from a matched study. Clin Orthop Relat Res 2006;451:101–6.
https://doi.org/10.1097/01.blo.0000224052.01873.20
36. Laurencin CT, Zelicof SB, Scott RD, Ewald FC. Unicompartmental versus total knee
arthroplasty in the same patient. A comparative study. Clin Orthop Relat Res 1991;273:151–6.
https://doi.org/10.1097/00003086-199112000-00023
37. Soohoo NF, Sharifi H, Kominski G, Lieberman JR. Cost-effectiveness analysis of unicompartmental
knee arthroplasty as an alternative to total knee arthroplasty for unicompartmental osteoarthritis.
J Bone Joint Surg Am 2006;88:1975–82. https://doi.org/10.2106/00004623-200609000-00011
38. Slover J, Espehaug B, Havelin LI, Engesaeter LB, Furnes O, Tomek I, Tosteson A. Cost-effectiveness
of unicompartmental and total knee arthroplasty in elderly low-demand patients. A Markov
decision analysis. J Bone Joint Surg Am 2006;88:2348–55. https://doi.org/10.2106/00004623-
200611000-00005
39. Costa CR, Johnson AJ, Mont MA, Bonutti PM. Unicompartmental and total knee arthroplasty
in the same patient. J Knee Surg 2011;24:273–8. https://doi.org/10.1055/s-0031-1280970
40. Sun PF, Jia YH. Mobile bearing UKA compared to fixed bearing TKA: a randomized
prospective study. Knee 2012;19:103–6. https://doi.org/10.1016/j.knee.2011.01.006
41. Kulshrestha V, Datta B, Kumar S, Mittal G. Outcome of Unicondylar Knee Arthroplasty vs
Total Knee Arthroplasty for Early Medial Compartment Arthritis: A Randomized Study.
J Arthroplasty 2017;32:1460–9. https://doi.org/10.1016/j.arth.2016.12.014
42. ClinicalTrials.gov. Unicompartmental Knee Arthroplasty (UKA) Versus Total Knee Arthroplasty
(TKA) of Medial Osteoarthritis. URL: www.ClinicalTrials.gov/show/NCT03457051 (accessed
December 2018).
43. ClinicalTrials.gov. Finnish Unicompartmental and Total Knee Arthroplasty Investigation (FUNCTION).
URL: www.clinicaltrials.gov/ct2/show/NCT02481427 (accessed 18 December 2018).
44. ClinicalTrials.gov. Medial Unicondylar Knee Arthroplasty vs Total Knee Arthroplasty.
URL: www.clinicaltrials.gov/ct2/show/NCT03396640 (accessed December 2018).
DOI: 10.3310/hta24200 Health Technology Assessment 2020 Vol. 24 No. 20
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
75
45. ClinicalTrials.gov. Unicondylar Knee Arthroplasty Versus Total Knee Arthroplasty in Patients With
Anteromedial Osteoarthritis of the Knee. URL: https://clinicaltrials.gov/ct2/show/NCT02430129
(accessed March 2020).
46. ClinicalTrials.gov. Unicondylar- or Total Knee Replacement? Patient Satisfaction, Function and
Muscle Mass. URL: www.clinicaltrials.gov/ct2/show/NCT02563756 (accessed December 2018).
47. Arirachakaran A, Choowit P, Putananon C, Muangsiri S, Kongtharvonskul J. Is unicompartmental
knee arthroplasty (UKA) superior to total knee arthroplasty (TKA)? A systematic review and
meta-analysis of randomized controlled trial. Eur J Orthop Surg Traumatol 2015;25:799–806.
https://doi.org/10.1007/s00590-015-1610-9
48. Schwab PE, Lavand’homme P, Yombi JC, Thienpont E. Lower blood loss after unicompartmental
than total knee arthroplasty. Knee Surg Sports Traumatol Arthrosc 2015;23:3494–500.
https://doi.org/10.1007/s00167-014-3188-x
49. Siman H, Kamath AF, Carrillo N, Harmsen WS, Pagnano MW, Sierra RJ. Unicompartmental
knee arthroplasty vs total knee arthroplasty for medial compartment arthritis in patients
older than 75 years: comparable reoperation, revision, and complication rates. J Arthroplasty
2017;32:1792–7. https://doi.org/10.1016/j.arth.2017.01.020
50. Bolognesi MP, Greiner MA, Attarian DE, Watters TS, Wellman SS, Curtis LH, et al.
Unicompartmental knee arthroplasty and total knee arthroplasty among Medicare beneficiaries,
2000 to 2009. J Bone Joint Surg Am 2013;95:e174. https://doi.org/10.2106/JBJS.L.00652
51. Duchman KR, Gao Y, Pugely AJ, Martin CT, Callaghan JJ. Differences in short-term complications
between unicompartmental and total knee arthroplasty: a propensity score matched analysis.
J Bone Joint Surg Am 2014;96:1387–94. https://doi.org/10.2106/JBJS.M.01048
52. Drager J, Hart A, Khalil JA, Zukor DJ, Bergeron SG, Antoniou J. Shorter hospital stay and
lower 30-day readmission after unicondylar knee arthroplasty compared to total knee
arthroplasty. J Arthroplasty 2016;31:356–61. https://doi.org/10.1016/j.arth.2015.09.014
53. Burn E, Liddle AD, Hamilton TW, Pai S, Pandit HG, Murray DW, Pinedo-Villanueva R.
Choosing between unicompartmental and total knee replacement: what can economic
evaluations tell us? A systematic review. Pharmacoecon Open 2017;1:241–53. https://doi.org/
10.1007/s41669-017-0017-4
54. Burn E, Liddle AD, Hamilton TW, Judge A, Pandit HG, Murray DW, Pinedo-Villanueva R.
Cost-effectiveness of unicompartmental compared with total knee replacement: a population-
based study using data from the National Joint Registry for England and Wales. BMJ Open
2018;8:e020977. https://doi.org/10.1136/bmjopen-2017-020977
55. Wiik AV, Aqil A, Tankard S, Amis AA, Cobb JP. Downhill walking gait pattern discriminates
between types of knee arthroplasty: improved physiological knee functionality in UKA
versus TKA. Knee Surg Sports Traumatol Arthrosc 2015;23:1748–55. https://doi.org/10.1007/
s00167-014-3240-x
56. Fabre-Aubrespy M, Ollivier M, Pesenti S, Parratte S, Argenson JN. Unicompartmental
knee arthroplasty in patients older than 75 results in better clinical outcomes and similar
survivorship compared to total knee arthroplasty. A matched controlled study. J Arthroplasty
2016;31:2668–71. https://doi.org/10.1016/j.arth.2016.06.034
57. Lum ZC, Lombardi AV, Hurst JM, Morris MJ, Adams JB, Berend KR. Early outcomes of twin-peg
mobile-bearing unicompartmental knee arthroplasty compared with primary total knee
arthroplasty. Bone Joint J 2016;98-B(Suppl. 10):28–33. https://doi.org/10.1302/0301-620X.
98B10.BJJ-2016-0414.R1
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
58. Zuiderbaan HA, van der List JP, Khamaisy S, Nawabi DH, Thein R, Ishmael C, et al.
Unicompartmental knee arthroplasty versus total knee arthroplasty: which type of artificial
joint do patients forget? Knee Surg Sports Traumatol Arthrosc 2017;25:681–6. https://doi.org/
10.1007/s00167-015-3868-1
59. Burn E, Sanchez-Santos MT, Pandit HG, Hamilton TW, Liddle AD, Murray DW,
Pinedo-Villanueva R. Ten-year patient-reported outcomes following total and minimally invasive
unicompartmental knee arthroplasty: a propensity score-matched cohort analysis. Knee Surg Sports
Traumatol Arthrosc 2018;26:1455–64. https://doi.org/10.1007/s00167-016-4404-7
60. Kim MS, Koh IJ, Choi YJ, Lee JY, In Y. Differences in patient-reported outcomes between
unicompartmental and total knee arthroplasties: a propensity score-matched analysis.
J Arthroplasty 2017;32:1453–9. https://doi.org/10.1016/j.arth.2016.11.034
61. Liddle AD, Judge A, Pandit H, Murray DW. Adverse outcomes after total and
unicompartmental knee replacement in 101,330 matched patients: a study of data from the
National Joint Registry for England and Wales. Lancet 2014;384:1437–45. https://doi.org/
10.1016/S0140-6736(14)60419-0
62. Chawla H, van der List JP, Christ AB, Sobrero MR, Zuiderbaan HA, Pearle AD. Annual
revision rates of partial versus total knee arthroplasty: a comparative meta-analysis. Knee
2017;24:179–90. https://doi.org/10.1016/j.knee.2016.11.006
63. Migliorini F, Tingart M, Niewiera M, Rath B, Eschweiler J. Unicompartmental versus total
knee arthroplasty for knee osteoarthritis. Eur J Orthop Surg Traumatol 2019;29:947–55.
https://doi.org/10.1007/s00590-018-2358-9
64. Cook JA, Elders A, Boachie C, Bassinga T, Fraser C, Altman DG, et al. A systematic review
of the use of an expertise-based randomised controlled trial design. Trials 2015;16:241.
https://doi.org/10.1186/s13063-015-0739-5
65. Dawson J, Fitzpatrick R, Murray D, Carr A. Questionnaire on the perceptions of patients
about total knee replacement. J Bone Joint Surg Br 1998;80:63–9. https://doi.org/10.1302/
0301-620x.80b1.7859
66. Beard DJ, Harris K, Dawson J, Doll H, Murray DW, Carr AJ, Price AJ. Meaningful changes for
the Oxford hip and knee scores after joint replacement surgery. J Clin Epidemiol 2015;68:73–9.
https://doi.org/10.1016/j.jclinepi.2014.08.009
67. Insall JN, Dorr LD, Scott RD, Scott WN. Rationale of the Knee Society clinical rating system.
Clin Orthop Relat Res 1989;248:13–14. https://doi.org/10.1097/00003086-198911000-00004
68. Martimbianco AL, Calabrese FR, Iha LA, Petrilli M, Lira Neto O, Carneiro Filho M. Reliability
of the ‘American Knee Society Score’ (AKSS). Acta Ortop Bras 2012;20:34–8. https://doi.org/
10.1590/S1413-78522012000100007
69. Zahiri CA, Schmalzried TP, Szuszczewicz ES, Amstutz HC. Assessing activity in joint replacement
patients. J Arthroplasty 1998;13:890–5. https://doi.org/10.1016/S0883-5403(98)90195-4
70. Talbot S, Hooper G, Stokes A, Zordan R. Use of a new high-activity arthroplasty score to assess
function of young patients with total hip or knee arthroplasty. J Arthroplasty 2010;25:268–73.
https://doi.org/10.1016/j.arth.2008.09.019
71. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72. https://doi.org/
10.1016/0168-8510(96)00822-6
72. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108.
https://doi.org/10.1097/00005650-199711000-00002
DOI: 10.3310/hta24200 Health Technology Assessment 2020 Vol. 24 No. 20
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
77
73. Robertsson O, Dunbar M, Pehrsson T, Knutson K, Lidgren L. Patient satisfaction after knee
arthroplasty: a report on 27,372 knees operated on between 1981 and 1995 in Sweden.
Acta Orthop Scand 2000;71:262–7. https://doi.org/10.1080/000164700317411852
74. Dawson J, Beard DJ, McKibbin H, Harris K, Jenkinson C, Price AJ. Development of a
patient-reported outcome measure of activity and participation (the OKS-APQ) to
supplement the Oxford knee score. Bone Joint J 2014;96–B:332–8. https://doi.org/10.1302/
0301-620X.96B3.32845
75. Murray DW, Fitzpatrick R, Rogers K, Pandit H, Beard DJ, Carr AJ, Dawson J. The use of the
Oxford hip and knee scores. J Bone Joint Surg Br 2007;89:1010–14. https://doi.org/10.1302/
0301-620X.89B8.19424
76. Cook JA, Ramsay CR, Fayers P. Statistical evaluation of learning curve effects in surgical trials.
Clin Trials 2004;1:421–7. https://doi.org/10.1191/1740774504cn042oa
77. Department of Health and Social Care (DHSC). NHS Reference Costs 2016 to 2017. London:
DHSC; 2017. URL: https://improvement.nhs.uk/resources/reference-costs/#archive
(accessed September 2018).
78. Curtis L, Burns A. Unit Costs of Health and Social Care 2017. Canterbury: PSSRU, University of
Kent; 2017.
79. Information Services Division (ISD). Scottish Health Service Costs. Edinburgh: ISD; 2018.
URL: www.isdscotland.org/Health-Topics/Finance/Publications/2018-11-20/2018-11-20-Costs-
Report.pdf (accessed September 2018).
80. Stokes EA, Wordsworth S, Staves J, Mundy N, Skelly J, Radford K, Stanworth SJ. Accurate costs of
blood transfusion: a microcosting of administering blood products in the United Kingdom National
Health Service. Transfusion 2018;58:846–53. https://doi.org/10.1111/trf.14493
81. World Health Organization (WHO). International Classification of Diseases. 10th edn. Geneva:
WHO; 2016.
82. NHS Digital. Costing – HRG4+ 2016/17. Reference Costs Grouper. 2018. URL: https://digital.nhs.
uk/services/national-casemix-office/downloads-groupers-and-tools/grouper-and-tools-archive/
costing-hrg4-2016-17-reference-costs-grouper (accessed September 2018).
83. NHS Improvement. Reference Costs 2017/18: Highlights, Analysis and Introduction to the Data.
2018. URL: https://improvement.nhs.uk/documents/1972/1_-_Reference_costs_201718.pdf
(accessed September 2018).
84. Leal J, Manetti S, Buchanan J. The impact of hospital costing methods on cost-effectiveness
analysis: a case study. PharmacoEconomics 2018;36:1263–72. https://doi.org/10.1007/s40273-
018-0673-y
85. Office of Population Censuses and Surveys. OPCS Classification of Surgical Operations and
Procedures, Fourth Revision. Leeds: NHS Digital; 1992.
86. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness
analysis conducted within randomised controlled trials. PharmacoEconomics 2014;32:1157–70.
https://doi.org/10.1007/s40273-014-0193-3
87. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology
Appraisal 2013. London: NICE; 2013. URL: www.nice.org.uk/process/pmg9/chapter/foreword
(accessed September 2018).
88. Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves – facts, fallacies and
frequently asked questions. Health Econ 2004;13:405–15. https://doi.org/10.1002/hec.903
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
89. Skou ST, Roos EM, Laursen MB, Rathleff MS, Arendt-Nielsen L, Simonsen O, Rasmussen S.
A randomized, controlled trial of total knee replacement. N Engl J Med 2015;373:1597–606.
https://doi.org/10.1056/NEJMoa1505467
90. Liddle AD, Pandit H, Judge A, Murray DW. Patient-reported outcomes after total and
unicompartmental knee arthroplasty: a study of 14,076 matched patients from the National
Joint Registry for England and Wales. Bone Joint J 2015;97–B:793–801. https://doi.org/
10.1302/0301-620X.97B6.35155
91. Wilson HA, Middleton R, Abram SGF, Smith S, Alvand A, Jackson WF, et al. Patient relevant
outcomes of unicompartmental versus total knee replacement: systematic review and
meta-analysis. BMJ 2019;364:l352. https://doi.org/10.1136/bmj.l352
92. Hunt LP, Ben-Shlomo Y, Clark EM, Dieppe P, Judge A, MacGregor AJ, et al. 45-day mortality
after 467,779 knee replacements for osteoarthritis from the National Joint Registry for England
and Wales: an observational study. Lancet 2014;384:1429–36. https://doi.org/10.1016/
S0140-6736(14)60540-7
93. Rothwell AG, Hooper GJ, Hobbs A, Frampton CM. An analysis of the Oxford hip and knee
scores and their relationship to early joint revision in the New Zealand Joint Registry.
J Bone Joint Surg Br 2010;92:413–18. https://doi.org/10.1302/0301-620X.92B3.22913
94. Zhang Q, Zhang Q, Guo W, Liu Z, Cheng L, Yue D, Zhang N. The learning curve for minimally
invasive Oxford phase 3 unicompartmental knee arthroplasty: cumulative summation test
for learning curve (LC-CUSUM). J Orthop Surg Res 2014;9:81. https://doi.org/10.1186/
s13018-014-0081-8
95. Liddle AD, Pandit H, Judge A, Murray DW. Optimal usage of unicompartmental knee
arthroplasty: a study of 41,986 cases from the National Joint Registry for England and Wales.
Bone Joint J 2015;97–B:1506–11. https://doi.org/10.1302/0301-620X.97B11.35551
96. Liddle AD, Pandit H, Judge A, Murray DW. Effect of surgical caseload on revision rate
following total and unicompartmental knee replacement. J Bone Joint Surg Am 2016;98:1–8.
https://doi.org/10.2106/JBJS.N.00487
97. Baker P, Jameson S, Critchley R, Reed M, Gregg P, Deehan D. Center and surgeon volume
influence the revision rate following unicondylar knee replacement: an analysis of 23,400
medial cemented unicondylar knee replacements. J Bone Joint Surg Am 2013;95:702–9.
https://doi.org/10.2106/JBJS.L.00520
98. Reilly KA, Beard DJ, Barker KL, Dodd CA, Price AJ, Murray DW. Efficacy of an accelerated
recovery protocol for Oxford unicompartmental knee arthroplasty – a randomised controlled trial.
Knee 2005;12:351–7. https://doi.org/10.1016/j.knee.2005.01.002
99. Liddle AD, Judge A, Pandit H, Murray DW. Determinants of revision and functional outcome
following unicompartmental knee replacement. Osteoarthritis Cartilage 2014;22:1241–50.
https://doi.org/10.1016/j.joca.2014.07.006
100. Hobbs FDR, Bankhead C, Mukhtar T, Stevens S, Perera-Salazar R, Holt T, Salisbury C, National
Institute for Health Research School for Primary Care Research. Clinical workload in UK
primary care: a retrospective analysis of 100 million consultations in England, 2007–14. Lancet
2016;387:2323–30. https://doi.org/10.1016/S0140-6736(16)00620-6
101. The Information Centre, Primary Care Statistics. 2006/07 UK General Practice Workload Survey.
Leeds: Department of Health and Social Care; 2007.
DOI: 10.3310/hta24200 Health Technology Assessment 2020 Vol. 24 No. 20
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
79
102. National Joint Registry. National Joint Registry for England and Wales: 9th Annual Report. 2012.
Prostheses Used in Hip, Knee, Ankle, Elbow and Shoulder Replacement Procedures 2011. URL: www.
njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/Prostheses%20used%20in%
20hip%20knee%20and%20ankle%20replacements%202011.pdf (accessed November 2018).
103. National Joint Registry. National Joint Registry for England and Wales: 11th Annual Report. 2014.
Prostheses Used in Hip, Knee, Ankle, Elbow and Shoulder Replacement Procedures 2013. URL:
www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/11th_annual_report/
NJR%2011th%20AR%20Prostheses%20used%20in%20hip,%20knee,%20ankle,%20elbow%
20and%20shoulder%20replacements%202013.pdf (accessed November 2018).
104. National Joint Registry. National Joint Registry For England And Wales: 10th Annual Report. 2013.
Prostheses Used in Hip, Knee, Ankle, Elbow and Shoulder Replacement Procedures 2012. URL:
www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/10th_annual_report/
NJR%20Prostheses%20used%20in%20hip,%20knee,%20ankle,%20shoulder%20and%20elbow
%20replacements%202012.pdf (accessed November 2018).
105. National Joint Registry. National Joint Registry For England And Wales: 8th Annual Report. 2011.
Prostheses Used in Hip, Knee, Ankle, Elbow and Shoulder Replacement Procedures 2010. URL:
www.njrcentre.org.uk/njrcentre/Portals/0/Documents/England/Reports/Prostheses%20used%20in
%20hip%20knee%20and%20ankle%20replacements%202010.pdf (accessed November 2018).
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
Appendix 1 Changes to TOPKAT protocol
TABLE 26 Summary of changes to protocol
Protocol version number Date issued Details of changes made
1 9 June 2009 Original protocol
2 10 June 2010 Inclusion of the HAAS to the secondary outcome measures
Revision of criteria on surgeon/site inclusion form
3 3 June 2012 Inclusion of additional OKS questionnaire at 1 year post surgery
for participants with a time between randomisation and surgery
> 12 weeks
Revision of primary procedure hospital form and inclusion of
re-admission form
Clarity given to the inclusion and exclusion criteria
4 4 April 2014 Inclusion of the OKS-APQ to the secondary outcome measures
Clarity given to the reporting procedures for serious adverse
events and post-surgical complications. Inclusion of post-operative
event non-re-admission form
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Appendix 2 The CONSORT time points
2 months to 5 years
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249 14 247 254 0 0 239 12 239 244 0 0
1 year 248 15 247 239 1 0 246 14 244 238 4 2
1 year
(post surgery)
54 – 54 – 2 0 40 – 40 – 4 1
2 years 240 21 240 – 2 1 238 19 238 – 4 3
3 years 219 41 218 – 3 2 228 27 226 – 6 3
4 years 209 49 205 – 4 3 219 34 219 – 7 4































Appendix 3 Suspected complications
TABLE 28 Suspected complications
Measure PKR (N= 264), n (%) TKR (N= 264), n (%)
Received surgery 263 251
Postoperative
Number of participants with complications 0 2 (0.8)
Thrombolytic – 2
Required re-admission
Required medical treatment only
Number of participants 2 (0.8) 4 (1.6)




DVT and infection – 1
Did not require re-admission
2-month follow-up




Number of participants and complications – 1 (0.4)
DVT – 1
DVT, deep-vein thrombosis.
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Appendix 4 Health-care costs
TABLE 29 Use and costs of implant devices by treatment allocation
Type of implant PKR (n) TKR (n) Cost per device (£)
PKR
Oxford Partial Knee 150 7 812.73
Zimmer 36 4 993.23
M/G Unicompartmental Knee System 22 1 988.07
Uniglide 9 0 633.27
AMC 5 0 1082.96
Du Puy 4 0 896.28
Mathys 4 0 931.34
Mecdata 1 0 930.31
Sigma 1 0 896.28
Vanguard 0 1 1310.89
TKR
Low Contact Stress 10 61 1441.88
PFC/Sigma 3 54 1047.89
Vanguard 3 41 1310.89
NexGen 8 29 1480.04
Triathlon 4 27 1291.30
Genesis 2 7 –
Scorpio/Kinemax 1 7 1528.52
ACS 0 6 650.81
EUROS 0 2 –
AGC 0 1 1099.46
AllPoly 0 1 –
Oxinium xlpe poly 0 1 –
Unknown 0 1 –
None 1 13 0
The costs come from a 2014–15 audit by the NJR and are inflated from 2014–15 prices to 2016–17 prices using the
hospital and community health services index. Missing data on components of the index surgery (e.g. implant type)
were imputed using mean imputation by treatment allocation.
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TABLE 30 Unit costs of health-care services
Resource type Unit cost (£) Details
Theatre time (per minute) 17.03 Table R142X from Scottish cost tables79
Blood transfusion 49.00 Red blood cell costs from a bottom-up UK costing study80
Hospital bed-day 327.61 Weighted average cost per excess bed data for elective HRG HN22
(major knee procedures) from the NHS Reference Costs 2016–17,77
where the weights reflect national activity levels
Day in critical care 699.11 From NHS Reference Costs 2016–17,77 currency code CCU02 (i.e. surgical
adult patient, unspecified specialty, with zero organs supported)
GP consultation 38.00 Annual cost from table 10.3b of Unit Costs of Health and Social Care,78
and an average duration of consultation of 9.22 minutes100
Practice nurse consultation 15.50 Annual cost from table 10.2 of Unit Costs of Health and Social Care78
and average duration of contact of 15.50 minutes101
Physiotherapist or occupational
therapist appointment
50.74 Weighted average of costs of physiotherapy and occupational therapy
appointments from NHS Reference Cost Schedule 2016–1777 (service
codes 650–651) for non-admitted patient follow-up face-to-face
attendances, non-consultant led, and community health-care services
(allied health-care professionals, physiotherapists and occupational
therapists, adults only)
Outpatient appointments 133.05 Non-admitted patient follow-up face-to-face attendance from NHS
Reference Cost Schedule 2016–1777 for rheumatology (service code 410).
Weighted average of consultant and non-consultant appointments
and procedures
TABLE 31 Costing post-operative complications
Complication n ICD-10 HRG code HRG description Cost (£)
Acute respiratory failure 1 J960 DZ27 Respiratory failure 1533.20
Atrial fibrillation 1 I489 EB07 Arrhythmia or conduction disorders 1239.46
Acute kidney injury 2 N179 LA07 Acute kidney injury 2261.14
Chest infection 2 J22X DZ22 Unspecified acute lower respiratory infection 2344.26
Dural tear 1 G961 AA25 Cerebral degenerations or miscellaneous
disorders of the nervous system
2412.83
DVT 1 I829 YQ51 DVT 928.44
Hyponatraemia 1 E871 KC05 Fluid or electrolyte disorders 1546.12
Hypoxaemia 3 J960 DZ27 Respiratory failure –
PE 3 I269 DZ09 Pulmonary embolus 1493.75
Pneumonia 1 J198 DZ11 Lobar, atypical or viral pneumonia 2952.03
Pyrexia 1 R509 WJ07 Fever of unknown origin 1476.70
Urinary retention 1 R398 LB37 Miscellaneous urinary tract findings 1404.79
Unallocateda 5 – – – –
DVT, deep-vein thrombosis; PE, pulmonary embolus.
The costs are a weighted average of costs associated with elective admissions for each four-character HRG, across
five-character codes that reflect differential complication scores and interventions, where the weights reflect national
activity levels.
a Insufficient detail provided to enable the allocation of an ICD-10 code.
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TABLE 32 The ICD-10 codes attached to reasons for re-admission
Complication n ICD-10 ICD-10 description
Unexplained pain 28 M255 Pain in joint
Knee stiffness 16 M256 Stiffness of joint
Bearing dislocation 7 T840 Mechanical complication of internal joint prosthesis
Suspected DVT 5 I829 Embolism and thrombosis of unspecified vein
Device loosening (tibia) 3 T840 Mechanical complication of internal joint prosthesis
Infection 2 T845 Infection and inflammatory reaction due to internal
joint prosthesis
Suspected infection 2 A499 Bacterial infection, unspecified
Ligamentous instability 2 M235 Chronic instability of knee
Wound breakdown 2 T813 Disruption of operation wound, not elsewhere
classified
Mechanical failure 2 T840 Mechanical complication of internal joint prosthesis
Renal and urological problems 2 N298 Other disorders of kidney and ureter in other
diseases classified elsewhere
Treated DVT or PE 1 I269 Pulmonary embolism without mention of acute cor
pulmonale
Cellulitis 1 L039 Cellulitis, unspecified
Periprosthetic fracture 1 M966 Fracture of bone following insertion of orthopaedic
implant, joint prosthesis, or bone plate
Bronchopneumonia 1 J180 Bronchopneumonia, unspecified
Pain from trauma 1 S899 Unspecified injury of lower leg
Superficial infection 1 – –
Swelling 1 M254 Effusion of joint
Skin complications 1 – –
DVT, deep-vein thrombosis; PE, pulmonary embolus.
TABLE 33 The OPCS-4 codes attached to re-admission procedures
Treatment n OPCS-4 OPCS-4 description
Revisiona 20 O183 Revision of hybrid prosthetic replacement of knee
joint using cement
Manipulation under anaesthetic 13 W789 Unspecified release of contracture of joint
Arthroscopy 7 W852 Endoscopic irrigation of knee joint
Aspiration 4 W901; Z846 Aspiration of joint; knee joint
Debridement/exploration/
washout
4 W851 Endoscopic removal of loose body from knee joint
Patella resurfacing 3 W851; Z787 Endoscopic removal of loose body from knee joint;
patella
Polyethylene exchange 3 W424; Y036;
Z949
Attention to total prosthetic replacement of knee
joint NEC; adjustment to prosthesis in organ NOC;
other branch of thoracic aorta NEC
continued
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TABLE 33 The OPCS-4 codes attached to re-admission procedures (continued )
Treatment n OPCS-4 OPCS-4 description
Open reduction and internal
fixation of avulsion fracture
(tibial tuberosity)
1 W201 Primary open reduction of fracture of long bone
and extramedullary fixation using plate NEC
Marcain injection 2 W903 Injection of therapeutic substance into joint
Wound debridement/
management
1 S571 Debridement of skin NEC
Examination under anaesthetic 1 W789 Unspecified release of contracture of joint
Biopsy 1 W871 Diagnostic endoscopic examination of knee joint
and biopsy of lesion of knee joint
Partial medial meniscectomy 1 W822 Endoscopic resection of semilunar cartilage NEC
NEC, not elsewhere specified; NOC, not otherwise classified.
a There are many OPCS-4 codes indicating revision. Most lead to the same HRG (HN81 – complex hip or knee
procedures for non-trauma), and so 0183 is used arbitrarily.
TABLE 34 Costs of hospital admissions
HRG code HRG description n Cost (£)
HD24 Non-inflammatory bone or joint disorders 27 1235.47
HN81 Complex hip or knee procedures for non-trauma 18 9336.47
HN24 Intermediate knee procedures for non-trauma 4 1960.64
HN25 Minor knee procedures for non-trauma 4 1579.58
YH30 Image guided aspiration of joint 4 825.34
HN80 Very complex hip or knee procedures for non-trauma 2 14,174.96
HN93 Other muscle, tendon, fascia or ligament procedures 2 1614.49
JC42 Intermediate skin procedures 1 1120.93
Costs are taken from the 2016–17 NHS Reference Cost Schedule83 and are a weighted average of elective, non-elective
and day-case admissions, and complication scores where the weights are based on national activity levels. We did not
add costs for excess bed-days.
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Appendix 5 Economic analysis
TABLE 35 Response level data for EQ-5D-3L questionnaires at each follow-up time point, by treatment allocation
Dimension
and level
Baseline 2 months 1 year 2 years 3 years 4 years 5 years




7 9 44 36 54 48 59 50 48 48 46 48 51 47
Some
problems
91 87 47 53 37 41 30 42 34 37 33 36 37 37
Extreme
problems
0 0 0 0 0 0 0 0 0 0 0 0 0 0




65 66 76 74 80 72 77 75 71 68 67 66 73 66
Some
problems
33 29 14 16 11 17 12 17 11 18 12 18 14 18
Extreme
problems
0 1 0 0 0 0 0 0 0 0 0 0 1 0
Missing 3 5 10 11 9 11 11 8 18 14 21 16 13 16
Usual activities (% responses)
No
problems
14 11 35 30 51 45 56 48 48 47 49 45 51 47
Some
problems
76 77 49 54 38 41 31 39 32 37 27 35 33 32
Extreme
problems
8 7 6 5 2 3 2 5 3 2 3 4 4 4




1 1 19 13 36 30 41 36 35 35 36 35 42 38
Some
problems
62 51 67 72 51 53 44 48 43 44 40 42 39 37
Extreme
problems
35 43 5 5 3 5 5 7 4 7 3 7 7 9




60 56 69 63 72 69 71 67 68 66 63 65 67 64
Some
problems
33 34 19 24 17 18 15 23 13 16 15 16 17 17
Extreme
problems
4 6 3 2 2 2 3 2 1 4 2 4 3 3
Missing 3 5 10 11 9 11 11 8 18 14 21 16 13 16
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TABLE 36 Data values for EQ-5D utility and health-care costs for each follow-up period following multiple imputation
Follow-up time
EQ-5D utility, mean (SD) Health-care costs,a mean (SD) Total costs, mean (SD)
PKR TKR PKR TKR PKR TKR
2 months 0.428 (0.545) 0.381 (0.563) 423 (17) 450 (19) 651 (46) 508 (41)
1 year 0.680 (0.499) 0.656 (0.488) 292 (20) 339 (18) 4018 (50) 4622 (63)
2 years 0.759 (0.499) 0.711 (0.521) 221 (17) 379 (24) 422 (48) 501 (54)
3 years 0.763 (0.518) 0.715 (0.532) 93 (13) 144 (18) 240 (39) 397 (64)
4 years 0.766 (0.501) 0.723 (0.539) 59 (14) 86 (16) 225 (57) 342 (70)
5 years 0.772 (0.498) 0.724 (0.542) 54 (14) 83 (16) 396 (67) 294 (53)
a These exclude inpatient care costs.
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Appendix 6 Distribution of knee
replacement implants
The study was pragmatic in terms of implant selection for the knee replacement operation. Thedistribution of implants used in the study is detailed in Tables 37 and 38. Data on implant use in
clinical practice over the recruitment period of the trial, obtained from the NJR,102–105 is also presented
in Tables 39 and 40.
TABLE 37 Distribution of partial knee implants used in TOPKAT
PKR implants used in TOPKAT N= 245, n %
Oxford Partial Knee 157 64.1
Zimmer unicompartmental 40 16.3




Mathys unicondylar knee 4 1.6



















FIGURE 7 The PKR implants used in TOPKAT from 2010 to 2014.
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TABLE 38 Distribution of total knee implants used in TOPKAT
TKR implants TOPKAT N= 269, n %
Low Contact Stress complete 71 26.4


































FIGURE 8 The TKR implants used in TOPKAT from 2010 to 2014.
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TABLE 39 Distribution of partial implants used in clinical practice (NJR)
PKR implants NJR 2010–14 N= 6984, n %
Oxford partial knee 4520 65
Zimmer unicompartmental 864 12
AMC/Uniglide 291 4
Mathys unicondylar knee 54 1
Sigma HP 881 13
Sled 40 1
Triathlon uni 96 1
Othera 238 3
a Other: Genesis Uni Oxinium (Smith & Nephew, Memphis, TN, USA); U-Kneetec (Corin Group, Cirencester, UK);
Journey Uni Oxinium (Smith & Nephew, Cordova, TN, USA); Optetrak Unicondylar (Exactech, Gainesville, FL, USA);
MG Uni (Zimmer Biomet, Warsaw, IN, USA); Genesis Uni (Smith & Nephew); UC-Plus (Plus Orthopaedics UK Ltd,
London, UK); iuni G2 (Conformis, Billerica, MA, USA); GMK Uni (Medacta International, Castel San Pietro, Switzerland);
HLS Evolution (Corin Group); Euros Unicondylar (Euros SAS, La Ciotat, France); Preservation (DePuy Orthopaedics Inc.,
Warsaw, IN, USA); EIUS (Stryker, Mahwah, NJ, USA); Repicci (Zimmer Biomet); Deuce (Smith & Nephew); LCS UNI
















FIGURE 9 The PKR implants used in clinical practice (NJR) from 2010 to 2014.
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TABLE 40 Distribution of total knee implants used in clinical practice (NJR)
TKR implants NJR 2010–14 N= 72,762, n %
LCS complete 2279 3




Genesis 2 6265 9
AGC 5414 7
Othera 8446 12
a Other: Columbus Total Knee System (Braun, Sheffield, UK), Genesis 2 Oxinium (Smith & Nephew, London, UK),
Medial Rotation Knee (MatOrtho, Leatherhead, UK), Endoplus Bicondylar Knee [Endo Plus (UK) Limited, Swindon,
UK], E-Motion Bicondylar Knee (Braun Medical UK Ltd, Sheffield, UK), Optetrak (Exactech Inc, Gainesville, FL, USA),
Natural Knee II (Zimmer Biomet, Winterthur, Switzerland), AMP Stature (Wright Medical Technology Inc., Arlington,
TN, USA), Rotaglide (Corin Group, Cirencester, UK), Legion (Smith & Nephew, London, UK), Journey Oxinium (Smith
& Nephew, Cordova, TN, USA), ACS (Implantcast, Buxtehude, Germany), Medial Rotation Knee (MatOrtho Limited,
Leatherhead, UK), Maxim (Biomet Orthopedics, Warsaw, IN, USA), Attune CR (DePuy Orthopaedics Inc., Warsaw,
IN, USA), Profix (Smith & Nephew, Cordova, TN, USA), GMK (Medacta International, Castel San Pietro, Switzerland),
Mathys Bicondylar Knee (Mathys Ltd, Bettlach, Switzerland), Advance PS (Palex Medical, Madrid, Spain), Logic
(Exactech, Gainesville, FL, USA), Nexgen LCCK (Zimmer Biomet, Warsaw, IN, USA), Joint Medica Bicondylar (Joint
Medica, Worcestershire, UK), CR Flex (Zimmer Biomet, Warsaw, IN, USA), Alpina (Zimmer Biomet, Warsaw, IN, USA),
Legion Oxinium (Smith & Nephew, Cordova, TN, USA), Saiph (MatOrtho Limited, Leatherhead, UK), Legacy Posterior
Stabilized (Zimmer Biomet, Warsaw, IN, USA), Smiles Knee (Stanmore Implants, Elstree, UK), 3D (DJO Global Inc.,
Lewisville, TX, USA), TC Plus (Smith & Nephew, Cordova, TN, USA), Euros Bicondylar (Euros SAS, La Ciotat, France),
Unity (Corin Group, Cirencester, UK), Insall-Burstein 2 (Wright Medical Group Inc., Memphis, TN, USA), iDuo G2
(Conformis, Billerica, MA, USA), Profix Oxinium (Smith & Nephew, Cordova, TN, USA), SMILES Bicondylar (Stanmore
Implants, Elstree, UK), Attune PS (Depuy Orthopaedics Inc., Warsaw, IN, USA), Medacta Bicondylar (Medacta
International, Castel San Pietro, Switzerland), St Leger (Zynergy Orthopaedics Ltd, Rotherham, UK), NRG (Stryker,
Mahwah, NJ, USA), Aequos G1 (Aequos, Gräfelfing, Germany), Rotaglide + (sphere, Corin Group, Cirencester, UK),
Mobile Bearing Knee System (Consensus Orthopedics Inc., El Dorado Hills, CA, USA), Consensus Knee System
(Consensus Orthopedics Inc., El Dorado Hills, CA, USA), AMC (Corin Group, Cirencester, UK), LCS (DePuy
Orthopaedics Inc., Warsaw, IN, USA), Dual Bearing Knee (DBK) prosthesis (Finsbury Orthopaedics, Leatherhead,
UK), CCI (Implantcast, Buxtehude, Germany), Kinemax (Stryker, Kalamazoo, MI, USA), Advance CCK (Wright Medical
Group Inc., Memphis, TN, USA), Natural Knee II (Zimmer Biomet, Warsaw, IN, USA), FS (Zimmer Biomet, Warsaw, IN,
USA), INNEX (Zimmer Biomet, Warsaw, IN, USA), Deuce Bicondylar (Smith & Nephew, Cordova, TN, USA), Advantim
(Wright Medical Group Inc., Memphis, TN, USA), Gemini (Link UK, Edinburgh, UK), Columbus (Braun, Tuttlingen,
Germany), ASDM TCK (Advanced Surgical Design & Manufacture Limited, NSW, Australia), Dual Bearing Knee
prosthesis (Finsbury Orthopaedics, Leatherhead, UK), Insall-Burstein 2 (Zimmer Biomet, Warsaw, IN, USA), LCS
Complete revision (DePuy Orthopaedics Inc., Warsaw, IN, USA), Press Fit Condylar Bicondylar knee (Johnson &
Johnson, Raynham, MA, USA), Natural Knee (Zimmer Biomet, Warsaw, IN, USA), Oxford TMK (Zimmer Biomet,
Warsaw, IN, USA), Self-Aligning (SAL) total knee prosthesis (Sulzer Medica, Winterthur, Switzerland), AMK (DePuy
Orthopaedics Inc., Warsaw, IN, USA), ST LEGER (Zynergy Orthopaedics Ltd, Rotherham, UK), JRI Bicondylar knee
(JRI Orthopaedics CCI, Sheffield, UK), Advance Bicondylar Knee (Microport Orthopedics Inc., Arlington, TN, USA),
NK2 Bicondylar Knee, (Zimmer Biomet, Warsaw, IN, USA), Implantcast Bicondylar (Implantcast, Buxtehude,
Germany), Balansys Bicondylar Knee (Mathys Ltd, Bettlach, Switzerland), FS (Zimmer Biomet, Warsaw, IN, USA),
SCORE (Amplitude SAS, Valence, France), Optetrak (Exactech Inc., Gainesville, FL, USA), REnasys Bicondylar Knee
(Smith & Nephew, Cordova, TN, USA), Guardian (Wright Medical Technology Inc., Arlington, TN, USA).
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FIGURE 10 The TKR implants used in clinical practice (NJR) from 2010 to 2014.
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